2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phosphonomethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
was	O	O
obtained	O	O
from	O	O
the	O	O
appropriate	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloropyrimidine	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
by	O	O
alkaline	O	O
hydrolysis	O	O
and	O	O
ester	O	O
cleavage	O	O
.	O	O
These	O	O
results	O	O
indicate	O	O
that	O	O
substantial	O	O
modification	O	O
of	O	O
the	O	O
framework	O	O
of	O	O
peptide	O	O
-	O	O
based	O	O
siderophores	O	O
can	O	O
be	O	O
tolerated	O	O
by	O	O
microbial	O	O
iron	O	O
-	O	O
transport	O	O
systems	O	O
.	O	O
Of	O	O
the	O	O
alkyl	O	O
-	O	O
substituted	O	O
1	O	O
-	O	O
position	O	O
analogs	O	O
of	O	O
oxytocin	O	O
studied	O	O
so	O	O
far	O	O
,	O	O
[	B-IUPAC	O
1	I-IUPAC	O
-	I-IUPAC	O
beta	I-IUPAC	O
-	I-IUPAC	O
mercapto	I-IUPAC	O
-	I-IUPAC	O
beta	I-IUPAC	O
,	I-IUPAC	O
beta	I-IUPAC	O
-	I-IUPAC	O
pentamethylenepropionic	I-IUPAC	O
acid	I-IUPAC	O
]	I-IUPAC	O
oxytocin	I-IUPAC	O
is	O	O
the	O	O
most	O	O
potent	O	O
antioxytocic	O	O
agent	O	O
.	O	O
These	O	O
compounds	O	O
were	O	O
radiolabeled	O	O
with	O	O
fluorine	O	O
-	O	O
18	O	O
,	O	O
and	O	O
their	O	O
biological	O	O
properties	O	O
were	O	O
evaluated	O	O
in	O	O
rats	O	O
and	O	O
compared	O	O
with	O	O
those	O	O
of	O	O
[	O	O
11C	O	O
]	O	O
carbonyl	O	O
WAY	O	O
100635	O	O
(	O	O
[	O	O
carbonyl	O	O
-	O	O
11C	O	O
]	O	O
4a	O	O
)	O	O
.	O	O
ABPA	O	O
proved	O	O
to	O	O
be	O	O
equipotent	O	O
with	O	O
AMPA	O	O
both	O	O
as	O	O
an	O	O
inhibitor	O	O
of	O	O
AMPA	O	O
binding	O	O
and	O	O
as	O	O
a	O	O
neuronal	O	O
excitant	O	O
.	O	O
The	O	O
tetrahydropyridine	O	O
analog	O	O
of	O	O
10	O	O
,	O	O
compound	O	O
13	O	O
,	O	O
showed	O	O
a	O	O
markedly	O	O
lower	O	O
receptor	O	O
affinity	O	O
(	O	O
IC50	O	O
=	O	O
32	O	O
+	O	O
/	O	O
-	O	O
10	O	O
microM	O	O
)	O	O
and	O	O
apparently	O	O
a	O	O
lower	O	O
relative	O	O
efficacy	O	O
than	O	O
10	O	O
.	O	O
Methotrexate	O	O
poly	O	O
(	O	B-IUPAC
gamma	O	I-IUPAC
-	O	I-IUPAC
L	O	I-IUPAC
-	O	I-IUPAC
glutamate	O	I-IUPAC
)	O	O
s	O	O
bearing	O	O
two	O	O
and	O	O
three	O	O
glutamate	O	O
units	O	O
above	O	O
that	O	O
present	O	O
in	O	O
methotrexate	O	O
have	O	O
been	O	O
synthesized	O	O
by	O	O
extension	O	O
of	O	O
a	O	O
previously	O	O
described	O	O
route	O	O
used	O	O
to	O	O
synthesize	O	O
the	O	O
lower	O	O
conjugate	O	O
bearing	O	O
one	O	O
added	O	O
glutamate	O	O
unit	O	O
.	O	O
Therefore	O	O
,	O	O
the	O	O
interaction	O	O
of	O	O
the	O	O
drug	O	O
with	O	O
the	O	O
binding	O	O
site	O	O
,	O	O
responsible	O	O
for	O	O
its	O	O
biological	O	O
activity	O	O
,	O	O
appears	O	O
to	O	O
be	O	O
governed	O	O
by	O	O
a	O	O
dynamic	O	O
process	O	O
.	O	O
Compound	O	O
5e	O	O
showed	O	O
high	O	O
affinity	O	O
for	O	O
rat	O	O
A	O	O
(	O	O
2A	O	O
)	O	O
AR	O	O
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
8	O	O
nM	O	O
)	O	O
,	O	O
human	O	O
recombinant	O	O
A	O	O
(	O	O
2A	O	O
)	O	O
AR	O	O
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
5	O	O
nM	O	O
)	O	O
,	O	O
and	O	O
human	O	O
native	O	O
A	O	O
(	O	O
2A	O	O
)	O	O
AR	O	O
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
15	O	O
nM	O	O
)	O	O
and	O	O
was	O	O
highly	O	O
selective	O	O
versus	O	O
rat	O	O
A	O	O
(	O	O
1	O	O
)	O	O
AR	O	O
(	O	O
110	O	O
-	O	O
fold	O	O
)	O	O
,	O	O
human	O	O
recombinant	O	O
A	O	O
(	O	O
2A	O	O
)	O	O
AR	O	O
(	O	O
500	O	O
-	O	O
fold	O	O
)	O	O
,	O	O
human	O	O
A	O	O
(	O	O
2B	O	O
)	O	O
AR	O	O
(	O	O
&	O	O
gt	O	O
;	O	O
2000	O	O
-	O	O
fold	O	O
)	O	O
,	O	O
and	O	O
human	O	O
A	O	O
(	O	O
3	O	O
)	O	O
AR	O	O
(	O	O
&	O	O
gt	O	O
;	O	O
2000	O	O
-	O	O
fold	O	O
)	O	O
.	O	O
Furthermore	O	O
,	O	O
when	O	O
9a	O	O
was	O	O
given	O	O
twice	O	O
daily	O	O
at	O	O
a	O	O
dosage	O	O
of	O	O
40	O	O
mg	O	O
/	O	O
kg	O	O
for	O	O
6	O	O
consecutive	O	O
days	O	O
,	O	O
a	O	O
T	O	O
/	O	O
C	O	O
value	O	O
of	O	O
165	O	O
was	O	O
obtained	O	O
and	O	O
60%	O	O
of	O	O
the	O	O
mice	O	O
were	O	O
60	O	O
-	O	O
day	O	O
long	O	O
-	O	O
term	O	O
survivors	O	O
.	O	O
b	O	O
.	O	O
Of	O	O
the	O	O
20	O	O
compounds	O	O
evaluated	O	O
,	O	O
six	O	O
exhibited	O	O
biologically	O	O
significant	O	O
anti	O	O
-	O	O
L1210	O	O
activity	O	O
in	O	O
BD2F1	O	O
mice	O	O
and	O	O
reduced	O	O
body	O	O
burdens	O	O
of	O	O
viable	O	O
L1210	O	O
cells	O	O
more	O	O
than	O	O
90-97%	O	O
by	O	O
single	O	O
treatment	O	O
.	O	O
4,5,6,7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylimidazo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4,5,1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
jk	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,4	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzodiazepin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
(	O	O
TIBO	O	O
)	O	O
,	O	O
1	O	O
,	O	O
have	O	O
been	O	O
shown	O	O
to	O	O
significantly	O	O
inhibit	O	O
HIV	O	O
-	O	O
1	O	O
replication	O	O
in	O	O
vitro	O	O
by	O	O
interfering	O	O
with	O	O
the	O	O
virus	O	O
's	O	O
reverse	O	O
transcriptase	O	O
enzyme	O	O
.	O	O
A	O	O
more	O	O
specific	O	O
process	O	O
was	O	O
used	O	O
for	O	O
the	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
compound	B-MODIFIER	B-MODIFIER
,	O	O
i.e.	O	O
,	O	O
nucleophilic	O	O
displacement	O	O
of	O	O
nitrite	O	O
from	O	O
methyl	B-IUPAC	B-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nitro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinecarboxylate	I-IUPAC	I-IUPAC
by	O	O
sodioformanilide	O	O
and	O	O
subsequent	O	O
hydrolysis	O	O
.	O	O
As	O	O
an	O	O
inhibitor	O	O
of	O	O
TS	O	O
from	O	O
H35F	O	O
/	O	O
F	O	O
cells	O	O
,	O	O
4	O	O
gave	O	O
an	O	O
IC50	O	O
value	O	O
showing	O	O
it	O	O
to	O	O
be	O	O
approximately	O	O
6	O	O
-	O	O
fold	O	O
less	O	O
inhibitory	O	O
than	O	O
PDDF	O	O
(	O	O
90	O	O
nM	O	O
for	O	O
4	O	O
vs	O	O
14	O	O
nM	O	O
for	O	O
PDDF	O	O
)	O	O
.	O	O
2beta	O	B-IUPAC
-	O	I-IUPAC
(	O	I-IUPAC
R	O	I-IUPAC
)	O	I-IUPAC
-	O	I-IUPAC
Carbo	O	I-IUPAC
-	O	I-IUPAC
1	O	I-IUPAC
-	O	I-IUPAC
fluoro	O	I-IUPAC
-	O	I-IUPAC
2	O	I-IUPAC
-	O	I-IUPAC
propoxy	O	I-IUPAC
-	O	I-IUPAC
3beta	O	I-IUPAC
-	O	I-IUPAC
(	O	I-IUPAC
4	O	I-IUPAC
-	O	I-IUPAC
chlorophenyl	O	I-IUPAC
)	O	I-IUPAC
tro	O	I-IUPAC
pane	O	I-IUPAC
(	O	O
(	O	O
R	O	O
)	O	O
-	O	O
FIPCT	O	O
,	O	O
R	O	O
-	O	O
6	O	O
)	O	O
and	O	O
2beta	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carbo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chlorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
tro	I-IUPAC	I-IUPAC
pane	I-IUPAC	I-IUPAC
(	O	O
(	O	O
S	O	O
)	O	O
-	O	O
FIPCT	O	O
,	O	O
S	O	O
-	O	O
6	O	O
)	O	O
were	O	O
prepared	O	O
and	O	O
evaluated	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
for	O	O
dopamine	O	O
transporter	O	O
(	O	O
DAT	O	O
)	O	O
selectivity	O	O
and	O	O
specificity	O	O
.	O	O
Compound	O	O
4	O	O
was	O	O
found	O	O
to	O	O
be	O	O
the	O	O
most	O	O
active	O	O
agent	O	O
of	O	O
this	O	O
series	O	O
of	O	O
compounds	O	O
.	O	O
The	O	O
symmetrical	O	O
diamidines	O	O
14a	O	O
,	O	O
b	O	O
were	O	O
synthesized	O	O
through	O	O
the	O	O
corresponding	O	O
bis	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetoxyamidoxime	I-IUPAC	I-IUPAC
followed	O	O
by	O	O
hydrogenation	O	O
.	O	O
New	O	O
histamine	O	O
derivatives	O	O
characterized	O	O
by	O	O
a	O	O
(	O	O
substituted	O	O
)	O	O
aryl	O	O
,	O	O
heteroaryl	O	B-IUPAC
,	O	O
benzyl	O	B-IUPAC
,	O	O
or	O	O
heteroarylmethyl	O	O
substituent	O	O
in	O	O
the	O	O
C2	O	O
position	O	O
of	O	O
the	O	O
imidazole	O	O
ring	O	O
have	O	O
been	O	O
prepared	O	O
from	O	O
appropriate	O	O
imidates	O	O
or	O	O
amidines	O	O
,	O	O
respectively	O	O
,	O	O
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phthalimido	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
acetate	I-IUPAC	I-IUPAC
(	O	O
1	O	O
)	O	O
.	O	O
A	O	O
composite	O	O
hydrogen	O	O
-	O	O
bonding	O	O
environment	O	O
has	O	O
been	O	O
constructed	O	O
for	O	O
the	O	O
TRH	O	O
analogue	O	O
system	O	O
and	O	O
examined	O	O
for	O	O
its	O	O
inference	O	O
with	O	O
respect	O	O
to	O	O
receptor	O	O
binding	O	O
.	O	O
Derivatives	O	O
of	O	O
the	O	O
nonselective	O	O
excitatory	O	O
amino	O	O
acid	O	O
antagonist	O	O
kynurenic	O	O
acid	O	O
(	O	B-IUPAC
4	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydroquinoline	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
,	O	O
1	O	O
)	O	O
have	O	O
been	O	O
synthesized	O	O
and	O	O
evaluated	O	O
for	O	O
in	O	O
vitro	O	O
antagonist	O	O
activity	O	O
at	O	O
the	O	O
excitatory	O	O
amino	O	O
acid	O	O
receptors	O	O
sensitive	O	O
to	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aspartic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
NMDA	O	O
)	O	O
,	O	O
quisqualic	O	O
acid	O	O
(	O	O
QUIS	O	O
or	O	O
AMPA	O	O
)	O	O
,	O	O
and	O	O
kainic	O	O
acid	O	O
(	O	O
KA	O	O
)	O	O
.	O	O
Compound	O	O
7g	O	O
turned	O	O
out	O	O
to	O	O
be	O	O
a	O	O
very	O	O
weak	O	O
AMPA	O	O
receptor	O	O
agonist	O	O
(	O	O
IC50	O	O
=	O	O
12	O	O
+	O	O
/	O	O
-	O	O
0.7	O	O
microM	O	O
;	O	O
EC50	O	O
=	O	O
160	O	O
+	O	O
/	O	O
-	O	O
15	O	O
microM	O	O
)	O	O
.	O	O
The	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	O
and	O	O
the	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	O
isomer	B-MODIFIER	O
possessed	O	O
similar	O	O
potencies	O	O
as	O	O
D	O	O
-	O	O
1	O	O
antagonists	O	O
.	O	O
The	O	O
other	O	O
assay	O	O
measured	O	O
retinoid	O	O
-	O	O
induced	O	O
differentiation	O	O
of	O	O
the	O	O
human	O	O
myoloid	O	O
leukemia	O	O
cell	O	O
line	O	O
HL	O	O
-	O	O
60	O	O
.	O	O
In	O	O
general	O	O
,	O	O
the	O	O
compounds	O	O
structurally	O	O
related	O	O
to	O	O
BTCP	O	O
exhibited	O	O
greater	O	O
selectivity	O	O
for	O	O
sites	O	O
labeled	O	O
by	O	O
[	O	O
3H	O	O
]	O	O
BTCP	O	O
.	O	O
The	O	O
most	O	O
potent	O	O
broad	O	O
spectrum	O	O
agent	O	O
in	O	O
the	O	O
NCI	O	O
cell	O	O
panel	O	O
was	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorobenzothiazole	I-IUPAC	I-IUPAC
(	O	O
10h	O	O
)	O	O
which	O	O
,	O	O
unlike	O	O
the	O	O
6	B-IUPAC	O
-	I-IUPAC	O
fluoro	I-IUPAC	O
isomer	B-MODIFIER	O
(	O	O
10d	O	O
)	O	O
,	O	O
produces	O	O
no	O	O
exportable	O	O
metabolites	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
sensitive	O	O
MCF	O	O
-	O	O
7	O	O
cells	O	O
.	O	O
Treatment	O	O
of	O	O
spermine	O	O
with	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethoxybenzoyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
thiazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
idine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thione	I-IUPAC	I-IUPAC
(	O	O
1	O	O
)	O	O
(	O	O
molar	O	O
ratio	O	O
2	O	O
:	O	O
1	O	O
)	O	O
gave	O	O
1,14	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethoxybenzoyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,5,10,14	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetraazatetradecane	I-IUPAC	I-IUPAC
(	O	O
2	O	O
,	O	O
DiCAM	O	O
-	O	O
spermine	O	O
)	O	O
in	O	O
80%	O	O
yield	O	O
.	O	O
CNS	O	O
-	O	O
stimulating	O	O
activity	O	O
was	O	O
also	O	O
evaluated	O	O
by	O	O
examining	O	O
the	O	O
promotional	O	O
effect	O	O
on	O	O
the	O	O
recovery	O	O
from	O	O
cerebral	O	O
concussion	O	O
induced	O	O
coma	O	O
in	O	O
mice	O	O
.	O	O
Regeneration	O	O
of	O	O
the	O	O
5,6	O	O
-	O	O
olefinic	O	O
bond	O	O
to	O	O
give	O	O
AZT	O	O
,	O	O
upon	O	O
incubation	O	O
of	O	O
the	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
halo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
compounds	B-MODIFIER	B-MODIFIER
with	O	O
glutathione	O	O
,	O	O
mouse	O	O
blood	O	O
,	O	O
or	O	O
mouse	O	O
liver	O	O
homogenate	O	O
,	O	O
was	O	O
dependent	O	O
upon	O	O
the	O	O
nature	O	O
of	O	O
the	O	O
5	B-IUPAC	O
-	I-IUPAC	O
halo	I-IUPAC	O
substituent	B-MODIFIER	O
(	O	O
I	O	O
&	O	O
gt	O	O
;	O	O
Br	O	O
)	O	O
.	O	O
Structure	O	O
-	O	O
-	O	O
activity	O	O
relationships	O	O
for	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2p	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
arylmethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
piperidines	I-IUPAC	I-IUPAC
are	O	O
generally	O	O
similar	O	O
to	O	O
the	O	O
profile	O	O
established	O	O
for	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
arylspiro	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
isobenzofuran	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidines	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
.	O	O
This	O	O
suggests	O	O
that	O	O
new	O	O
,	O	O
more	O	O
stable	O	O
and	O	O
selective	O	O
nucleotide	O	O
agonists	O	O
may	O	O
be	O	O
designed	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
the	O	O
(	O	O
N	O	O
)	O	O
-	O	O
conformation	O	O
,	O	O
which	O	O
greatly	O	O
enhanced	O	O
potency	O	O
at	O	O
P2Y	O	O
(	O	O
1	O	O
)	O	O
receptors	O	O
.	O	O
The	O	O
MAP	O	O
facility	O	O
within	O	O
the	O	O
Chem	O	O
-	O	O
X	O	O
molecular	O	O
modeling	O	O
program	O	O
was	O	O
then	O	O
used	O	O
to	O	O
calculate	O	O
the	O	O
region	O	O
of	O	O
steric	O	O
interference	O	O
(	O	O
termed	O	O
the	O	O
receptor	O	O
essential	O	O
volume	O	O
,	O	O
REV	O	O
)	O	O
from	O	O
these	O	O
accessible	O	O
conformers	O	O
.	O	O
Nonclassical	O	O
antifolates	O	O
,	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	O
substituted	I-IUPAC	B-MODIFIER
-	I-IUPAC	O
furo	I-IUPAC	O
[	I-IUPAC	B-IUPAC
2	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidines	I-IUPAC	I-IUPAC
3-12	O	O
with	O	O
bridge	O	O
region	O	O
variations	O	O
of	O	O
C8	O	O
-	O	O
S9	O	O
,	O	O
C8	O	O
-	O	O
N9	O	O
,	O	O
and	O	O
C8	O	O
-	O	O
O9	O	O
and	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
naphthyl	I-IUPAC	I-IUPAC
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
naphthyl	I-IUPAC	I-IUPAC
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenoxyphenyl	I-IUPAC	I-IUPAC
,	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenoxyphenyl	I-IUPAC	I-IUPAC
,	O	O
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
biphenyl	I-IUPAC	I-IUPAC
side	B-MODIFIER	B-MODIFIER
chains	I-MODIFIER	I-MODIFIER
were	O	O
synthesized	O	O
as	O	O
phenyl	O	O
ring	O	O
appended	O	O
analogues	O	O
of	O	O
previously	O	O
reported	O	O
2	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
anilinomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
furo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidines	I-IUPAC	I-IUPAC
.	O	O
Novel	O	O
requisite	O	O
heterocycles	B-MODIFIER	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinone	I-IUPAC	I-IUPAC
(	O	O
7a	O	O
)	O	O
and	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bromo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinone	I-IUPAC	I-IUPAC
(	O	O
7b	O	O
)	O	O
were	O	O
prepared	O	O
by	O	O
halogenating	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinone	I-IUPAC	I-IUPAC
(	O	O
5	O	O
)	O	O
.	O	O
New	O	O
boron	O	O
-	O	O
containing	O	O
polyamine	O	O
have	O	O
been	O	O
synthesized	O	O
:	O	O
(	B-IUPAC	B-IUPAC
aminoalkylamine	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
aminoalkyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
azanonaborane	I-IUPAC	I-IUPAC
(	O	O
11	O	O
)	O	O
derivatives	B-MODIFIER	O
[	O	O
H	O	O
(	O	O
2	O	O
)	O	O
N	O	O
(	O	O
CH	O	O
(	O	O
2	O	O
)	O	O
)	O	O
(	O	O
n	O	O
)	O	O
H	O	O
(	O	O
2	O	O
)	O	O
NB	O	O
(	O	O
8	O	O
)	O	O
H	O	O
(	O	O
11	O	O
)	O	O
NH	O	O
(	O	O
CH	O	O
(	O	O
2	O	O
)	O	O
)	O	O
(	O	O
n	O	O
)	O	O
NH	O	O
(	O	O
2	O	O
)	O	O
]	O	O
,	O	O
where	O	O
n	O	O
=	O	O
4-6	O	O
and	O	O
12	O	O
,	O	O
and	O	O
[	O	O
H	O	O
(	O	O
2	O	O
)	O	O
N	O	O
(	O	O
CH	O	O
(	O	O
2	O	O
)	O	O
)	O	O
(	O	O
3	O	O
)	O	O
H	O	O
(	O	O
2	O	O
)	O	O
NB	O	O
(	O	O
8	O	O
)	O	O
H	O	O
(	O	O
11	O	O
)	O	O
NH	O	O
(	O	O
CH	O	O
(	O	O
2	O	O
)	O	O
)	O	O
(	O	O
4	O	O
)	O	O
NH	O	O
(	O	O
2	O	O
)	O	O
]	O	O
.	O	O
The	O	O
rat	O	O
antipressor	O	O
potency	O	O
of	O	O
[	B-IUPAC	B-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deaminopenicillamine	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
oxytocin	I-IUPAC	I-IUPAC
was	O	O
also	O	O
determined	O	O
in	O	O
this	O	O
study	O	O
:	O	O
pA2	O	O
=	O	O
6.27	O	O
.	O	O
The	O	O
tested	O	O
compounds	O	O
showed	O	O
high	O	O
affinity	O	O
for	O	O
5	O	O
-	O	O
HT	O	O
(	O	O
1A	O	O
)	O	O
and	O	O
alpha	O	O
(	O	O
1	O	O
)	O	O
receptors	O	O
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
1.1-87	O	O
and	O	O
10-62	O	O
nM	O	O
,	O	O
respectively	O	O
)	O	O
and	O	O
moderate	O	O
to	O	O
low	O	O
affinity	O	O
for	O	O
5	O	O
-	O	O
HT	O	O
(	O	O
2A	O	O
)	O	O
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
56-881	O	O
nM	O	O
)	O	O
and	O	O
D	O	O
(	O	O
2	O	O
)	O	O
receptors	O	O
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
94-1245	O	O
nM	O	O
)	O	O
.	O	O
An	O	O
alternate	O	O
procedure	O	O
which	O	O
consisted	O	O
of	O	O
reacting	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
formylpyridine	I-IUPAC	I-IUPAC
ethylene	I-IUPAC	I-IUPAC
acetal	I-IUPAC	I-IUPAC
with	O	O
various	O	O
amines	O	O
,	O	O
followed	O	O
by	O	O
hydrolysis	O	O
and	O	O
reaction	O	O
with	O	O
thiosemicarbazide	O	O
,	O	O
was	O	O
also	O	O
employed	O	O
.	O	O
8	O	O
was	O	O
shown	O	O
to	O	O
be	O	O
photochemically	O	O
active	O	O
and	O	O
is	O	O
a	O	O
potential	O	O
photoaffinity	O	O
label	O	O
for	O	O
the	O	O
recognition	O	O
site	O	O
of	O	O
the	O	O
AMPA	O	O
receptors	O	O
.	O	O
Compounds	O	O
7a	O	O
-	O	O
c	O	O
failed	O	O
to	O	O
increase	O	O
the	O	O
life	O	O
span	O	O
of	O	O
mice	O	O
infected	O	O
with	O	O
B16	O	O
melanoma	O	O
.	O	O
A	O	O
substitution	O	O
of	O	O
DTrp	O	O
(	O	O
8	O	O
)	O	O
by	O	O
D2Nal	O	O
(	O	O
8	O	O
)	O	O
in	O	O
7	O	O
to	O	O
yield	O	O
des	O	O
-	O	O
AA	O	O
(	O	O
1,2,5	O	O
)	O	O
-	O	O
[	O	O
D2Nal	O	O
(	O	O
8	O	O
)	O	O
,	O	O
IAmp	O	O
(	O	O
9	O	O
)	O	O
]	O	O
-	O	O
SRIF	O	O
(	O	O
13	O	O
)	O	O
and	O	O
in	O	O
16	O	O
to	O	O
yield	O	O
des	O	O
-	O	O
AA	O	O
(	O	O
1,5	O	O
)	O	O
-	O	O
[	O	O
Tyr	O	O
(	O	O
2	O	O
)	O	O
,	O	O
D2Nal	O	O
(	O	O
8	O	O
)	O	O
,	O	O
IAmp	O	O
(	O	O
9	O	O
)	O	O
]	O	O
-	O	O
SRIF	O	O
(	O	O
17	O	O
)	O	O
was	O	O
intended	O	O
to	O	O
increase	O	O
chemical	O	O
stability	O	O
,	O	O
selectivity	O	O
,	O	O
and	O	O
affinity	O	O
and	O	O
resulted	O	O
in	O	O
two	O	O
analogues	O	O
that	O	O
were	O	O
less	O	O
potent	O	O
or	O	O
equipotent	O	O
with	O	O
similar	O	O
selectivity	O	O
,	O	O
respectively	O	O
.	O	O
The	O	O
family	O	O
of	O	O
cyclosteroids	O	O
should	O	O
be	O	O
useful	O	O
for	O	O
future	O	O
structure	O	O
-	O	O
activity	O	O
relationship	O	O
studies	O	O
of	O	O
steroid	O	O
modulation	O	O
of	O	O
other	O	O
GABA	O	O
(	O	O
A	O	O
)	O	O
receptor	O	O
subtypes	O	O
.	O	O
All	O	O
the	O	O
bromomethylpyrazole	O	O
nucleosides	O	O
described	O	O
showed	O	O
significant	O	O
cytostatic	O	O
activity	O	O
against	O	O
HeLa	O	O
cell	O	O
cultures	O	O
.	O	O
A	O	O
number	O	O
of	O	O
3	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
bromo	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
,	O	O
3	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
nitro	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
,	O	O
and	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ethoxycarbonyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dialkylpyrazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidines	I-IUPAC	I-IUPAC
were	O	O
synthesized	O	O
and	O	O
screened	O	O
as	O	O
in	O	O
vitro	O	O
cAMP	O	O
phosphodiesterase	O	O
inhibitors	O	O
.	O	O
The	O	O
presence	O	O
of	O	O
a	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyl	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
increased	O	O
selectivity	O	O
of	O	O
flavonols	O	O
for	O	O
human	O	O
A3	O	O
receptors	O	O
.	O	O
Two	O	O
of	O	O
the	O	O
designed	O	O
ligands	O	O
(	O	O
10e	O	O
and	O	O
10f	O	O
)	O	O
showed	O	O
the	O	O
highest	O	O
affinities	O	O
(	O	O
34	O	O
and	O	O
24	O	O
nM	O	O
,	O	O
respectively	O	O
)	O	O
reported	O	O
so	O	O
far	O	O
for	O	O
a	O	O
DAG	O	O
analogue	O	O
.	O	O
In	O	O
contrast	O	O
,	O	O
reaction	O	O
of	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iodoethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
(	O	O
11a	O	O
)	O	O
with	O	O
sodium	O	O
carbonate	O	O
in	O	O
methanol	O	O
afforded	O	O
a	O	O
mixture	O	O
of	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxyethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
(	O	O
13	O	O
)	O	O
and	O	O
2,3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ribofuranosyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
furano	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
(	O	O
14	O	O
)	O	O
.	O	O
The	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
allylindoline	I-IUPAC	I-IUPAC
4d	O	O
is	O	O
more	O	O
potent	O	O
than	O	O
idazoxan	O	O
in	O	O
vitro	O	O
and	O	O
is	O	O
equipotent	O	O
in	O	O
vivo	O	O
,	O	O
but	O	O
is	O	O
less	O	O
receptor	O	O
selective	O	O
(	O	O
alpha	O	O
2	O	O
vs.	O	O
alpha	O	O
1	O	O
)	O	O
than	O	O
idazoxan	O	O
.	O	O
Condensation	O	O
of	O	O
2	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
(	I-PARTIUPAC	I-PARTIUPAC
tert	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
butylsulfenyl	I-PARTIUPAC	I-PARTIUPAC
)	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carbomethoxyethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
sulfenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
tryptophan	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
ester	I-IUPAC	I-IUPAC
,	O	O
obtained	O	O
by	O	O
reaction	O	O
of	O	O
methyl	B-IUPAC	B-IUPAC
3a	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,3,3	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
8,8	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hexahydropyrrolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
indole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxyla	I-IUPAC	I-IUPAC
te	I-IUPAC	O
with	O	O
the	O	O
corresponding	O	O
thiol	O	O
,	O	O
with	O	O
Z	O	O
-	O	O
Lys	O	O
(	O	O
Z	O	O
)	O	O
-	O	O
OSu	O	O
afforded	O	O
Z	O	O
-	O	O
Lys	O	O
(	O	O
Z	O	O
)	O	O
-	O	O
Trp	O	O
(	O	O
t	O	O
-	O	O
BuS	O	O
)	O	O
-	O	O
OMe	O	O
and	O	O
Z	O	O
-	O	O
Lys	O	O
(	O	O
Z	O	O
)	O	O
-	O	O
Trp	O	O
(	O	O
CmES	O	O
)	O	O
-	O	O
OMe	O	O
,	O	O
which	O	O
on	O	O
treatment	O	O
with	O	O
Me3SiI	O	O
/	O	O
CH3CN	O	O
provided	O	O
23	O	O
and	O	O
24	O	O
,	O	O
respectively	O	O
.	O	O
1c	O	O
was	O	O
equally	O	O
potent	O	O
against	O	O
a	O	O
CHO	O	O
variant	O	O
that	O	O
was	O	O
20	O	O
-	O	O
fold	O	O
resistant	O	O
to	O	O
FU	O	O
.	O	O
Polyamines	O	O
containing	O	O
two	O	O
nitrogen	O	O
atoms	O	O
showed	O	O
optimal	O	O
binding	O	O
at	O	O
both	O	O
sigma	O	O
-	O	O
1	O	O
and	O	O
sigma	O	O
-	O	O
2	O	O
receptor	O	O
subtypes	O	O
.	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
galactose	I-IUPAC	I-IUPAC
and	O	O
its	O	O
enantiomer	O	O
4a	O	O
were	O	O
found	O	O
to	O	O
be	O	O
effective	O	O
inhibitors	O	O
of	O	O
D	B-IUPAC	O
-	I-IUPAC	O
[	I-IUPAC	O
3H	I-IUPAC	O
]	I-IUPAC	O
galactose	I-IUPAC	O
and	O	O
L	B-IUPAC	O
-	I-IUPAC	O
[	I-IUPAC	O
3H	I-IUPAC	O
]	I-IUPAC	O
fucose	I-IUPAC	O
incorporation	O	O
,	O	O
respectively	O	O
,	O	O
into	O	O
macromolecular	O	O
components	O	O
of	O	O
human	O	O
mammary	O	O
tumor	O	O
cells	O	O
.	O	O
The	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nitrobenzyladenine	I-IUPAC	I-IUPAC
and	O	O
its	O	O
ribonucleoside	O	O
were	O	O
found	O	O
to	O	O
be	O	O
noncompetitive	O	O
inhibitors	O	O
of	O	O
adenosine	O	O
aminohydrolase	O	O
.	O	O
As	O	O
with	O	O
DENSPM	O	O
and	O	O
(	O	O
2R	O	O
,	O	O
10R	O	O
)	O	O
-	O	O
(	O	O
HO	O	O
)	O	O
(	O	O
2	O	O
)	O	O
DENSPM	O	O
,	O	O
both	O	O
cyclopropyl	B-PARTIUPAC	O
analogues	B-MODIFIER	O
diminished	O	O
ornithine	O	O
decarboxylase	O	O
and	O	O
S	B-IUPAC	O
-	I-IUPAC	O
adenosylmethionine	I-IUPAC	O
decarboxylase	O	O
activity	O	O
.	O	O
The	O	O
incorporation	O	O
of	O	O
these	O	O
residues	O	O
in	O	O
the	O	O
mAZ	O	O
-	O	O
pTyr	O	O
-	O	O
Xaa	O	O
-	O	O
Asn	O	O
-	O	O
NH2	O	O
series	O	O
provided	O	O
compounds	O	O
with	O	O
very	O	O
high	O	O
affinity	O	O
for	O	O
the	O	O
Grb2	O	O
SH2	O	O
domain	O	O
,	O	O
in	O	O
the	O	O
10	O	O
(	O	O
-	O	O
8	O	O
)	O	O
-	O	O
10	O	O
(	O	O
-	O	O
9	O	O
)	O	O
range	O	O
of	O	O
Kd	O	O
values	O	O
.	O	O
Compound	O	O
3	O	O
inhibited	O	O
the	O	O
growth	O	O
of	O	O
tumor	O	O
cells	O	O
in	O	O
culture	O	O
(	O	O
IC50	O	O
10	O	O
(	O	O
-	O	O
7	O	O
)	O	O
M	O	O
)	O	O
while	O	O
4	O	O
showed	O	O
a	O	O
low	O	O
level	O	O
of	O	O
growth	O	O
inhibitory	O	O
activity	O	O
.	O	O
Specifically	O	O
-	O	O
CH2CH2	O	O
-	O	O
and	O	O
-	O	O
CH2NHCH2	O	O
-	O	O
bridged	O	O
analogues	O	O
,	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diaminofuro	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzoyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
glutamic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
3	O	O
)	O	O
and	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diaminofuro	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzoyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
glutamic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
4	O	O
)	O	O
,	O	O
respectively	O	O
,	O	O
were	O	O
synthesized	O	O
.	O	O
Both	O	O
the	O	O
interaction	O	O
with	O	O
the	O	O
receptor	O	O
and	O	O
inhibition	O	O
of	O	O
cell	O	O
growth	O	O
by	O	O
these	O	O
two	O	O
glucocorticoids	O	O
are	O	O
reversible	O	O
.	O	O
Structural	O	O
alterations	O	O
in	O	O
both	O	O
series	O	O
did	O	O
little	O	O
to	O	O
enhance	O	O
the	O	O
inhibitory	O	O
activity	O	O
of	O	O
the	O	O
parent	O	O
compounds	O	O
2,6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydroxyacetophenone	I-IUPAC	I-IUPAC
(	O	O
3	O	O
)	O	O
and	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydroxyacetophenone	I-IUPAC	I-IUPAC
(	O	O
27	O	O
)	O	O
.	O	O
These	O	O
monomethyl	O	O
ester	O	O
precursors	O	O
were	O	O
synthesized	O	O
from	O	O
the	O	O
known	O	O
analogous	O	O
aldehyde	O	O
via	O	O
an	O	O
O	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
trimethylsilyl	I-IUPAC	I-IUPAC
cyanohydrin	I-IUPAC	I-IUPAC
.	O	O
To	O	O
investigate	O	O
the	O	O
fate	O	O
of	O	O
radiolabels	O	O
after	O	O
lysosomal	O	O
proteolysis	O	O
,	O	O
hepatic	O	O
parenchymal	O	O
cells	O	O
were	O	O
used	O	O
as	O	O
a	O	O
model	O	O
nontarget	O	O
tissue	O	O
and	O	O
131I	O	O
-	O	O
labeled	O	O
MIH	O	O
was	O	O
conjugated	O	O
with	O	O
galactosyl	O	B-IUPAC
-	O	I-IUPAC
neoglycoalbumin	O	I-IUPAC
(	O	O
NGA	O	O
)	O	O
.	O	O
A	O	O
series	O	O
of	O	O
osteotropic	O	O
(	O	O
bone	O	O
-	O	O
seeking	O	O
)	O	O
[	B-IUPAC	O
(	I-IUPAC	B-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phosphonomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
kappaN	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
acetato	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
kappaO	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
platinum	I-IUPAC	I-IUPAC
(	I-IUPAC	O
II	I-IUPAC	O
)	I-IUPAC	O
complexes	B-MODIFIER	O
attached	O	O
to	O	O
diammine	B-IUPAC	O
,	O	O
ethane	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diamine	I-IUPAC	I-IUPAC
,	O	O
cis	B-IUPAC	O
-	I-IUPAC	O
R	I-IUPAC	O
,	I-IUPAC	O
S	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
cyclohexane	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diamine	I-IUPAC	I-IUPAC
,	O	O
trans	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyclohexane	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diamine	I-IUPAC	I-IUPAC
,	O	O
or	O	O
trans	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
R	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
R	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyclohexane	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diamine	I-IUPAC	I-IUPAC
has	O	O
been	O	O
synthesized	O	O
in	O	O
accord	O	O
with	O	O
the	O	O
concept	O	O
of	O	O
drug	O	O
targeting	O	O
and	O	O
characterized	O	O
by	O	O
elemental	O	O
analysis	O	O
,	O	O
(	O	O
1	O	O
)	O	O
H	O	O
,	O	O
(	O	O
13	O	O
)	O	O
C	O	O
,	O	O
and	O	O
(	O	O
31	O	O
)	O	O
P	O	O
NMR	O	O
spectroscopy	O	O
.	O	O
In	O	O
the	O	O
second	O	O
approach	O	O
,	O	O
the	O	O
iodination	O	O
of	O	O
a	O	O
17	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
18,19,20	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trinorprostaglandin	I-IUPAC	I-IUPAC
F2	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	O
delivered	O	O
17	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
azido	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iodophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
18,19,20	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trinorprostaglandin	I-IUPAC	I-IUPAC
F2	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
,	O	O
which	O	O
exhibited	O	O
competitive	O	O
binding	O	O
with	O	O
natural	O	O
[	O	O
3H	O	O
]	O	O
PGF2	O	O
alpha	O	O
to	O	O
ovine	O	O
luteal	O	O
cells	O	O
and	O	O
to	O	O
plasma	O	O
membranes	O	O
of	O	O
bovine	O	O
corpora	O	O
lutea	O	O
.	O	O
These	O	O
compounds	O	O
and	O	O
the	O	O
corresponding	O	O
4	B-IUPAC	B-PARTIUPAC
-	I-IUPAC	I-PARTIUPAC
amino	I-IUPAC	I-PARTIUPAC
-	O	I-PARTIUPAC
and	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyimidazol	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
c	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,2,6	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
thiadiazine	I-IUPAC	I-IUPAC
2,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dioxides	I-IUPAC	I-IUPAC
were	O	O
examined	O	O
as	O	O
potential	O	O
transition	O	O
-	O	O
state	O	O
analogue	O	O
inhibitors	O	O
of	O	O
xanthine	O	O
oxidase	O	O
and	O	O
guanine	O	O
aminohydrolase	O	O
.	O	O
The	O	O
corresponding	O	O
unsaturated	O	O
analog	O	O
of	O	O
11	O	O
,	O	O
compound	O	O
14	O	O
,	O	O
showed	O	O
a	O	O
slightly	O	O
weaker	O	O
receptor	O	O
affinity	O	O
(	O	O
IC50	O	O
=	O	O
4.0	O	O
+	O	O
/	O	O
-	O	O
2.0	O	O
microM	O	O
)	O	O
but	O	O
a	O	O
significantly	O	O
higher	O	O
relative	O	O
efficacy	O	O
(	O	O
50-55%	O	O
)	O	O
than	O	O
11	O	O
.	O	O
Reductive	O	O
dialkylation	O	O
of	O	O
THF	O	O
with	O	O
formaldehyde	O	O
gave	O	O
5,10	O	O
-	O	O
(	O	O
CH3	O	O
)	O	O
2	O	O
-	O	O
THF	O	O
(	O	O
27	O	O
)	O	O
,	O	O
whereas	O	O
glyoxal	O	O
gave	O	O
5,10	O	O
-	O	O
CH2CH2	O	O
)	O	O
-	O	O
THF	O	O
(	O	O
10	O	O
)	O	O
.	O	O
These	O	O
substitutions	O	O
were	O	O
designed	O	O
to	O	O
probe	O	O
the	O	O
spatial	O	O
limitations	O	O
of	O	O
the	O	O
receptor	O	O
's	O	O
cavity	O	O
and	O	O
to	O	O
map	O	O
the	O	O
steric	O	O
and	O	O
ionic	O	O
boundaries	O	O
.	O	O
Finally	O	O
,	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chlorothien	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
arabinofuranosyluracil	I-IUPAC	I-IUPAC
and	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bromothien	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
arabinofuranosyluracil	I-IUPAC	I-IUPAC
were	O	O
obtained	O	O
by	O	O
halogenation	O	O
of	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
thien	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
arabinofuranosyluracil	I-IUPAC	I-IUPAC
.	O	O
None	O	O
of	O	O
these	O	O
new	O	O
compounds	O	O
showed	O	O
detectable	O	O
effects	O	O
at	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aspartic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
NMDA	O	O
)	O	O
or	O	O
kainic	O	O
acid	O	O
receptors	O	O
in	O	O
vitro	O	O
.	O	O
Both	O	O
were	O	O
found	O	O
to	O	O
be	O	O
substantially	O	O
longer	O	O
acting	O	O
after	O	O
oral	O	O
administration	O	O
than	O	O
the	O	O
corresponding	O	O
S	O	O
enantiomers	O	O
in	O	O
the	O	O
guinea	O	O
pig	O	O
bronchoconstriction	O	O
assay	O	O
.	O	O
1994	O	O
,	O	O
116	O	O
,	O	O
429-436	O	O
)	O	O
.	O	O
This	O	O
was	O	O
converted	O	O
to	O	O
(	B-IUPAC	B-IUPAC
+	I-IUPAC	I-IUPAC
/	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,12	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
azanaphthacene	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6,11	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dione	I-IUPAC	I-IUPAC
by	O	O
dehydration	O	O
to	O	O
the	O	O
4	B-IUPAC	O
-	I-IUPAC	O
keto	I-IUPAC	O
analogue	B-MODIFIER	O
followed	O	O
by	O	O
cyanoborohydride	O	O
reduction	O	O
either	O	O
stepwise	O	O
or	O	O
in	O	O
situ	O	O
.	O	O
Our	O	O
studies	O	O
identify	O	O
an	O	O
absolute	O	O
requirement	O	O
for	O	O
the	O	O
carboxylic	O	O
acid	O	O
moiety	O	O
on	O	O
the	O	O
aromatic	O	O
ring	O	O
to	O	O
be	O	O
para	O	O
relative	O	O
to	O	O
the	O	O
amide	O	O
linkage	O	O
for	O	O
activity	O	O
.	O	O
All	O	O
of	O	O
the	O	O
diamidines	O	O
showed	O	O
strong	O	O
DNA	O	O
affinities	O	O
as	O	O
judged	O	O
by	O	O
high	O	O
DeltaT	O	O
(	O	O
m	O	O
)	O	O
values	O	O
.	O	O
)	O	O
afforded	O	O
symmetrical	O	O
dialkylpyrazolo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
1,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidines	I-IUPAC	I-IUPAC
(	O	O
5	O	O
)	O	O
.	O	O
Pyrazolo	O	B-IUPAC
[	O	I-IUPAC
3,4	O	I-IUPAC
-	O	I-IUPAC
d	O	I-IUPAC
]	O	I-IUPAC
pyrimidines	O	I-IUPAC
are	O	O
pyrazolo	O	O
analogues	O	O
of	O	O
purines	O	O
.	O	O
Its	O	O
inhibitory	O	O
activity	O	O
in	O	O
IL	O	O
-	O	O
4	O	O
production	O	O
test	O	O
from	O	O
Th	O	O
-	O	O
2	O	O
cells	O	O
was	O	O
identical	O	O
to	O	O
that	O	O
of	O	O
the	O	O
reference	O	O
histamine	O	O
antagonist	O	O
(	O	O
IC50	O	O
=	O	O
8.0	O	O
microM	O	O
)	O	O
and	O	O
twice	O	O
higher	O	O
in	O	O
IL	O	O
-	O	O
5	O	O
assay	O	O
:	O	O
IC50	O	O
=	O	O
1.5	O	O
and	O	O
3.3	O	O
microM	O	O
,	O	O
respectively	O	O
.	O	O
The	O	O
most	O	O
potent	O	O
compound	O	O
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
diethylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1benzothieno2	I-IUPAC	I-IUPAC
,	I-IUPAC	O
3	I-IUPAC	O
-	I-IUPAC	O
d1	I-IUPAC	O
,	I-IUPAC	O
3	I-IUPAC	O
\C5	I-IUPAC	O
\8F	I-IUPAC	O
xazin	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
,	O	O
exhibited	O	O
a	O	O
K	O	O
(	O	O
i	O	O
)	O	O
value	O	O
of	O	O
5.8	O	O
nM	O	O
.	O	O
Long	O	O
duration	O	O
of	O	O
action	O	O
was	O	O
demonstrated	O	O
both	O	O
in	O	O
ex	O	O
vivo	O	O
binding	O	O
(	O	O
T1/2	O	O
approximately	O	O
20	O	O
h	O	O
)	O	O
and	O	O
in	O	O
the	O	O
black	O	O
/	O	O
white	O	O
box	O	O
exploration	O	O
test	O	O
.	O	O
In	O	O
addition	O	O
,	O	O
3	O	O
was	O	O
equipotent	O	O
with	O	O
1	O	O
and	O	O
2	O	O
in	O	O
[	O	O
(	O	O
3	O	O
)	O	O
H	O	O
]	O	O
dopamine	O	O
uptake	O	O
inhibition	O	O
studies	O	O
,	O	O
while	O	O
4	O	O
was	O	O
10	O	O
-	O	O
fold	O	O
less	O	O
potent	O	O
.	O	O
The	O	O
benzopyran	O	O
and	O	O
naphthopyran	O	O
derivatives	O	O
were	O	O
prepared	O	O
by	O	O
the	O	O
classical	O	O
von	O	O
Pechmann	O	O
reaction	O	O
.	O	O
Of	O	O
those	O	O
,	O	O
some	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
acylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carbamoylimidazoles	I-IUPAC	I-IUPAC
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
thioalkyl	I-IUPAC	I-IUPAC
-	O	O
substituted	B-MODIFIER	O
purines	B-IUPAC	O
exhibited	O	O
very	O	O
good	O	O
inhibitory	O	O
activity	O	O
,	O	O
being	O	O
at	O	O
least	O	O
500	O	O
times	O	O
more	O	O
effective	O	O
than	O	O
allopurinol	O	O
.	O	O
These	O	O
compounds	O	O
will	O	O
allow	O	O
further	O	O
study	O	O
of	O	O
the	O	O
structure	O	O
and	O	O
function	O	O
of	O	O
the	O	O
"	O	O
cocaine	O	O
"	O	O
receptor	O	O
as	O	O
well	O	O
as	O	O
the	O	O
development	O	O
of	O	O
potential	O	O
cocaine	O	O
antagonists	O	O
.	O	O
Compounds	O	O
(	O	O
+	O	O
)	O	O
-	O	O
1	O	O
,	O	O
(	O	O
-	O	O
)	O	O
-	O	O
1	O	O
,	O	O
(	O	O
-	O	O
)	O	O
-	O	O
2	O	O
,	O	O
and	O	O
(	O	O
+	O	O
)	O	O
-	O	O
2	O	O
were	O	O
compared	O	O
for	O	O
their	O	O
binding	O	O
affinities	O	O
at	O	O
kappa	O	O
opioid	O	O
,	O	O
sigma	O	O
,	O	O
D2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dopamine	I-IUPAC	I-IUPAC
,	O	O
and	O	O
phencyclidine	O	O
(	O	O
PCP	O	O
)	O	O
receptors	O	O
in	O	O
competitive	O	O
binding	O	O
assays	O	O
using	O	O
[	O	O
3H	O	O
]	O	O
bremazocine	O	O
(	O	O
[	O	O
3H	O	O
]	O	O
BREM	O	O
)	O	O
or	O	O
[	O	O
3H	O	O
]	O	O
U69	O	O
,	O	O
593	O	O
,	O	O
[	B-IUPAC	B-IUPAC
3H	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
+	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
piperidine	I-IUPAC	I-IUPAC
[	O	O
[	O	O
3H	O	O
]	O	O
-	O	O
(	O	O
+	O	O
)	O	O
-	O	O
3	O	O
-	O	O
PPP	O	O
]	O	O
,	O	O
or	O	O
[	B-IUPAC	B-IUPAC
3H	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
di	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
o	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tolyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
guanidine	I-IUPAC	I-IUPAC
(	O	O
[	O	O
3H	O	O
]	O	O
DTG	O	O
)	O	O
,	O	O
[	B-IUPAC	B-IUPAC
3H	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
sulpiride	I-IUPAC	I-IUPAC
[	O	O
[	O	O
3H	O	O
]	O	O
-	O	O
(	O	O
-	O	O
)	O	O
SULP	O	O
]	O	O
,	O	O
and	O	O
[	B-IUPAC	B-IUPAC
3H	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thienyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
cyclohexyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
piperidine	I-IUPAC	I-IUPAC
(	O	O
[	O	O
3H	O	O
]	O	O
TCP	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O
The	O	O
synthesis	O	O
of	O	O
various	O	O
substituted	B-MODIFIER	B-MODIFIER
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinecarboxylic	I-IUPAC	I-IUPAC
acids	I-IUPAC	I-IUPAC
and	O	O
their	O	O
derivatives	O	O
is	O	O
described	O	O
by	O	O
three	O	O
general	O	O
methods	O	O
:	O	O
(	O	O
1	O	O
)	O	O
reductive	O	O
alkylation	O	O
of	O	O
methyl	B-IUPAC	B-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinecarboxylates	I-IUPAC	I-IUPAC
(	O	O
2	O	O
)	O	O
and	O	O
subsequent	O	O
hydrolysis	O	O
;	O	O
(	O	O
2	O	O
)	O	O
alkylation	O	O
of	O	O
the	O	O
urethane	O	O
(	O	O
9	O	O
)	O	O
,	O	O
followed	O	O
by	O	O
hydrolysis	O	O
;	O	O
and	O	O
(	O	O
3	O	O
)	O	O
selective	O	O
NaBH4	O	O
reduction	O	O
of	O	O
the	O	O
appropriate	O	O
amide	O	O
of	O	O
(	O	O
2	O	O
)	O	O
,	O	O
followed	O	O
by	O	O
hydrolysis	O	O
.	O	O
Although	O	O
beta	B-IUPAC	O
,	I-IUPAC	O
gamma	I-IUPAC	O
-	I-IUPAC	O
methylene	I-IUPAC	O
-	I-IUPAC	O
ATP	I-IUPAC	O
was	O	O
inactive	O	O
at	O	O
P2Y	O	O
receptors	O	O
,	O	O
beta	B-IUPAC	O
,	I-IUPAC	O
gamma	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methylene	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methanocarba	I-IUPAC	I-IUPAC
-	I-IUPAC	O
ATP	I-IUPAC	O
was	O	O
a	O	O
potent	O	O
hP2Y	O	O
(	O	O
1	O	O
)	O	O
receptor	O	O
agonist	O	O
with	O	O
an	O	O
EC	O	O
(	O	O
50	O	O
)	O	O
of	O	O
160	O	O
nM	O	O
and	O	O
was	O	O
selective	O	O
versus	O	O
hP2Y	O	O
(	O	O
2	O	O
)	O	O
and	O	O
hP2Y	O	O
(	O	O
4	O	O
)	O	O
receptors	O	O
.	O	O
Unexpectedly	O	O
it	O	O
was	O	O
not	O	O
possible	O	O
to	O	O
remove	O	O
the	O	O
N	B-IUPAC	O
-	I-IUPAC	O
trifluoroacetyl	I-IUPAC	O
blocking	B-MODIFIER	O
group	I-MODIFIER	O
without	O	O
aromatization	O	O
to	O	O
the	O	O
azanaphthaquinone	O	O
.	O	O
Other	O	O
potent	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
compounds	B-MODIFIER	B-MODIFIER
are	O	O
those	O	O
in	O	O
which	O	O
the	O	O
heterocyclic	O	O
imine	O	O
is	O	O
replaced	O	O
with	O	O
pyrrolidine	O	O
(	O	O
19	O	O
)	O	O
(	O	O
IC50	O	O
9	O	O
nM	O	O
)	O	O
or	O	O
trimethylammonium	O	O
(	O	O
22	O	O
)	O	O
(	O	O
IC50	O	O
18	O	O
nM	O	O
)	O	O
.	O	O
The	O	O
binding	O	O
affinity	O	O
of	O	O
the	O	O
multimeric	O	O
RGD	O	O
compounds	O	O
for	O	O
alpha	O	O
(	O	O
v	O	O
)	O	O
beta	O	O
(	O	O
3	O	O
)	O	O
integrin	O	O
receptor	O	O
(	O	O
ABIR	O	O
)	O	O
showed	O	O
a	O	O
remarkable	O	O
increase	O	O
relative	O	O
to	O	O
the	O	O
monomer	O	O
cypate	O	O
-	O	O
RGD	O	O
-	O	O
NH	O	O
(	O	O
2	O	O
)	O	O
.	O	O
The	O	O
T	O	O
/	O	O
C	O	O
values	O	O
of	O	O
281	O	O
and	O	O
300	O	O
were	O	O
obtained	O	O
for	O	O
compounds	O	O
11	O	O
and	O	O
12	O	O
,	O	O
respectively	O	O
,	O	O
in	O	O
the	O	O
case	O	O
of	O	O
mice	O	O
bearing	O	O
EAC	O	O
cells	O	O
.	O	O
Furthermore	O	O
,	O	O
(	B-IUPAC	B-IUPAC
3RS	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4SR	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxypiperidine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
14	O	O
)	O	O
,	O	O
related	O	O
to	O	O
the	O	O
specific	O	O
GABA	O	O
agonist	O	O
piperidine	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
isonipecotic	O	O
acid	O	O
)	O	O
,	O	O
has	O	O
been	O	O
synthesized	O	O
.	O	O
Base	O	O
-	O	O
catalyzed	O	O
elimination	O	O
of	O	O
HBr	O	O
resulted	O	O
in	O	O
the	O	O
formation	O	O
of	O	O
(	B-PARTIUPAC	B-PARTIUPAC
Z	I-PARTIUPAC	I-PARTIUPAC
)	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
(	B-IUPAC	B-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylenecyclopropanecarboxylic	I-IUPAC	I-IUPAC
esters	I-IUPAC	I-IUPAC
26	O	O
+	O	O
27	O	O
.	O	O
Deprotection	O	O
of	O	O
the	O	O
key	O	O
intermediate	O	O
1,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
di	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
allyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,5,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tri	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxybenzyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
myo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
inositol	I-IUPAC	I-IUPAC
by	O	O
isomerization	O	O
of	O	O
allyl	O	O
groups	O	O
followed	O	O
by	O	O
mild	O	O
acid	O	O
hydrolysis	O	O
gave	O	O
2,4,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
tri	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxybenzyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
myo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
inositol	I-IUPAC	I-IUPAC
,	O	O
which	O	O
was	O	O
converted	O	O
to	O	O
the	O	O
diastereoisomeric	O	O
(	O	O
bis	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
camphanates	I-IUPAC	I-IUPAC
.	O	O
The	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
values	O	O
ranged	O	O
from	O	O
0.5	O	O
to	O	O
26	O	O
nM	O	O
.	O	O
However	O	O
,	O	O
their	O	O
usefulness	O	O
for	O	O
in	O	O
vivo	O	O
chelation	O	O
of	O	O
actinide	O	O
(	O	O
IV	O	O
)	O	O
is	O	O
limited	O	O
,	O	O
because	O	O
catechol	O	O
and	O	O
hydroxamate	O	O
are	O	O
such	O	O
weak	O	O
acids	O	O
that	O	O
the	O	O
potential	O	O
for	O	O
octadentate	O	O
binding	O	O
of	O	O
actinide	O	O
(	O	O
IV	O	O
)	O	O
cannot	O	O
be	O	O
achieved	O	O
at	O	O
physiological	O	O
pH	O	O
.	O	O
In	O	O
the	O	O
colon	O	O
cancer	O	O
cell	O	O
studies	O	O
,	O	O
trans	O	O
-	O	O
[	O	O
PtCl2	O	O
(	O	O
NH3	O	O
)	O	O
(	O	O
pip	O	O
-	O	O
pip	O	O
)	O	O
]	O	O
x	O	O
HCl	O	O
was	O	O
slightly	O	O
less	O	O
potent	O	O
than	O	O
cisplatin	O	O
in	O	O
the	O	O
in	O	O
vitro	O	O
studies	O	O
but	O	O
had	O	O
efficacy	O	O
comparable	O	O
to	O	O
that	O	O
of	O	O
cisplatin	O	O
in	O	O
the	O	O
in	O	O
vivo	O	O
xenograft	O	O
model	O	O
.	O	O
These	O	O
compounds	O	O
may	O	O
be	O	O
useful	O	O
as	O	O
delivery	O	O
agents	O	O
for	O	O
boron	O	O
neutron	O	O
capture	O	O
therapy	O	O
.	O	O
Activity	O	O
at	O	O
P2X	O	O
-	O	O
purinoceptors	O	O
was	O	O
established	O	O
by	O	O
measurement	O	O
of	O	O
contraction	O	O
of	O	O
rabbit	O	O
saphenous	O	O
artery	O	O
and	O	O
of	O	O
the	O	O
guinea	O	O
pig	O	O
vas	O	O
deferens	O	O
and	O	O
urinary	O	O
bladder	O	O
.	O	O
Structure	O	O
-	O	O
activity	O	O
studies	O	O
revealed	O	O
that	O	O
substitution	O	O
and	O	O
geometry	O	O
of	O	O
this	O	O
alkyl	O	O
group	O	O
,	O	O
and	O	O
substitution	O	O
on	O	O
the	O	O
benzodioxolyl	O	O
ring	O	O
,	O	O
are	O	O
important	O	O
in	O	O
optimizing	O	O
this	O	O
series	O	O
of	O	O
highly	O	O
ETA	O	O
selective	O	O
antagonists	O	O
.	O	O
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
acetylpyridine	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethylthiosemicarbazone	I-IUPAC	I-IUPAC
(	O	O
1	O	O
)	O	O
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
acetylpyridine	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrrolidinylthiosemicarbazone	I-IUPAC	I-IUPAC
(	O	O
2	O	O
)	O	O
,	O	O
acetylpyrazine	B-IUPAC	B-IUPAC
N	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethylthiosemicarbazone	I-IUPAC	I-IUPAC
(	O	O
3	O	O
)	O	O
,	O	O
acetylpyrazine	B-IUPAC	O
N	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
pyrrolidinylthiosemicarbazone	I-IUPAC	I-IUPAC
(	O	O
4	O	O
)	O	O
,	O	O
and	O	O
acetylpyrazine	B-IUPAC	O
N	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
piperidinylthiosemicarbazone	I-IUPAC	I-IUPAC
(	O	O
5	O	O
)	O	O
,	O	O
with	O	O
the	O	O
general	O	O
formula	O	O
[	O	O
GaLCl2	O	O
]	O	O
(	O	O
HL	O	O
=	O	O
1	O	O
and	O	O
2	O	O
)	O	O
and	O	O
[	O	O
ML2	O	O
]	O	O
[	O	O
Y	O	O
]	O	O
(	O	O
M	O	O
=	O	O
Ga	O	O
,	O	O
HL	O	O
=	O	O
1-5	O	O
,	O	O
Y	O	O
=	O	O
PF6	O	O
;	O	O
M	O	O
=	O	O
Fe	O	O
,	O	O
HL	O	O
=	O	O
1-5	O	O
,	O	O
Y	O	O
=	O	O
FeCl4	O	O
and	O	O
PF6	O	O
)	O	O
were	O	O
synthesized	O	O
and	O	O
characterized	O	O
by	O	O
elemental	O	O
analysis	O	O
,	O	O
a	O	O
number	O	O
of	O	O
spectroscopic	O	O
methods	O	O
(	O	O
NMR	O	O
,	O	O
IR	O	O
,	O	O
UV	O	O
-	O	O
vis	O	O
)	O	O
,	O	O
mass	O	O
spectrometry	O	O
,	O	O
and	O	O
X	O	O
-	O	O
ray	O	O
crystallography	O	O
.	O	O
Molecular	O	O
modeling	O	O
and	O	O
docking	O	O
to	O	O
a	O	O
crystal	O	O
structure	O	O
of	O	O
the	O	O
extracellular	O	O
binding	O	O
domain	O	O
of	O	O
the	O	O
AMPA	O	O
subunit	O	O
GluR2	O	O
has	O	O
enabled	O	O
identification	O	O
of	O	O
the	O	O
probable	O	O
active	O	O
conformation	O	O
and	O	O
binding	O	O
mode	O	O
of	O	O
6	O	O
.	O	O
The	O	O
pharmacological	O	O
results	O	O
indicate	O	O
that	O	O
this	O	O
isosteric	O	O
replacement	O	O
results	O	O
in	O	O
higher	O	O
selectivity	O	O
for	O	O
5	O	O
-	O	O
HT2	O	O
receptors	O	O
compared	O	O
to	O	O
the	O	O
former	O	O
series	O	O
.	O	O
Condensation	O	O
of	O	O
optically	O	O
pure	O	O
(	O	O
-	O	O
)	O	O
-	O	O
10	O	O
and	O	O
(	O	O
+	O	O
)	O	O
-	O	O
10	O	O
with	O	O
3,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dichlorophenylacetic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
furnished	O	O
(	O	O
+	O	O
)	O	O
-	O	O
1	O	O
and	O	O
(	O	O
-	O	O
)	O	O
-	O	O
1	O	O
,	O	O
respectively	O	O
.	O	O
However	O	O
,	O	O
when	O	O
silylated	O	O
DTPC	O	O
was	O	O
reacted	O	O
with	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chlorotetrahydropyran	I-IUPAC	I-IUPAC
,	O	O
two	O	O
tetrahydropyran	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
compounds	B-MODIFIER	B-MODIFIER
were	O	O
obtained	O	O
,	O	O
and	O	O
these	O	O
were	O	O
shown	O	O
to	O	O
be	O	O
positional	O	O
isomers	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
1H	O	O
NMR	O	O
and	O	O
UV	O	O
data	O	O
.	O	O
Diphenylphosphoryl	O	O
azide	O	O
was	O	O
used	O	O
as	O	O
the	O	O
coupling	O	O
reagent	O	O
in	O	O
each	O	O
conversion	O	O
producing	O	O
a	O	O
peptide	O	O
linkage	O	O
.	O	O
Oxidative	O	O
cyclization	O	O
of	O	O
either	O	O
4,5	B-PARTIUPAC	O
-	I-PARTIUPAC	O
or	O	O
5,6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diaminopyridines	I-IUPAC	I-IUPAC
with	O	O
aryl	O	O
aldehydes	O	O
produced	O	O
the	O	O
[	O	O
4,5	O	O
-	O	O
c	O	O
]	O	O
and	O	O
[	O	B-IUPAC
4,5	O	I-IUPAC
-	O	I-IUPAC
b	O	I-IUPAC
]	O	I-IUPAC
imidazopyridine	O	I-IUPAC
ring	O	B-MODIFIER
systems	O	I-MODIFIER
,	O	O
respectively	O	O
.	O	O
Jones	O	O
'	O	O
oxidation	O	O
of	O	O
17	B-PARTIUPAC	B-IUPAC
beta	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
hydroxy	I-PARTIUPAC	I-IUPAC
compounds	B-MODIFIER	B-MODIFIER
gave	O	O
the	O	O
17	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
keto	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
azasteroids	I-IUPAC	I-IUPAC
,	O	O
which	O	O
were	O	O
treated	O	O
with	O	O
amines	O	O
and	O	O
NaBH	O	O
(	O	O
OAc	O	O
)	O	O
3	O	O
/	O	O
NaBH3CN	O	O
to	O	O
give	O	O
17	B-IUPAC	B-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
/	I-IUPAC	I-IUPAC
arylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
azasteroids	I-IUPAC	I-IUPAC
10-27	O	O
.	O	O
)	O	O
gave	O	O
a	O	O
mixture	O	O
of	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alkylpyrazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
(	O	O
3	O	O
)	O	O
and	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylpyrazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidines	I-IUPAC	I-IUPAC
(	O	O
4	O	O
)	O	O
.	O	O
08	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
.	O	O
In	O	O
vivo	O	O
antitumor	O	O
evaluation	O	O
in	O	O
mice	O	O
against	O	O
L1210	O	O
lymphoid	O	O
leukemia	O	O
indicated	O	O
no	O	O
significant	O	O
activity	O	O
for	O	O
compound	O	O
2	O	O
.	O	O
However	O	O
,	O	O
the	O	O
heterocycles	O	O
and	O	O
several	O	O
of	O	O
the	O	O
N	O	O
-	O	O
4	O	O
glycosylated	O	O
derivatives	O	O
were	O	O
toxic	O	O
to	O	O
HFF	O	O
,	O	O
KB	O	O
and	O	O
L1210	O	O
cells	O	O
;	O	O
compounds	O	O
with	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
benzylthio	I-IUPAC	I-IUPAC
substituents	B-MODIFIER	B-MODIFIER
were	O	O
the	O	O
most	O	O
cytotoxic	O	O
agents	O	O
in	O	O
this	O	O
series	O	O
.	O	O
tthe	O	O
most	O	O
potent	O	O
inhibitor	O	O
was	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydroxyacetophenone	I-IUPAC	I-IUPAC
(	O	O
31	O	O
)	O	O
.	O	O
The	O	O
results	O	O
of	O	O
the	O	O
study	O	O
indicated	O	O
that	O	O
the	O	O
conformations	O	O
of	O	O
PCP	O	O
represented	O	O
by	O	O
6-9	O	O
are	O	O
not	O	O
optimal	O	O
for	O	O
potent	O	O
interaction	O	O
at	O	O
either	O	O
of	O	O
these	O	O
sites	O	O
.	O	O
Structure	O	O
-	O	O
activity	O	O
relationships	O	O
have	O	O
been	O	O
investigated	O	O
for	O	O
inhibition	O	O
of	O	O
DNA	O	O
-	O	O
dependent	O	O
protein	O	O
kinase	O	O
(	O	O
DNA	O	O
-	O	O
PK	O	O
)	O	O
and	O	O
ATM	O	O
kinase	O	O
by	O	O
a	O	O
series	O	O
of	O	O
pyran	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
,	O	O
pyran	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
,	O	O
thiopyran	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
,	O	O
and	O	O
pyridin	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
.	O	O
malayiat	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
x	O	O
5	O	O
days	O	O
(	O	O
ip	O	O
)	O	O
or	O	O
at	O	O
200	O	O
mg	O	O
/	O	O
kg	O	O
x	O	O
5	O	O
days	O	O
(	O	O
po	O	O
)	O	O
.	O	O
[	O	O
dPen1	O	O
,	O	O
cyclo	O	O
(	O	O
Glu4	O	O
,	O	O
Lys8	O	O
)	O	O
]	O	O
oxytocin	O	O
also	O	O
was	O	O
a	O	O
weak	O	O
antagonist	O	O
in	O	O
the	O	O
pressor	O	O
assay	O	O
with	O	O
a	O	O
pA2	O	O
of	O	O
6.3	O	O
.	O	O
A	O	O
series	O	O
of	O	O
analogues	O	O
of	O	O
the	O	O
analgesic	O	O
dipeptide	O	O
derivative	O	O
H	O	O
-	O	O
Lys	O	O
-	O	O
Trp	O	O
(	O	O
NPS	O	O
)	O	O
-	O	O
OMe	O	O
has	O	O
been	O	O
designed	O	O
to	O	O
determine	O	O
the	O	O
influence	O	O
of	O	O
the	O	O
(	B-IUPAC	B-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nitrophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
sulfenyl	I-IUPAC	I-IUPAC
(	O	O
NPS	O	O
)	O	O
moiety	B-MODIFIER	O
on	O	O
the	O	O
activity	O	O
.	O	O
Using	O	O
the	O	O
active	O	O
analog	O	O
approach	O	O
,	O	O
a	O	O
model	O	O
is	O	O
developed	O	O
of	O	O
a	O	O
region	O	O
of	O	O
steric	O	O
interference	O	O
at	O	O
this	O	O
receptor	O	O
using	O	O
the	O	O
active	O	O
cannabinoids	O	O
(	B-IUPAC	O
-	I-IUPAC	O
)	I-IUPAC	O
-	I-IUPAC	O
trans	I-IUPAC	O
-	I-IUPAC	O
delta	I-IUPAC	O
9	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydrocannabinol	I-IUPAC	I-IUPAC
,	O	O
(	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trans	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
delta	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydrocannabinol	I-IUPAC	I-IUPAC
,	O	O
(	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
11	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hexahydrocannabinol	I-IUPAC	I-IUPAC
,	O	O
and	O	O
a	O	O
(	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trans	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
11	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
delta	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydrocannabinol	I-IUPAC	I-IUPAC
dimethylheptyl	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
and	O	O
the	O	O
inactive	O	O
cannabinoids	O	O
(	B-IUPAC	O
9S	I-IUPAC	O
,	I-IUPAC	O
6aR	I-IUPAC	O
)	I-IUPAC	O
-	I-IUPAC	O
trans	I-IUPAC	O
-	I-IUPAC	O
delta	I-IUPAC	O
10,10	I-IUPAC	O
a	I-IUPAC	O
-	I-IUPAC	O
tetrahydrocannabinol	I-IUPAC	O
and	O	O
a	O	O
(	B-IUPAC	B-IUPAC
+	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trans	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
11	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
delta	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydrocannabinol	I-IUPAC	I-IUPAC
dimethylheptyl	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
.	O	O
They	O	O
have	O	O
also	O	O
demonstrated	O	O
potential	O	O
clinical	O	O
efficacy	O	O
in	O	O
combating	O	O
HIV	O	O
-	O	O
1	O	O
,	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
a	O	O
preliminary	O	O
study	O	O
.	O	O
Compounds	O	O
3-7	O	O
were	O	O
also	O	O
more	O	O
active	O	O
than	O	O
the	O	O
parent	O	O
drug	O	O
(	O	O
1	O	O
)	O	O
on	O	O
oral	O	O
administration	O	O
.	O	O
The	O	O
superimposition	O	O
of	O	O
contour	O	O
maps	O	O
on	O	O
the	O	O
active	O	O
site	O	O
of	O	O
serine	O	O
proteases	O	O
additionally	O	O
helps	O	O
in	O	O
understanding	O	O
the	O	O
structural	O	O
requirements	O	O
of	O	O
these	O	O
inhibitors	O	O
.	O	O
The	O	O
analogues	O	O
FDESPM	O	O
,	O	O
PIP	O	O
(	O	O
4,4,4	O	O
)	O	O
,	O	O
and	O	O
PYR	O	O
(	O	O
4,4,4	O	O
)	O	O
have	O	O
distances	O	O
between	O	O
their	O	O
nitrogen	O	O
atoms	O	O
almost	O	O
identical	O	O
to	O	O
those	O	O
of	O	O
DESPM	O	O
.	O	O
Upon	O	O
incubation	O	O
at	O	O
pH	O	O
7.4	O	O
and	O	O
37	O	O
degrees	O	O
C	O	O
,	O	O
it	O	O
undergoes	O	O
a	O	O
slow	O	O
hydrolysis	O	O
with	O	O
linear	O	O
regeneration	O	O
of	O	O
insulin	O	O
possessing	O	O
full	O	O
biological	O	O
potency	O	O
.	O	O
On	O	O
the	O	O
basis	O	O
of	O	O
in	O	O
vivo	O	O
functional	O	O
tests	O	O
,	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenylpiperazinoethylamino	I-IUPAC	I-IUPAC
(	O	O
11	O	O
)	O	O
,	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxyphenylpiperazino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethylamino	I-IUPAC	I-IUPAC
(	O	O
13	O	O
)	O	O
,	O	O
and	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenylpiperazinopropylamino	I-IUPAC	I-IUPAC
(	O	O
14	O	O
)	O	O
derivatives	B-MODIFIER	B-MODIFIER
of	O	O
1,3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrimido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
f	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
purine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dione	I-IUPAC	I-IUPAC
were	O	O
identified	O	O
as	O	O
potent	O	O
pre	O	O
-	O	O
and	O	O
postsynaptic	O	O
5	O	O
-	O	O
HT	O	O
(	O	O
1A	O	O
)	O	O
receptor	O	O
antagonists	O	O
.	O	O
Rotationally	O	O
restricted	O	O
analogues	O	O
of	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
deazapteroyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
glutamate	I-IUPAC	I-IUPAC
and	O	O
(	B-IUPAC	B-IUPAC
6R	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
6S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deaza	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,6,7,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydropteroyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
glutamate	I-IUPAC	I-IUPAC
with	O	O
a	O	O
one	O	O
-	O	O
carbon	O	O
bridge	O	O
between	O	O
the	O	O
amide	O	O
nitrogen	O	O
and	O	O
the	O	O
6'	O	O
-	O	O
position	O	O
of	O	O
the	O	O
p	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aminobenzoyl	I-IUPAC	I-IUPAC
moiety	B-MODIFIER	B-MODIFIER
were	O	O
synthesized	O	O
and	O	O
tested	O	O
as	O	O
substrates	O	O
for	O	O
folylpolyglutamate	O	O
synthetase	O	O
(	O	O
FPGS	O	O
)	O	O
,	O	O
a	O	O
key	O	O
enzyme	O	O
in	O	O
folate	O	O
metabolism	O	O
and	O	O
an	O	O
important	O	O
determinant	O	O
of	O	O
the	O	O
therapeutic	O	O
potency	O	O
and	O	O
selectivity	O	O
of	O	O
classical	O	O
antifolates	O	O
.	O	O
The	O	O
3	O	B-IUPAC
-	O	I-IUPAC
nitro	O	I-IUPAC
analogue	O	B-MODIFIER
(	O	O
4	O	O
,	O	O
IC50	O	O
=	O	O
1.32	O	O
microM	O	O
)	O	O
has	O	O
a	O	O
pKa	O	O
approximately	O	O
5	O	O
and	O	O
thus	O	O
exists	O	O
at	O	O
physiological	O	O
pH	O	O
as	O	O
an	O	O
anion	O	O
with	O	O
the	O	O
nitro	O	O
group	O	O
planar	O	O
to	O	O
the	O	O
quinolone	O	O
ring	O	O
.	O	O
An	O	O
alkoxy	O	O
group	O	O
at	O	O
position	O	O
7	O	O
of	O	O
the	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chromanone	I-IUPAC	I-IUPAC
moiety	B-MODIFIER	B-MODIFIER
was	O	O
important	O	O
for	O	O
potent	O	O
ACAT	O	O
inhibitory	O	O
activity	O	O
.	O	O
Two	O	O
compounds	O	O
,	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
5'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trimethoxyanilino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
quinazoline	I-IUPAC	I-IUPAC
(	O	O
9	O	O
)	O	O
and	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
5'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trimethoxybenzyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
quinazoline	I-IUPAC	I-IUPAC
(	O	O
15	O	O
)	O	O
,	O	O
were	O	O
also	O	O
tested	O	O
against	O	O
human	O	O
DHFR	O	O
and	O	O
were	O	O
found	O	O
to	O	O
have	O	O
an	O	O
IC50	O	O
/	O	O
[	O	O
E	O	O
]	O	O
of	O	O
0.5	O	O
,	O	O
indicating	O	O
that	O	O
their	O	O
binding	O	O
was	O	O
near	O	O
-	O	O
stoichiometric	O	O
.	O	O
four	O	O
compounds	O	O
6a	O	O
,	O	O
6c	O	O
,	O	O
6d	O	O
,	O	O
and	O	O
8a	O	O
were	O	O
curative	O	O
.	O	O
The	O	O
compounds	O	O
(	B-IUPAC	B-IUPAC
1S	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
2S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trans	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylcyclopropyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dichlorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
piperazine	I-IUPAC	I-IUPAC
(	O	O
5m	O	O
)	O	O
and	O	O
(	B-IUPAC	B-IUPAC
1S	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
2S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trans	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylcyclopropyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethylphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
piperazine	I-IUPAC	I-IUPAC
(	O	O
5t	O	O
)	O	O
were	O	O
selected	O	O
for	O	O
functional	O	O
antagonists	O	O
at	O	O
D	O	O
(	O	O
2	O	O
)	O	O
and	O	O
D	O	O
(	O	O
4	O	O
)	O	O
receptors	O	O
and	O	O
had	O	O
a	O	O
D	O	O
(	O	O
2	O	O
)	O	O
/	O	O
D	O	O
(	O	O
4	O	O
)	O	O
ratio	O	O
approximating	O	O
that	O	O
of	O	O
clozapine	O	O
;	O	O
they	O	O
proved	O	O
inactive	O	O
in	O	O
behavioral	O	O
tests	O	O
of	O	O
antipsychotic	O	O
activity	O	O
.	O	O
BTCP	O	O
and	O	O
7	O	O
were	O	O
the	O	O
most	O	O
potent	O	O
of	O	O
all	O	O
the	O	O
compounds	O	O
tested	O	O
in	O	O
terms	O	O
of	O	O
their	O	O
ability	O	O
to	O	O
inhibit	O	O
uptake	O	O
of	O	O
[	O	O
3H	O	O
]	O	O
DA	O	O
.	O	O
The	O	O
structurally	O	O
similar	O	O
monoprotic	O	O
and	O	O
more	O	O
acidic	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinone	I-IUPAC	I-IUPAC
(	O	O
1,2	O	O
-	O	O
HOPO	O	O
)	O	O
group	O	O
was	O	O
,	O	O
therefore	O	O
,	O	O
incorporated	O	O
into	O	O
multidentate	O	O
ligands	O	O
.	O	O
Treatment	O	O
of	O	O
the	O	O
iodohydrins	O	O
11a	O	O
-	O	O
c	O	O
with	O	O
methanolic	O	O
sulfuric	O	O
acid	O	O
afforded	O	O
the	O	O
corresponding	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iodoethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
(	O	O
12a	O	O
-	O	O
c	O	O
)	O	O
.	O	O
This	O	O
provides	O	O
further	O	O
support	O	O
for	O	O
the	O	O
dopamine	O	O
hypothesis	O	O
of	O	O
cocaine	O	O
abuse	O	O
.	O	O
Water	O	O
-	O	O
soluble	O	O
prodrugs	O	O
of	O	O
potent	O	O
,	O	O
A	O	O
(	O	O
2A	O	O
)	O	O
-	O	O
selective	O	O
adenosine	O	O
receptor	O	O
(	O	O
AR	O	O
)	O	O
antagonists	O	O
were	O	O
prepared	O	O
.	O	O
The	O	O
higher	O	O
toxicity	O	O
of	O	O
neonicotinoid	O	O
insecticides	O	O
such	O	O
as	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloropyridin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylmethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nitroiminoimidazolidine	I-IUPAC	I-IUPAC
(	O	O
imidacloprid	O	O
)	O	O
to	O	O
insects	O	O
than	O	O
mammals	O	O
is	O	O
due	O	O
in	O	O
large	O	O
part	O	O
to	O	O
target	O	O
site	O	O
specificity	O	O
at	O	O
the	O	O
corresponding	O	O
nicotinic	O	O
acetylcholine	O	O
receptors	O	O
(	O	O
nAChRs	O	O
)	O	O
.	O	O
A	O	O
number	O	O
of	O	O
N9	O	B-IUPAC
-	O	I-IUPAC
alkyl	O	I-IUPAC
-	O	O
substituted	O	O
purines	O	O
and	O	O
purine	O	O
ribonucleosides	O	O
have	O	O
been	O	O
synthesized	O	O
as	O	O
congeners	O	O
of	O	O
sulfinosine	O	O
and	O	O
evaluated	O	O
for	O	O
their	O	O
antileukemic	O	O
activity	O	O
in	O	O
mice	O	O
.	O	O
In	O	O
the	O	O
first	O	O
part	O	O
of	O	O
the	O	O
paper	O	O
,	O	O
we	O	O
report	O	O
the	O	O
synthesis	O	O
of	O	O
mimetics	O	O
of	O	O
the	O	O
constrained	O	O
(	O	O
alpha	O	O
-	O	O
Me	O	O
)	O	O
phosphotyrosine	O	O
residue	O	O
such	O	O
as	O	O
(	B-MODIFIER	O
alpha	I-MODIFIER	O
-	I-MODIFIER	O
Me	I-MODIFIER	O
)	I-MODIFIER	O
-	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phosphonomethylphenylalanine	I-IUPAC	I-IUPAC
(	O	O
-	O	O
CH2PO3H2	O	O
)	O	O
,	O	O
(	B-MODIFIER	O
alpha	I-MODIFIER	O
-	I-MODIFIER	O
Me	I-MODIFIER	O
)	I-MODIFIER	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phosphonodifluoromethylphenylalanine	I-IUPAC	I-IUPAC
(	O	O
-	O	O
CF2PO3H2	O	O
)	O	O
,	O	O
and	O	O
(	B-MODIFIER	B-IUPAC
alpha	I-MODIFIER	I-IUPAC
-	I-MODIFIER	I-IUPAC
Me	I-MODIFIER	I-IUPAC
)	I-MODIFIER	I-IUPAC
-	O	I-IUPAC
4	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phosphonophenylalanine	I-IUPAC	I-IUPAC
(	O	O
-	O	O
PO3H2	O	O
)	O	O
.	O	O
Exchanging	O	O
the	O	O
isobenzofuran	O	O
moiety	O	O
of	O	O
Lu	O	O
28-179	O	O
with	O	O
thioisobenzofuran	O	O
,	O	O
benzofuran	O	O
,	O	O
or	O	O
benzopyran	O	O
also	O	O
has	O	O
a	O	O
pronounced	O	O
effect	O	O
on	O	O
both	O	O
affinity	O	O
and	O	O
selectivity	O	O
for	O	O
sigma	O	O
binding	O	O
sites	O	O
.	O	O
Attempts	O	O
to	O	O
convert	O	O
20	O	O
or	O	O
23	O	O
to	O	O
bromocyclopropanes	O	O
21	O	O
and	O	O
22	O	O
by	O	O
reaction	O	O
with	O	O
ethyl	O	O
diazoacetate	O	O
catalyzed	O	O
by	O	O
Rh2	O	O
(	O	O
OAc	O	O
)	O	O
4	O	O
were	O	O
futile	O	O
.	O	O
The	O	O
3	O	B-IUPAC
-	O	I-IUPAC
bromo	O	I-IUPAC
derivatives	O	B-MODIFIER
were	O	O
much	O	O
more	O	O
active	O	O
than	O	O
the	O	O
3	O	O
-	O	O
unsubstituted	O	O
analogs	O	O
in	O	O
both	O	O
the	O	O
cytotoxicity	O	O
,	O	O
and	O	O
antiviral	O	O
assays	O	O
.	O	O
The	O	O
synthesis	O	O
of	O	O
this	O	O
latter	O	O
compound	O	O
has	O	O
been	O	O
improved	O	O
.	O	O
In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
have	O	O
investigated	O	O
,	O	O
for	O	O
comparative	O	O
purposes	O	O
,	O	O
halo	B-IUPAC	O
enol	I-IUPAC	O
lactones	I-IUPAC	O
with	O	O
aryl	O	O
functions	O	O
situated	O	O
beta	O	O
and	O	O
gamma	O	O
to	O	O
the	O	O
lactone	O	O
carbonyl	O	O
group	O	O
.	O	O
The	O	O
synthesis	O	O
and	O	O
pharmacological	O	O
activities	O	O
of	O	O
the	O	O
four	O	O
stereoisomers	O	O
of	O	O
methyl	B-IUPAC	B-IUPAC
tetrahydrofuran	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylmethyl	I-IUPAC	I-IUPAC
2,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nitrophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydropyridine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dicarboxylate	I-IUPAC	I-IUPAC
(	I-IUPAC	O
furnidipine	I-IUPAC	O
)	I-IUPAC	O
are	O	O
reported	O	O
.	O	O
On	O	O
the	O	O
basis	O	O
of	O	O
these	O	O
results	O	O
,	O	O
a	O	O
model	O	O
accounting	O	O
for	O	O
glycine	O	O
receptor	O	O
binding	O	O
of	O	O
the	O	O
1	O	O
derived	O	O
antagonists	O	O
is	O	O
proposed	O	O
,	O	O
comprising	O	O
(	O	O
a	O	O
)	O	O
size	O	O
-	O	O
limited	O	O
,	O	O
hydrophobic	O	O
binding	O	O
of	O	O
the	O	O
benzene	O	O
ring	O	O
,	O	O
(	O	O
b	O	O
)	O	O
hydrogen	O	O
-	O	O
bond	O	O
acceptance	O	O
by	O	O
the	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
,	O	O
(	O	O
c	O	O
)	O	O
hydrogen	O	O
-	O	O
bond	O	O
donation	O	O
by	O	O
the	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
,	O	O
and	O	O
(	O	O
d	O	O
)	O	O
a	O	O
Coulombic	O	O
attraction	O	O
of	O	O
the	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
carboxylate	I-IUPAC	I-IUPAC
.	O	O
The	O	O
9	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chlorodibenzodioxin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamide	I-IUPAC	I-IUPAC
was	O	O
also	O	O
curative	O	O
against	O	O
the	O	O
remotely	O	O
sited	O	O
Lewis	O	O
lung	O	O
carcinoma	O	O
.	O	O
Using	O	O
cultured	O	O
cerebral	O	O
cortical	O	O
neurons	O	O
and	O	O
whole	O	O
-	O	O
cell	O	O
patch	O	O
-	O	O
clamp	O	O
techniques	O	O
,	O	O
the	O	O
efficacies	O	O
of	O	O
these	O	O
compounds	O	O
relative	O	O
to	O	O
that	O	O
of	O	O
the	O	O
full	O	O
GABAA	O	O
agonist	O	O
,	O	O
isoguvacine	O	O
(	O	O
8	O	O
)	O	O
(	O	O
20	O	O
microM	O	O
)	O	O
,	O	O
were	O	O
determined	O	O
.	O	O
Syntheses	O	O
of	O	O
several	O	O
carbamate	O	O
analogues	O	O
of	O	O
2	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amidinophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
furan	I-IUPAC	I-IUPAC
(	O	O
1	O	O
)	O	O
under	O	O
mild	O	O
conditions	O	O
and	O	O
their	O	O
evaluation	O	O
as	O	O
prodrugs	O	O
against	O	O
Pneumocystis	O	O
carinii	O	O
pneumonia	O	O
(	O	O
PCP	O	O
)	O	O
in	O	O
an	O	O
immunosuppressed	O	O
rat	O	O
model	O	O
are	O	O
described	O	O
.	O	O
Biochim	O	O
.	O	O
Binding	O	O
sites	O	O
with	O	O
the	O	O
lowest	O	O
affinity	O	O
for	O	O
II	O	O
were	O	O
found	O	O
in	O	O
cortical	O	O
,	O	O
striatal	O	O
,	O	O
and	O	O
hippocampal	O	O
regions	O	O
(	O	O
IC50	O	O
values	O	O
greater	O	O
than	O	O
2.0	O	O
microM	O	O
)	O	O
.	O	O
In	O	O
in	O	O
vitro	O	O
studies	O	O
,	O	O
IC50	O	O
(	O	O
microM	O	O
)	O	O
values	O	O
obtained	O	O
for	O	O
4	O	O
vs	O	O
L1210	O	O
and	O	O
S180	O	O
of	O	O
1.50	O	O
and	O	O
2.35	O	O
,	O	O
respectively	O	O
,	O	O
were	O	O
similar	O	O
to	O	O
those	O	O
obtained	O	O
for	O	O
PDDF	O	O
(	O	O
2.61	O	O
and	O	O
1.97	O	O
)	O	O
.	O	O
All	O	O
compounds	O	O
were	O	O
subjected	O	O
to	O	O
in	O	O
vitro	O	O
pharmacological	O	O
studies	O	O
,	O	O
including	O	O
a	O	O
series	O	O
of	O	O
Glu	O	O
receptor	O	O
binding	O	O
assays	O	O
,	O	O
uptake	O	O
studies	O	O
on	O	O
native	O	O
as	O	O
well	O	O
as	O	O
cloned	O	O
Glu	O	O
uptake	O	O
systems	O	O
,	O	O
and	O	O
the	O	O
electrophysiological	O	O
rat	O	O
cortical	O	O
slice	O	O
model	O	O
.	O	O
An	O	O
array	O	O
of	O	O
NIR	O	O
fluorescent	O	O
RGD	O	O
compounds	O	O
was	O	O
prepared	O	O
efficiently	O	O
,	O	O
including	O	O
one	O	O
RGD	O	O
monomer	O	O
(	O	O
cypate	O	O
-	O	O
(	O	O
RGD	O	O
)	O	O
(	O	O
2	O	O
)	O	O
-	O	O
NH	O	O
(	O	O
2	O	O
)	O	O
)	O	O
,	O	O
two	O	O
RGD	O	O
dimers	O	O
(	O	O
cypate	O	O
-	O	O
(	O	O
RGD	O	O
)	O	O
(	O	O
2	O	O
)	O	O
-	O	O
NH	O	O
(	O	O
2	O	O
)	O	O
and	O	O
cypate	O	O
-	O	O
(	O	O
RGD	O	O
-	O	O
NH	O	O
(	O	O
2	O	O
)	O	O
)	O	O
(	O	O
2	O	O
)	O	O
)	O	O
,	O	O
one	O	O
trimer	O	O
(	O	O
cypate	O	O
-	O	O
(	O	O
RGD	O	O
)	O	O
(	O	O
3	O	O
)	O	O
-	O	O
NH	O	O
(	O	O
2	O	O
)	O	O
)	O	O
,	O	O
two	O	O
tetramers	O	O
(	O	O
cypate	O	O
-	O	O
(	O	O
RGD	O	O
)	O	O
(	O	O
4	O	O
)	O	O
-	O	O
NH	O	O
(	O	O
2	O	O
)	O	O
and	O	O
cypate	O	O
-	O	O
[	O	O
(	O	O
RGD	O	O
)	O	O
(	O	O
2	O	O
)	O	O
-	O	O
NH	O	O
(	O	O
2	O	O
)	O	O
]	O	O
(	O	O
2	O	O
)	O	O
)	O	O
,	O	O
one	O	O
hexamer	O	O
(	O	O
cypate	O	O
-	O	O
[	O	O
(	O	O
RGD	O	O
)	O	O
(	O	O
3	O	O
)	O	O
-	O	O
NH	O	O
(	O	O
2	O	O
)	O	O
]	O	O
(	O	O
2	O	O
)	O	O
)	O	O
,	O	O
and	O	O
one	O	O
octamer	O	O
(	O	O
cypate	O	O
-	O	O
[	O	O
(	O	O
RGD	O	O
)	O	O
(	O	O
4	O	O
)	O	O
-	O	O
NH	O	O
(	O	O
2	O	O
)	O	O
]	O	O
(	O	O
2	O	O
)	O	O
)	O	O
.	O	O
In	O	O
order	O	O
to	O	O
determine	O	O
the	O	O
active	O	O
site	O	O
binding	O	O
orientation	O	O
of	O	O
norepinephrine	O	O
,	O	O
a	O	O
series	O	O
of	O	O
conformationally	O	O
defined	O	O
analogues	O	O
of	O	O
the	O	O
tyramines	O	O
,	O	O
in	O	O
which	O	O
the	O	O
ethylamine	O	O
side	O	O
chain	O	O
is	O	O
held	O	O
fixed	O	O
by	O	O
incorporation	O	O
into	O	O
a	O	O
benzonorbornene	O	O
skeleton	O	O
,	O	O
were	O	O
prepared	O	O
and	O	O
evaluated	O	O
for	O	O
phenylethanolamine	O	O
N	O	O
-	O	O
methyltransferase	O	O
(	O	O
PNMT	O	O
)	O	O
activity	O	O
.	O	O
The	O	O
most	O	O
active	O	O
quinazolines	O	O
against	O	O
both	O	O
the	O	O
P	O	O
.	O	O
Electrical	O	O
recordings	O	O
using	O	O
cloned	O	O
receptors	O	O
expressed	O	O
in	O	O
Xenopus	O	O
oocytes	O	O
show	O	O
that	O	O
high	O	O
-	O	O
potency	O	O
antagonists	O	O
at	O	O
the	O	O
NR1A	O	O
/	O	O
2B	O	O
subtype	O	O
are	O	O
obtained	O	O
employing	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
omega	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylalkyl	I-IUPAC	I-IUPAC
)	I-IUPAC	B-MODIFIER
-	O	I-MODIFIER
substituted	B-MODIFIER	I-MODIFIER
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
piperidine	I-IUPAC	I-IUPAC
,	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxybenzyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
piperidine	I-IUPAC	I-IUPAC
,	O	O
and	O	O
(	B-IUPAC	B-IUPAC
+	I-IUPAC	I-IUPAC
/	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
pyrrolidine	I-IUPAC	I-IUPAC
as	O	O
exemplified	O	O
by	O	O
21	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
0.022	O	O
microM	O	O
)	O	O
,	O	O
33	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
0.059	O	O
microM	O	O
)	O	O
,	O	O
and	O	O
40	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
0.017	O	O
microM	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O
For	O	O
example	O	O
,	O	O
the	O	O
difference	O	O
between	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrrolidinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dichlorobenzyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
N'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethylethylenediamine	I-IUPAC	I-IUPAC
(	O	O
8	O	O
)	O	O
[	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
29.9	O	O
nM	O	O
at	O	O
sigma	O	O
-	O	O
1	O	O
receptor	O	O
and	O	O
18.3	O	O
nM	O	O
at	O	O
sigma	O	O
-	O	O
2	O	O
receptor	O	O
]	O	O
to	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrrolidinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dichlorobenzyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
N'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethylethylenediamine	I-IUPAC	I-IUPAC
(	O	O
10	O	O
)	O	O
[	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
1.49	O	O
nM	O	O
at	O	O
sigma	O	O
-	O	O
1	O	O
receptor	O	O
and	O	O
12.1	O	O
nM	O	O
at	O	O
sigma	O	O
-	O	O
2	O	O
receptor	O	O
]	O	O
illustrates	O	O
the	O	O
importance	O	O
of	O	O
internitrogen	O	O
spacing	O	O
.	O	O
Seven	O	O
1,2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydroacronycine	I-IUPAC	I-IUPAC
and	O	O
1,2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
demethoxyacronycine	I-IUPAC	I-IUPAC
esters	I-IUPAC	I-IUPAC
and	O	O
diesters	O	O
were	O	O
synthesized	O	O
via	O	O
osmic	O	O
oxidation	O	O
of	O	O
acronycine	O	O
or	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
demethoxyacronycine	I-IUPAC	I-IUPAC
followed	O	O
by	O	O
acylation	O	O
.	O	O
For	O	O
a	O	O
better	O	O
understanding	O	O
of	O	O
structure	O	O
-	O	O
activity	O	O
relationships	O	O
,	O	O
the	O	O
interaction	O	O
of	O	O
1	O	O
and	O	O
10	O	O
,	O	O
13	O	O
and	O	O
14	O	O
within	O	O
the	O	O
transmembrane	O	O
(	O	O
TM	O	O
)	O	O
domains	O	O
of	O	O
the	O	O
human	O	O
histamine	O	O
H	O	O
(	O	O
1	O	O
)	O	O
receptor	O	O
were	O	O
studied	O	O
using	O	O
molecular	O	O
dynamics	O	O
simulations	O	O
.	O	O
The	O	O
novel	O	O
compounds	O	O
were	O	O
characterized	O	O
as	O	O
dopaminergic	O	O
antagonists	O	O
or	O	O
inverse	O	O
agonists	O	O
.	O	O
The	O	O
synthesis	O	O
of	O	O
all	O	O
but	O	O
one	O	O
class	O	O
was	O	O
achieved	O	O
by	O	O
acylation	O	O
and	O	O
alane	O	O
reduction	O	O
of	O	O
the	O	O
appropriate	O	O
diamine	O	O
precursors	O	O
whose	O	O
synthesis	O	O
is	O	O
also	O	O
reported	O	O
.	O	O
Ethanethiol	O	O
gave	O	O
3'	B-IUPAC	B-IUPAC
.5	I-IUPAC	I-IUPAC
'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
ethylthio	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyacetanilide	I-IUPAC	I-IUPAC
.	O	O
However	O	O
all	O	O
the	O	O
compounds	O	O
were	O	O
more	O	O
potent	O	O
against	O	O
the	O	O
rat	O	O
liver	O	O
enzyme	O	O
than	O	O
the	O	O
P	O	O
.	O	O
Closely	O	O
following	O	O
in	O	O
activity	O	O
in	O	O
decreasing	O	O
order	O	O
were	O	O
N3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
n	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propylcarbamoyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
uracil	I-IUPAC	I-IUPAC
(	O	O
7	O	O
)	O	O
,	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
n	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propylcarbamoyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
saccharin	I-IUPAC	I-IUPAC
(	O	O
6	O	O
)	O	O
,	O	O
and	O	O
the	O	O
S	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
n	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propylcarbamoyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
(	O	O
9	O	O
)	O	O
of	O	O
benzyl	B-IUPAC	O
mercaptan	I-IUPAC	O
.	O	O
The	O	O
hydroosmotic	O	O
activity	O	O
of	O	O
the	O	O
biotinyl	O	O
analogue	O	O
was	O	O
reversed	O	O
following	O	O
addition	O	O
of	O	O
avidin	O	O
,	O	O
whereas	O	O
the	O	O
photoaffinity	O	O
analogue	O	O
induced	O	O
a	O	O
persistent	O	O
response	O	O
following	O	O
UV	O	O
irradiation	O	O
that	O	O
was	O	O
not	O	O
reversed	O	O
upon	O	O
repeated	O	O
and	O	O
prolonged	O	O
periods	O	O
of	O	O
washout	O	O
.	O	O
However	O	O
,	O	O
members	O	O
of	O	O
the	O	O
thiadiazolopyrimidine	B-IUPAC	O
class	O	O
of	O	O
mesoionics	O	O
exhibited	O	O
very	O	O
low	O	O
or	O	O
no	O	O
activity	O	O
as	O	O
antagonists	O	O
of	O	O
A2	O	O
-	O	O
adenosine	O	O
receptors	O	O
while	O	O
exhibiting	O	O
activity	O	O
only	O	O
2-4	O	O
-	O	O
fold	O	O
lower	O	O
than	O	O
that	O	O
of	O	O
theophylline	O	O
at	O	O
A1	O	O
-	O	O
adenosine	O	O
receptors	O	O
.	O	O
Many	O	O
of	O	O
these	O	O
antagonists	O	O
,	O	O
for	O	O
example	O	O
ifenprodil	O	O
(	O	O
1	O	O
)	O	O
,	O	O
incorporate	O	O
a	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
substituent	B-MODIFIER	B-MODIFIER
on	O	O
the	O	O
omega	O	O
-	O	O
phenyl	O	O
group	O	O
.	O	O
The	O	O
in	O	O
vitro	O	O
binding	O	O
results	O	O
from	O	O
symmetrically	O	O
substituted	O	O
diphenylguanidines	O	O
indicated	O	O
that	O	O
compounds	O	O
having	O	O
ortho	O	O
or	O	O
meta	O	O
substituents	O	O
(	O	O
with	O	O
respect	O	O
to	O	O
the	O	O
position	O	O
of	O	O
the	O	O
guanidine	O	O
nitrogen	O	O
)	O	O
on	O	O
the	O	O
phenyl	O	B-IUPAC
rings	O	B-MODIFIER
showed	O	O
greater	O	O
affinity	O	O
for	O	O
the	O	O
NMDA	O	O
receptor	O	O
ion	O	O
channel	O	O
site	O	O
compared	O	O
with	O	O
para	O	O
-	O	O
substituted	O	O
derivatives	O	O
.	O	O
These	O	O
analogues	O	O
when	O	O
examined	O	O
for	O	O
suppressive	O	O
activity	O	O
against	O	O
drug	O	O
-	O	O
sensitive	O	O
lines	O	O
of	O	O
Plasmodium	O	O
berghei	O	O
in	O	O
mice	O	O
were	O	O
not	O	O
as	O	O
active	O	O
as	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dichlorobenzyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
quinazoline	I-IUPAC	I-IUPAC
(	O	O
Ia	O	O
)	O	O
.	O	O
The	O	O
required	O	O
substituted	B-MODIFIER	B-MODIFIER
dibenzo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
1,4	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
dioxin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylic	I-IUPAC	I-IUPAC
acids	I-IUPAC	I-IUPAC
were	O	O
prepared	O	O
by	O	O
a	O	O
variety	O	O
of	O	O
methods	O	O
.	O	O
The	O	O
diester	O	O
of	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloromethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
(	O	O
27	O	O
)	O	O
treated	O	O
with	O	O
methanol	B-IUPAC	O
or	O	O
sodium	O	O
azide	O	O
gave	O	O
5	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
methoxymethyl	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
(	O	O
29	O	O
)	O	O
and	O	O
5	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
azidomethyl	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
(	O	I-IUPAC
31	O	I-IUPAC
)	O	I-IUPAC
2'	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridines	I-IUPAC	I-IUPAC
.	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
Hydroxyethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylimidazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamide	I-IUPAC	I-IUPAC
was	O	O
prepared	O	O
by	O	O
alkylation	O	O
of	O	O
the	O	O
imidazole	O	O
13	O	O
with	O	O
(	B-IUPAC	B-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetoxyethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
bromide	I-IUPAC	I-IUPAC
followed	O	O
by	O	O
treatment	O	O
with	O	O
methanolic	O	O
ammonia	O	O
.	O	O
The	O	O
ED	O	O
(	O	O
50	O	O
)	O	O
values	O	O
for	O	O
2beta	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isoxazoles	I-IUPAC	I-IUPAC
)	I-IUPAC	O
that	O	O
caused	O	O
locomotor	O	O
stimulation	O	O
ranged	O	O
from	O	O
0.2	O	O
to	O	O
12.8	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O
7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Benzyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,6,7,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethoxybenzyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3'	I-IUPAC	I-IUPAC
:	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
thieno	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
oxazin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
(	O	O
21	O	O
)	O	O
had	O	O
the	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
value	O	O
of	O	O
330	O	O
nM	O	O
for	O	O
AChE	O	O
inhibition	O	O
.	O	O
The	O	O
isoindolinylamide	B-IUPAC	O
side	B-MODIFIER	O
chain	I-MODIFIER	O
was	O	O
tolerated	O	O
if	O	O
the	O	O
5	O	O
-	O	O
position	O	O
was	O	O
unsubstituted	O	O
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
of	O	O
5a	O	O
=	O	O
123	O	O
nM	O	O
)	O	O
,	O	O
otherwise	O	O
affinity	O	O
was	O	O
abolished	O	O
(	O	O
5b	O	O
,	O	O
c	O	O
)	O	O
.	O	O
In	O	O
tissue	O	O
culture	O	O
assays	O	O
,	O	O
22	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxycholesterol	I-IUPAC	I-IUPAC
as	O	O
well	O	O
as	O	O
the	O	O
side	O	O
chain	O	O
modified	O	O
analogues	O	O
were	O	O
potent	O	O
inhibitors	O	O
of	O	O
HMG	O	O
CoA	O	O
reductase	O	O
.	O	O
The	O	O
nuclear	O	O
enzyme	O	O
poly	O	O
(	O	O
ADP	O	O
-	O	O
ribose	O	O
)	O	O
polymerase	O	O
(	O	O
PARP	O	O
)	O	O
facilitates	O	O
the	O	O
repair	O	O
of	O	O
DNA	O	O
strand	O	O
breaks	O	O
and	O	O
is	O	O
implicated	O	O
in	O	O
the	O	O
resistance	O	O
of	O	O
cancer	O	O
cells	O	O
to	O	O
certain	O	O
DNA	O	O
-	O	O
damaging	O	O
agents	O	O
.	O	O
Thus	O	O
,	O	O
4d	O	O
is	O	O
an	O	O
effective	O	O
and	O	O
highly	O	O
selective	O	O
inhibitor	O	O
of	O	O
calcium	O	O
chloride	O	O
-	O	O
dependent	O	O
[	O	O
3H	O	O
]	O	O
glutamic	O	O
acid	O	O
binding	O	O
and	O	O
may	O	O
be	O	O
a	O	O
useful	O	O
tool	O	O
for	O	O
studies	O	O
of	O	O
the	O	O
physiological	O	O
relevance	O	O
and	O	O
pharmacological	O	O
importance	O	O
of	O	O
this	O	O
binding	O	O
affinity	O	O
.	O	O
High	O	O
specific	O	O
activity	O	O
[	O	O
(	O	O
18	O	O
)	O	O
F	O	O
]	O	O
(	O	O
R	O	O
)	O	O
-	O	O
FIPCT	O	O
and	O	O
[	O	O
(	O	O
18	O	O
)	O	O
F	O	O
]	O	O
(	O	O
S	O	O
)	O	O
-	O	O
FIPCT	O	O
were	O	O
synthesized	O	O
in	O	O
5%	O	O
radiochemical	O	O
yield	O	O
(	O	O
decay	O	O
-	O	O
corrected	O	O
to	O	O
end	O	O
of	O	O
bombardment	O	O
(	O	O
EOB	O	O
)	O	O
)	O	O
by	O	O
preparation	O	O
of	O	O
the	O	O
precursors	O	O
2beta	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
carbo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
R	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
mesyloxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chlorop	I-IUPAC	I-IUPAC
hen	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
tropane	I-IUPAC	I-IUPAC
(	O	O
R	O	O
-	O	O
12	O	O
)	O	O
and	O	O
2beta	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
carbo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
mesyloxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chlorop	I-IUPAC	I-IUPAC
hen	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
tropane	I-IUPAC	I-IUPAC
(	O	O
S	O	O
-	O	O
12	O	O
)	O	O
followed	O	O
by	O	O
treatment	O	O
with	O	O
no	O	O
carrier	O	O
-	O	O
added	O	O
potassium	O	O
[	O	O
(	O	O
18	O	O
)	O	O
F	O	O
]	O	O
fluoride	O	O
and	O	O
kyrptofix	O	O
K222	O	O
in	O	O
acetonitrile	O	O
.	O	O
The	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
mesitylimino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
analogue	B-MODIFIER	B-MODIFIER
trequinsin	O	O
is	O	O
a	O	O
potent	O	O
antihypertensive	O	O
agent	O	O
and	O	O
displays	O	O
a	O	O
hemodynamic	O	O
profile	O	O
characteristic	O	O
of	O	O
an	O	O
arteriolar	O	O
dilator	O	O
.	O	O
A	O	O
series	O	O
of	O	O
substituted	B-MODIFIER	B-MODIFIER
dibenzo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
1,4	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
dioxin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamides	I-IUPAC	I-IUPAC
has	O	O
been	O	O
synthesized	O	O
and	O	O
evaluated	O	O
for	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
antitumor	O	O
activity	O	O
.	O	O
Also	O	O
,	O	O
six	O	O
of	O	O
the	O	O
eight	O	O
diamidines	O	O
gave	O	O
in	O	O
vitro	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
values	O	O
of	O	O
88	O	O
nM	O	O
or	O	O
less	O	O
vs	O	O
P	O	O
.	O	O
Reduction	O	O
of	O	O
26	O	O
+	O	O
27	O	O
and	O	O
31	O	O
+	O	O
32	O	O
with	O	O
DIBALH	O	O
afforded	O	O
(	B-PARTIUPAC	B-PARTIUPAC
Z	I-PARTIUPAC	I-PARTIUPAC
)	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
(	B-IUPAC	B-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylenecyclopropane	I-IUPAC	I-IUPAC
alcohols	I-IUPAC	I-IUPAC
14	O	O
+	O	O
16	O	O
and	O	O
33	O	O
+	O	O
34	O	O
.	O	O
10h	O	O
is	O	O
currently	O	O
the	O	O
focus	O	O
of	O	O
pharmaceutical	O	O
and	O	O
preclinical	O	O
development	O	O
.	O	O
Affinity	O	O
for	O	O
brain	O	O
A1	O	O
and	O	O
A2	O	O
adenosine	O	O
receptors	O	O
was	O	O
determined	O	O
in	O	O
binding	O	O
assays	O	O
for	O	O
these	O	O
and	O	O
other	O	O
xanthines	O	O
with	O	O
substituents	O	O
in	O	O
1	O	O
-	O	O
,	O	O
3	O	O
-	O	O
,	O	O
7	O	O
-	O	O
,	O	O
8	O	O
-	O	O
,	O	O
and	O	O
9	O	O
-	O	O
positions	O	O
.	O	O
This	O	O
is	O	O
consistent	O	O
with	O	O
the	O	O
binding	O	O
and	O	O
activation	O	O
of	O	O
CD81	O	O
and	O	O
represents	O	O
a	O	O
2	O	O
-	O	O
fold	O	O
improvement	O	O
compared	O	O
to	O	O
the	O	O
clinically	O	O
prescribed	O	O
anti	O	O
-	O	O
HCV	O	O
agent	O	O
,	O	O
amantidine	O	O
,	O	O
in	O	O
the	O	O
same	O	O
concentration	O	O
range	O	O
.	O	O
Results	O	O
of	O	O
these	O	O
studies	O	O
indicate	O	O
that	O	O
,	O	O
in	O	O
addition	O	O
to	O	O
the	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxoethyl	I-IUPAC	I-IUPAC
moiety	B-MODIFIER	B-MODIFIER
,	O	O
the	O	O
presence	O	O
of	O	O
an	O	O
acid	O	O
group	O	O
and	O	O
a	O	O
lipophilic	O	O
side	O	O
chain	O	O
,	O	O
as	O	O
well	O	O
as	O	O
the	O	O
spatial	O	O
relationship	O	O
of	O	O
these	O	O
three	O	O
functions	O	O
,	O	O
is	O	O
crucial	O	O
for	O	O
high	O	O
binding	O	O
affinity	O	O
with	O	O
LTB4	O	O
receptors	O	O
.	O	O
The	O	O
novel	O	O
compounds	O	O
featured	O	O
are	O	O
derived	O	O
structurally	O	O
from	O	O
two	O	O
key	O	O
lead	O	O
structures	O	O
:	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
adenosine	I-IUPAC	I-IUPAC
(	O	O
NNC	O	O
21-0041	O	O
,	O	O
9	O	O
)	O	O
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
adenosine	I-IUPAC	I-IUPAC
(	O	O
NNC	O	O
90-1515	O	O
,	O	O
4	O	O
)	O	O
.	O	O
Importantly	O	O
,	O	O
both	O	O
the	O	O
locomotor	O	O
activity	O	O
and	O	O
the	O	O
cocaine	O	O
discrimination	O	O
ED	O	O
(	O	O
50	O	O
)	O	O
values	O	O
were	O	O
correlated	O	O
with	O	O
the	O	O
DAT	O	O
binding	O	O
but	O	O
not	O	O
5	O	O
-	O	O
HTT	O	O
and	O	O
NET	O	O
binding	O	O
.	O	O
The	O	O
enantioselectivity	O	O
was	O	O
determined	O	O
by	O	O
high	O	O
-	O	O
pressure	O	O
liquid	O	O
chromatographic	O	O
analysis	O	O
of	O	O
the	O	O
enzymatically	O	O
formed	O	O
diastereomeric	O	O
products	O	O
.	O	O
The	O	O
two	O	O
isomers	O	O
display	O	O
different	O	O
binding	O	O
affinities	O	O
toward	O	O
dopamine	O	O
transporters	O	O
and	O	O
distinct	O	O
properties	O	O
of	O	O
localization	O	O
in	O	O
the	O	O
striatum	O	O
area	O	O
of	O	O
the	O	O
brain	O	O
where	O	O
the	O	O
transporters	O	O
are	O	O
located	O	O
.	O	O
While	O	O
it	O	O
is	O	O
unclear	O	O
whether	O	O
virus	O	O
entry	O	O
into	O	O
host	O	O
cells	O	O
is	O	O
directly	O	O
linked	O	O
to	O	O
virus	O	O
attachment	O	O
via	O	O
CD81	O	O
for	O	O
HCV	O	O
,	O	O
this	O	O
step	O	O
in	O	O
the	O	O
viral	O	O
life	O	O
cycle	O	O
has	O	O
recently	O	O
proven	O	O
to	O	O
be	O	O
an	O	O
effective	O	O
point	O	O
of	O	O
attack	O	O
for	O	O
other	O	O
viruses	O	O
including	O	O
HIV	O	O
and	O	O
rhinoviruses	O	O
.	O	O
Higher	O	O
binding	O	O
affinity	O	O
for	O	O
dopamine	O	O
transporters	O	O
was	O	O
observed	O	O
for	O	O
3B	O	O
(	O	O
Ki	O	O
=	O	O
13.87	O	O
and	O	O
8.42	O	O
nM	O	O
for	O	O
the	O	O
analogous	O	O
rhenium	O	O
complexes	O	O
3A	O	O
,	O	O
B	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O
Reaction	O	O
of	O	O
hydroxyl	O	O
-	O	O
protected	O	O
derivatives	O	O
of	O	O
hydroxyalkoxyamines	O	O
(	O	O
3a	O	O
,	O	O
b	O	O
,	O	O
c	O	O
)	O	O
with	O	O
either	O	O
4,6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dichloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diformamidopyrimidine	I-IUPAC	I-IUPAC
(	O	O
5	O	O
)	O	O
or	O	O
4,6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dichloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
formamidopyrimidine	I-IUPAC	I-IUPAC
(	O	O
31	O	O
)	O	O
and	O	O
subsequent	O	O
cyclization	O	O
of	O	O
the	O	O
resultant	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
alkoxyamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
pyrimidines	I-IUPAC	I-IUPAC
(	O	O
6	O	O
,	O	O
17	O	O
,	O	O
32	O	O
,	O	O
35	O	O
)	O	O
by	O	O
heating	O	O
with	O	O
diethoxymethyl	O	O
acetate	O	O
afforded	O	O
9	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
alkoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloropurines	I-IUPAC	I-IUPAC
(	O	O
7	O	O
,	O	O
18	O	O
,	O	O
33	O	O
,	O	O
36	O	O
)	O	O
,	O	O
which	O	O
were	O	O
converted	O	O
subsequently	O	O
to	O	O
9	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	I-IUPAC
3	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
hydroxypropoxy	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
and	O	O
9	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
hydroxymethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propoxy	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
of	O	O
guanine	O	O
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloropurine	I-IUPAC	I-IUPAC
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alkoxypurines	I-IUPAC	I-IUPAC
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aminopurine	I-IUPAC	I-IUPAC
,	O	O
2,6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diaminopurine	I-IUPAC	I-IUPAC
,	O	O
adenine	O	O
,	O	O
hypoxanthine	O	B-IUPAC
,	O	O
and	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methoxypurine	I-IUPAC	I-IUPAC
(	O	O
8	O	O
,	O	O
12	O	O
,	O	O
13	O	O
,	O	O
19-21	O	O
,	O	O
23-26	O	O
,	O	O
34	O	O
,	O	O
37-39	O	O
)	O	O
.	O	O
None	O	O
of	O	O
these	O	O
compounds	O	O
extended	O	O
the	O	O
life	O	O
span	O	O
of	O	O
Plasmodium	O	O
berghei	O	O
infected	O	O
mice	O	O
or	O	O
showed	O	O
significant	O	O
in	O	O
vitro	O	O
inhibition	O	O
of	O	O
HGPRT	O	O
from	O	O
H	O	O
.	O	O
Apyrogenic	O	O
samples	O	O
of	O	O
[	B-IUPAC	B-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
11	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
C	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
temozolomide	I-IUPAC	I-IUPAC
(	O	O
9	O	O
)	O	O
and	O	O
[	B-IUPAC	B-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
11	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
C	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carbonyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
temozolomide	I-IUPAC	I-IUPAC
(	O	O
11	O	O
)	O	O
,	O	O
with	O	O
good	O	O
chemical	O	O
and	O	O
radiochemical	O	O
purities	O	O
,	O	O
have	O	O
been	O	O
prepared	O	O
and	O	O
used	O	O
in	O	O
human	O	O
PET	O	O
studies	O	O
.	O	O
Many	O	O
of	O	O
these	O	O
derivatives	O	O
exhibit	O	O
K	O	O
(	O	O
i	O	O
)	O	O
values	O	O
for	O	O
PARP	O	O
inhibition	O	O
&	O	O
lt	O	O
;	O	O
10	O	O
nM	O	O
,	O	O
with	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxymethylphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzimidazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamide	I-IUPAC	I-IUPAC
(	O	O
78	O	O
,	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
1.6	O	O
nM	O	O
)	O	O
being	O	O
one	O	O
of	O	O
the	O	O
most	O	O
potent	O	O
.	O	O
The	O	O
affinity	O	O
of	O	O
3,5,5	B-IUPAC	B-IUPAC
'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
triphenylimidazolidine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dione	I-IUPAC	I-IUPAC
and	O	O
3,5,5	B-IUPAC	B-IUPAC
'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
triphenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thioxoimidazolidin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
,	O	O
possessing	O	O
the	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
benzhydryl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylurea	I-IUPAC	I-IUPAC
and	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
benzhydryl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylthiourea	I-IUPAC	I-IUPAC
moiety	B-MODIFIER	B-MODIFIER
,	O	O
respectively	O	O
,	O	O
was	O	O
also	O	O
evaluated	O	O
.	O	O
The	O	O
significance	O	O
of	O	O
their	O	O
sigma	O	O
-	O	O
binding	O	O
activity	O	O
in	O	O
light	O	O
of	O	O
their	O	O
dopaminergic	O	O
properties	O	O
is	O	O
unclear	O	O
.	O	O
Previous	O	O
correlation	O	O
of	O	O
fluorescence	O	O
and	O	O
NMR	O	O
data	O	O
suggested	O	O
that	O	O
the	O	O
11R	O	O
,	O	O
11aS	O	O
and	O	O
the	O	O
11S	O	O
,	O	O
11aS	O	O
diastereomers	O	O
of	O	O
tomaymycin	O	O
could	O	O
bind	O	O
to	O	O
DNA	O	O
in	O	O
two	O	O
orientations	O	O
relative	O	O
to	O	O
the	O	O
covalently	O	O
modified	O	O
guanine	O	O
(	O	O
Barkley	O	O
,	O	O
M	O	O
.	O	O
Syntheses	O	O
of	O	O
the	O	O
trans	B-IUPAC	O
-	I-IUPAC	O
dihydrodiol	I-IUPAC	O
derivatives	B-MODIFIER	O
implicated	O	O
as	O	O
the	O	O
proximate	O	O
carcinogenic	O	O
metabolites	O	O
of	O	O
the	O	O
polycyclic	O	O
hydrocarbons	O	O
cholanthrene	O	O
,	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methylcholanthrene	I-IUPAC	I-IUPAC
,	O	O
benz	B-IUPAC	O
[	I-IUPAC	O
a	I-IUPAC	O
]	I-IUPAC	O
anthracene	I-IUPAC	O
,	O	O
and	O	O
7	B-PARTIUPAC	O
-	I-PARTIUPAC	O
and	O	O
12	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methylbenz	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
anthracene	I-IUPAC	I-IUPAC
are	O	O
described	O	O
.	O	O
Generally	O	O
,	O	O
the	O	O
divalent	O	O
linear	O	O
arrays	O	O
of	O	O
the	O	O
multimeric	O	O
RGD	O	O
units	O	O
bound	O	O
the	O	O
ABIR	O	O
with	O	O
slightly	O	O
higher	O	O
affinity	O	O
than	O	O
their	O	O
monovalent	O	O
analogues	O	O
.	O	O
Some	O	O
of	O	O
these	O	O
analogues	O	O
displayed	O	O
weak	O	O
antagonist	O	O
properties	O	O
.	O	O
The	O	O
trisubstituted	O	O
guanidine	O	O
,	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethylphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylguanidine	I-IUPAC	I-IUPAC
(	O	O
40	O	O
)	O	O
and	O	O
its	O	O
close	O	O
analogues	O	O
showed	O	O
good	O	O
in	O	O
vivo	O	O
neuroprotection	O	O
and	O	O
are	O	O
potential	O	O
neuroprotective	O	O
drug	O	O
candidates	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
stroke	O	O
and	O	O
other	O	O
neurodegenerative	O	O
disorders	O	O
.	O	O
The	O	O
expected	O	O
thermodynamic	O	O
stability	O	O
resulting	O	O
from	O	O
the	O	O
preorganization	O	O
of	O	O
the	O	O
pseudosugar	O	O
rings	O	O
into	O	O
a	O	O
Northern	O	O
conformation	O	O
,	O	O
typical	O	O
of	O	O
A	O	O
-	O	O
DNA	O	O
,	O	O
was	O	O
evident	O	O
by	O	O
the	O	O
increase	O	O
in	O	O
Tm	O	O
of	O	O
the	O	O
corresponding	O	O
DNA	O	O
/	O	O
RNA	O	O
heteroduplex	O	O
.	O	O
In	O	O
conclusion	O	O
,	O	O
TRODAT	O	O
-	O	O
1	O	O
formed	O	O
at	O	O
least	O	O
two	O	O
diastereomers	O	O
after	O	O
complexing	O	O
with	O	O
a	O	O
metal	O	O
(	O	O
V	O	O
)	O	O
-	O	O
oxo	O	O
(	O	O
M	O	O
=	O	O
99mTc	O	O
,	O	O
Re	O	O
)	O	O
center	O	O
core	O	O
.	O	O
Selected	O	O
isomeric	O	O
1	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthyridin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
were	O	O
also	O	O
prepared	O	O
in	O	O
order	O	O
to	O	O
evaluate	O	O
the	O	O
relative	O	O
contributions	O	O
of	O	O
both	O	O
ring	O	O
A	O	O
aza	O	O
atoms	O	O
of	O	O
the	O	O
related	O	O
pyrido	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
8H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
to	O	O
the	O	O
inhibitory	O	O
activity	O	O
.	O	O
The	O	O
observed	O	O
relationships	O	O
between	O	O
nonquaternary	O	O
compound	O	O
structure	O	O
,	O	O
reactivation	O	O
potency	O	O
,	O	O
and	O	O
anti	O	O
-	O	O
AChE	O	O
activity	O	O
reveal	O	O
important	O	O
molecular	O	O
requirements	O	O
for	O	O
high	O	O
reactivity	O	O
toward	O	O
phosphonylated	O	O
AChE	O	O
.	O	O
Conformational	O	O
studies	O	O
on	O	O
30g	O	O
indicated	O	O
that	O	O
the	O	O
two	O	O
stable	O	O
conformers	O	O
of	O	O
30g	O	O
are	O	O
quite	O	O
similar	O	O
to	O	O
those	O	O
of	O	O
CP	O	O
-	O	O
99,994	O	O
.	O	O
Plutonium	O	O
excretion	O	O
after	O	O
injection	O	O
of	O	O
either	O	O
CAM	O	O
-	O	O
HOPO	O	O
ligand	O	O
was	O	O
700%	O	O
of	O	O
that	O	O
for	O	O
24	O	O
-	O	O
h	O	O
Pu	O	O
-	O	O
injected	O	O
controls	O	O
,	O	O
140%	O	O
of	O	O
that	O	O
for	O	O
mice	O	O
given	O	O
the	O	O
tetracatecholate	O	O
analogue	O	O
3,4,3	O	O
-	O	O
LICAM	O	O
(	O	O
significantly	O	O
more	O	O
,	O	O
p	O	O
&	O	O
lt	O	O
;	O	O
0.01	O	O
)	O	O
,	O	O
but	O	O
only	O	O
80%	O	O
of	O	O
that	O	O
promoted	O	O
by	O	O
3,4,3	O	O
-	O	O
LIHOPO	O	O
(	O	O
significantly	O	O
less	O	O
)	O	O
.	O	O
This	O	O
has	O	O
never	O	O
been	O	O
seen	O	O
for	O	O
(	O	O
S	O	O
)	O	O
-	O	O
(	O	O
-	O	O
)	O	O
-	O	O
3	O	O
-	O	O
PPP	O	O
without	O	O
tropolone	O	O
pretreatment	O	O
and	O	O
might	O	O
indicate	O	O
that	O	O
,	O	O
in	O	O
this	O	O
special	O	O
case	O	O
,	O	O
the	O	O
catecholic	O	O
metabolite	O	O
affects	O	O
the	O	O
in	O	O
vivo	O	O
pharmacological	O	O
profile	O	O
of	O	O
(	O	O
S	O	O
)	O	O
-	O	O
(	O	O
-	O	O
)	O	O
-	O	O
3	O	O
-	O	O
PPP	O	O
.	O	O
A	O	O
study	O	O
of	O	O
ring	O	O
-	O	O
expanded	O	O
analogues	O	O
of	O	O
the	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
propananilido	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
piperidine	I-IUPAC	I-IUPAC
analgesics	O	B-MODIFIER
has	O	O
been	O	O
undertaken	O	O
in	O	O
order	O	O
to	O	O
evaluate	O	O
the	O	O
influence	O	O
of	O	O
this	O	O
structural	O	O
modification	O	O
on	O	O
both	O	O
analgesic	O	O
activity	O	O
and	O	O
physical	O	O
-	O	O
dependence	O	O
capacity	O	O
.	O	O
Using	O	O
the	O	O
patch	O	O
-	O	O
clamp	O	O
technique	O	O
in	O	O
primary	O	O
cultures	O	O
of	O	O
granule	O	O
neurons	O	O
we	O	O
tested	O	O
compounds	O	O
10	O	O
and	O	O
21	O	O
for	O	O
their	O	O
ability	O	O
to	O	O
modulate	O	O
currents	O	O
evoked	O	O
by	O	O
KA	O	O
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tert	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butylisoxazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propionic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
ATPA	O	O
)	O	O
.	O	O
A	O	O
series	O	O
of	O	O
28	O	O
new	O	O
pyrrolo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amines	I-IUPAC	I-IUPAC
,	O	O
pyrimido	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
indole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amines	I-IUPAC	I-IUPAC
,	O	O
and	O	O
tetrahydropyrimido	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
indole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amines	I-IUPAC	I-IUPAC
was	O	O
synthesized	O	O
and	O	O
their	O	O
adenosine	O	O
receptor	O	O
affinity	O	O
determined	O	O
in	O	O
radioligand	O	O
binding	O	O
assays	O	O
at	O	O
rat	O	O
A	O	O
(	O	O
1	O	O
)	O	O
and	O	O
A	O	O
(	O	O
2A	O	O
)	O	O
adenosine	O	O
receptors	O	O
(	O	O
ARs	O	O
)	O	O
.	O	O
All	O	O
DTACs	O	O
and	O	O
indenes	O	O
were	O	O
competitive	O	O
inhibitors	O	O
of	O	O
[	O	B-IUPAC
3H	O	I-IUPAC
]	O	I-IUPAC
estradiol	O	I-IUPAC
binding	O	O
in	O	O
the	O	O
immature	O	O
rat	O	O
uterine	O	O
cytosol	O	O
receptor	O	O
assay	O	O
,	O	O
with	O	O
relative	O	O
binding	O	O
affinities	O	O
of	O	O
0.1-3.6%	O	O
of	O	O
estradiol	O	O
.	O	O
The	O	O
isomeric	O	O
4	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
(	I-PARTIUPAC	I-PARTIUPAC
3	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
chloro	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
4	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
hydroxyphenyl	I-PARTIUPAC	I-PARTIUPAC
)	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydroisoquinolines	I-IUPAC	I-IUPAC
,	O	O
the	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
of	O	O
the	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
isomer	B-MODIFIER	B-MODIFIER
,	O	O
and	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydroisoquinoline	I-IUPAC	I-IUPAC
were	O	O
synthesized	O	O
and	O	O
evaluated	O	O
for	O	O
dopamine	O	O
D	O	O
-	O	O
1	O	O
antagonist	O	O
activity	O	O
.	O	O
These	O	O
compounds	O	O
show	O	O
promising	O	O
activity	O	O
for	O	O
further	O	O
testing	O	O
on	O	O
in	O	O
vivo	O	O
models	O	O
.	O	O
Useful	O	O
activity	O	O
in	O	O
the	O	O
5,10	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dideaza	I-IUPAC	I-IUPAC
series	B-MODIFIER	B-MODIFIER
was	O	O
only	O	O
observed	O	O
for	O	O
5,10	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dideazaaminopterin	I-IUPAC	I-IUPAC
and	O	O
its	O	O
10	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
analogue	B-MODIFIER	B-MODIFIER
.	O	O
A	O	O
single	O	O
subcutaneous	O	O
administration	O	O
of	O	O
(	O	O
FMS	O	O
)	O	O
(	O	O
3	O	O
)	O	O
-	O	O
insulin	O	O
to	O	O
streptozocin	O	O
-	O	O
treated	O	O
rats	O	O
lowered	O	O
circulating	O	O
glucose	O	O
levels	O	O
for	O	O
a	O	O
prolonged	O	O
period	O	O
(	O	O
t	O	O
(	O	O
1/2	O	O
)	O	O
=	O	O
30	O	O
h	O	O
)	O	O
.	O	O
Both	O	O
43	O	O
(	O	O
ED	O	O
(	O	O
50	O	O
)	O	O
=	O	O
150	O	O
micromol	O	O
/	O	O
kg	O	O
)	O	O
and	O	O
44	O	O
(	O	O
ED	O	O
(	O	O
50	O	O
)	O	O
=	O	O
220	O	O
micromol	O	O
/	O	O
kg	O	O
)	O	O
showed	O	O
anticonvulsant	O	O
effects	O	O
,	O	O
and	O	O
this	O	O
effect	O	O
of	O	O
43	O	O
was	O	O
shown	O	O
to	O	O
reside	O	O
in	O	O
the	O	O
(	O	O
R	O	O
)	O	O
-	O	O
(	O	O
+	O	O
)	O	O
-	O	O
enantiomer	O	O
,	O	O
45	O	O
(	O	O
ED	O	O
(	O	O
50	O	O
)	O	O
=	O	O
44	O	O
micromol	O	O
/	O	O
kg	O	O
)	O	O
.	O	O
Compound	O	O
8	O	O
,	O	O
a	O	O
pyrrolo	O	O
analogue	O	O
of	O	O
7	O	O
,	O	O
was	O	O
devoid	O	O
of	O	O
inotropic	O	O
activity	O	O
,	O	O
while	O	O
the	O	O
pyrido	B-IUPAC	O
analogues	B-MODIFIER	O
9	O	O
were	O	O
equiactive	O	O
to	O	O
7	O	O
and	O	O
amrinone	O	O
.	O	O
A	O	O
series	O	O
of	O	O
(	B-MODIFIER	O
+	I-MODIFIER	O
)	I-MODIFIER	O
-	I-MODIFIER	O
3	I-MODIFIER	O
-	I-MODIFIER	O
substituted	I-MODIFIER	B-MODIFIER
-	O	O
17	B-IUPAC	O
-	I-IUPAC	O
methylmorphinans	I-IUPAC	O
,	O	O
which	O	O
are	O	O
structurally	O	O
similar	O	O
to	O	O
1	O	O
but	O	O
are	O	O
either	O	O
not	O	O
expected	O	O
to	O	O
be	O	O
metabolized	O	O
to	O	O
2	O	O
or	O	O
might	O	O
do	O	O
so	O	O
at	O	O
a	O	O
reduced	O	O
rate	O	O
,	O	O
as	O	O
compared	O	O
to	O	O
1	O	O
,	O	O
were	O	O
prepared	O	O
.	O	O
Carbamoylation	O	O
of	O	O
the	O	O
N	O	O
-	O	O
terminus	O	O
as	O	O
in	O	O
des	O	O
-	O	O
AA	O	O
(	O	O
1,2,5	O	O
)	O	O
-	O	O
[	O	O
DTrp	O	O
(	O	O
8	O	O
)	O	O
,	O	O
IAmp	O	O
(	O	O
9	O	O
)	O	O
,	O	O
Tyr	O	O
(	O	O
11	O	O
)	O	O
]	O	O
-	O	O
Cbm	O	O
-	O	O
SRIF	O	O
(	O	O
27	O	O
)	O	O
increased	O	O
affinity	O	O
slightly	O	O
as	O	O
well	O	O
as	O	O
improved	O	O
selectivity	O	O
.	O	O
These	O	O
structure	O	O
-	O	O
affinity	O	O
findings	O	O
were	O	O
exploited	O	O
to	O	O
produce	O	O
nicotinamides	O	O
(	O	O
e.g.	O	O
13ii	O	O
and	O	O
25x	O	O
)	O	O
and	O	O
pyrazolo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyridines	I-IUPAC	I-IUPAC
(	O	O
e.g.	O	O
37f	O	O
and	O	O
37y	O	O
)	O	O
ligands	O	O
with	O	O
nanomolar	O	O
affinity	O	O
at	O	O
the	O	O
alpha	O	O
1	O	O
-	O	O
AR	O	O
subtype	O	O
prevalent	O	O
in	O	O
the	O	O
human	O	O
lower	O	O
urinary	O	O
tract	O	O
(	O	O
pA2	O	O
values	O	O
:	O	O
8.8	O	O
,	O	O
10.7	O	O
,	O	O
9.3	O	O
,	O	O
and	O	O
9.9	O	O
,	O	O
respectively	O	O
)	O	O
and	O	O
displaying	O	O
2-3	O	O
orders	O	O
of	O	O
magnitude	O	O
selectivity	O	O
over	O	O
the	O	O
alpha	O	O
1D	O	O
-	O	O
AR	O	O
.	O	O
Further	O	O
molecular	O	O
modifications	O	O
involve	O	O
the	O	O
pendant	O	O
phenyl	O	O
ring	O	O
as	O	O
well	O	O
as	O	O
quaternary	O	O
amine	O	O
compounds	O	O
.	O	O
In	O	O
contrast	O	O
,	O	O
the	O	O
compounds	O	O
with	O	O
a	O	O
phenethyl	O	B-IUPAC
ester	O	I-IUPAC
group	O	B-MODIFIER
,	O	O
which	O	O
exhibited	O	O
antagonist	O	O
activity	O	O
(	O	O
IC50	O	O
=	O	O
10	O	O
(	O	O
-	O	O
5	O	O
)	O	O
-	O	O
10	O	O
(	O	O
-	O	O
7	O	O
)	O	O
M	O	O
range	O	O
)	O	O
on	O	O
GPILSM	O	O
,	O	O
were	O	O
devoid	O	O
of	O	O
cardiac	O	O
agonist	O	O
activity	O	O
on	O	O
GPLA	O	O
.	O	O
Of	O	O
the	O	O
four	O	O
compounds	O	O
examined	O	O
,	O	O
only	O	O
compound	O	O
2	O	O
showed	O	O
significant	O	O
direct	O	O
activity	O	O
on	O	O
beta1	O	O
-	O	O
and	O	O
beta2	O	O
-	O	O
adrenergic	O	O
receptors	O	O
.	O	O
The	O	O
intrinsic	O	O
activity	O	O
of	O	O
the	O	O
compounds	O	O
was	O	O
evaluated	O	O
by	O	O
measuring	O	O
their	O	O
effect	O	O
on	O	O
VIP	O	O
-	O	O
stimulated	O	O
cAMP	O	O
production	O	O
in	O	O
GH4ZD10	O	O
cells	O	O
stably	O	O
transfected	O	O
with	O	O
the	O	O
5	O	O
-	O	O
HT1A	O	O
receptor	O	O
.	O	O
The	O	O
major	O	O
structural	O	O
differences	O	O
between	O	O
2a	O	O
and	O	O
(	O	O
3S	O	O
,	O	O
4R	O	O
)	O	O
-	O	O
3	O	O
are	O	O
that	O	O
2a	O	O
possesses	O	O
a	O	O
different	O	O
absolute	O	O
stereochemistry	O	O
and	O	O
has	O	O
an	O	O
ethylene	O	O
bridge	O	O
not	O	O
present	O	O
in	O	O
3	O	O
.	O	O
To	O	O
develop	O	O
potential	O	O
antitumor	O	O
agents	O	O
directed	O	O
toward	O	O
HER2	O	O
/	O	O
ErbB2	O	O
overexpression	O	O
in	O	O
cancer	O	O
,	O	O
we	O	O
have	O	O
designed	O	O
inhibitors	O	O
of	O	O
the	O	O
recognition	O	O
between	O	O
the	O	O
phosphotyrosine	O	O
of	O	O
the	O	O
receptor	O	O
and	O	O
the	O	O
SH2	O	O
domain	O	O
of	O	O
the	O	O
adaptor	O	O
protein	O	O
Grb2	O	O
.	O	O
Glycosylation	O	O
of	O	O
ethyl	B-IUPAC	B-IUPAC
3	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
bromomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
pyrazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylate	I-IUPAC	I-IUPAC
(	O	O
3	O	O
)	O	O
and	O	O
3	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
bromomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
pyrazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamide	I-IUPAC	I-IUPAC
(	O	O
4	O	O
)	O	O
with	O	O
poly	O	O
-	O	O
O	O	O
-	O	O
acetylated	O	O
sugars	O	O
via	O	O
an	O	O
acid	O	O
-	O	O
catalyzed	O	O
fusion	O	O
method	O	O
afforded	O	O
the	O	O
corresponding	O	O
ethyl	B-IUPAC	B-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
bromomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
pyrazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylate	I-IUPAC	I-IUPAC
and	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
bromomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
pyrazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamide	I-IUPAC	I-IUPAC
substituted	B-MODIFIER	B-MODIFIER
nucleosides	I-MODIFIER	O
5	I-MODIFIER	O
and	O	O
7	B-MODIFIER	O
,	O	O
respectively	O	O
.	O	O
The	O	O
compounds	O	O
are	O	O
related	O	O
to	O	O
Lu	O	O
28-179	O	O
(	O	B-IUPAC
1'	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
indol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
spiro	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
isobenzofuran	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidine	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
)	O	I-IUPAC
that	O	O
has	O	O
been	O	O
demonstrated	O	O
to	O	O
be	O	O
a	O	O
selective	O	O
sigma	O	O
2	O	O
ligand	O	O
with	O	O
affinity	O	O
in	O	O
the	O	O
subnanomolar	O	O
range	O	O
.	O	O
Substitution	O	O
at	O	O
position	O	O
1	O	O
or	O	O
3	O	O
with	O	O
methyl	O	O
or	O	O
fluorine	O	O
atoms	O	O
always	O	O
led	O	O
to	O	O
more	O	O
active	O	O
compounds	O	O
.	O	O
N1	B-IUPAC	O
-	I-IUPAC	O
Allylchlorpropamide	I-IUPAC	O
3	O	O
was	O	O
,	O	O
as	O	O
expected	O	O
,	O	O
a	O	O
potent	O	O
inhibitor	O	O
of	O	O
hepatic	O	O
AlDH	O	O
in	O	O
rats	O	O
,	O	O
as	O	O
indicated	O	O
by	O	O
the	O	O
4	O	O
-	O	O
fold	O	O
increase	O	O
in	O	O
the	O	O
levels	O	O
of	O	O
ethanol	O	O
-	O	O
derived	O	O
blood	O	O
acetaldehyde	O	O
relative	O	O
to	O	O
that	O	O
elicited	O	O
by	O	O
chlorpropamide	O	O
itself	O	O
.	O	O
coli	O	O
thymidine	O	O
kinase	O	O
(	O	O
TK	O	O
)	O	O
,	O	O
and	O	O
of	O	O
yeast	O	O
hexokinase	O	O
(	O	O
HK	O	O
)	O	O
and	O	O
rat	O	O
KH	O	O
I	O	O
,	O	O
II	O	O
,	O	O
and	O	O
III	O	O
isozymes	O	O
.	O	O
Hence	O	O
rotational	O	O
restriction	O	O
of	O	O
the	O	O
side	O	O
chain	O	O
did	O	O
not	O	O
interfere	O	O
with	O	O
the	O	O
initial	O	O
FPGS	O	O
-	O	O
catalyzed	O	O
reaction	O	O
and	O	O
indeed	O	O
seemed	O	O
to	O	O
facilitate	O	O
it	O	O
,	O	O
but	O	O
the	O	O
ensuing	O	O
gamma	O	O
-	O	O
glutamyl	O	O
adduct	O	O
was	O	O
no	O	O
longer	O	O
an	O	O
efficient	O	O
substrate	O	O
for	O	O
the	O	O
enzyme	O	O
.	O	O
All	O	O
these	O	O
imidazole	O	O
nucleosides	O	O
were	O	O
tested	O	O
in	O	O
HeLa	O	O
cell	O	O
cultures	O	O
against	O	O
type	O	O
1	O	O
herpes	O	O
simplex	O	O
and	O	O
vesicular	O	O
stomatitis	O	O
viruses	O	O
.	O	O
We	O	O
describe	O	O
a	O	O
new	O	O
versatile	O	O
synthesis	O	O
of	O	O
this	O	O
homologue	O	O
of	O	O
AMPA	O	O
and	O	O
the	O	O
synthesis	O	O
of	O	O
compound	O	O
10	O	O
.	O	O
The	O	O
prototype	O	O
of	O	O
such	O	O
a	O	O
compound	O	O
was	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidinyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
indole	I-IUPAC	I-IUPAC
,	O	O
11a	O	O
(	O	O
code	O	O
no	O	O
.	O	O
The	O	O
polyamine	O	O
spacer	O	O
units	O	O
ranged	O	O
from	O	O
generic	O	O
(	O	O
4,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
triamine	I-IUPAC	I-IUPAC
,	O	O
4,3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
triamine	I-IUPAC	I-IUPAC
,	O	O
and	O	O
diaminooctane	O	O
)	O	O
spacers	O	O
to	O	O
more	O	O
exotic	O	O
[	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
ethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethanoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
containing	B-MODIFIER	I-IUPAC
diamine	B-IUPAC	I-IUPAC
,	O	O
hydroxylated	B-MODIFIER	O
4,3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
triamine	I-IUPAC	I-IUPAC
,	O	O
and	O	O
cyclohexylene	O	O
-	O	O
containing	O	O
triamine	O	O
]	O	O
spacers	O	O
.	O	O
A	O	O
number	O	O
of	O	O
conjugates	O	O
of	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluoroorotic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
and	O	O
peptides	O	O
were	O	O
synthesized	O	O
using	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
ethoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carbonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydroquinoline	I-IUPAC	I-IUPAC
as	O	O
the	O	O
coupling	O	O
agent	O	O
.	O	O
1c	O	O
and	O	O
FU	O	O
inhibited	O	O
the	O	O
growth	O	O
of	O	O
Chinese	O	O
hamster	O	O
ovary	O	O
(	O	O
CHO	O	O
)	O	O
cells	O	O
in	O	O
culture	O	O
at	O	O
a	O	O
concentration	O	O
of	O	O
5	O	O
x	O	O
10	O	O
(	O	O
-	O	O
6	O	O
)	O	O
M	O	O
.	O	O
The	O	O
relationship	O	O
between	O	O
the	O	O
key	O	O
PAF	O	O
antagonist	O	O
pharmacophores	O	O
of	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylimidazo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
c	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyridine	I-IUPAC	I-IUPAC
,	O	O
a	O	O
triazolothienodiazepine	O	O
(	O	O
WEB2170	O	O
)	O	O
,	O	O
and	O	O
a	O	O
pyrrolothiazolidine	O	O
(	O	O
RP	O	O
-	O	O
52,770	O	O
)	O	O
is	O	O
discussed	O	O
.	O	O
The	O	O
formation	O	O
of	O	O
a	O	O
gamma	O	O
-	O	O
lactone	O	O
ring	O	O
in	O	O
the	O	O
side	O	O
chain	O	O
,	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzopyran	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylbutyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxoethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
butan	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
olid	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
ammonium	I-IUPAC	I-IUPAC
chloride	I-IUPAC	I-IUPAC
(	O	O
6	O	O
)	O	O
,	O	O
resulted	O	O
in	O	O
a	O	O
small	O	O
decrease	O	O
in	O	O
activity	O	O
.	O	O
Optimization	O	O
of	O	O
substituents	O	O
at	O	O
these	O	O
two	O	O
positions	O	O
identified	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyclohexyladenine	I-IUPAC	I-IUPAC
(	O	O
12	O	O
)	O	O
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cycloheptyladenine	I-IUPAC	I-IUPAC
(	O	O
19	O	O
)	O	O
,	O	O
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenylamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
endo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
norbornyladenine	I-IUPAC	I-IUPAC
(	O	O
21	O	O
)	O	O
as	O	O
potent	O	O
A	O	O
(	O	O
3	O	O
)	O	O
AR	O	O
ligands	O	O
with	O	O
K	O	O
(	O	O
i	O	O
)	O	O
values	O	O
of	O	O
51	O	O
,	O	O
42	O	O
,	O	O
and	O	O
37	O	O
nM	O	O
,	O	O
respectively	O	O
,	O	O
with	O	O
30-200	O	O
-	O	O
fold	O	O
selectivity	O	O
in	O	O
comparison	O	O
to	O	O
A	O	O
(	O	O
1	O	O
)	O	O
and	O	O
A	O	O
(	O	O
2A	O	O
)	O	O
ARs	O	O
.	O	O
In	O	O
Chinese	O	O
hamster	O	O
ovary	O	O
cells	O	O
stably	O	O
transfected	O	O
with	O	O
human	O	O
A2B	O	O
receptor	O	O
cDNA	O	O
,	O	O
inhibition	O	O
of	O	O
agonist	O	O
-	O	O
induced	O	O
cyclic	O	O
AMP	O	O
production	O	O
was	O	O
measured	O	O
.	O	O
Placement	O	O
of	O	O
the	O	O
epoxyalkyl	O	O
group	O	O
at	O	O
the	O	O
carboxy	O	O
terminus	O	O
led	O	O
to	O	O
potent	O	O
rapid	O	O
inactivation	O	O
.	O	O
Evaluation	O	O
of	O	O
minimum	O	O
inhibitory	O	O
concentrations	O	O
of	O	O
peptide	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorocytosine	I-IUPAC	I-IUPAC
conjugates	B-MODIFIER	O
suggest	O	O
that	O	O
these	O	O
conjugates	O	O
enter	O	O
C	O	O
.	O	O
Of	O	O
the	O	O
other	O	O
agents	O	O
,	O	O
4	O	O
exhibited	O	O
the	O	O
most	O	O
favorable	O	O
pharmaceutical	O	O
profile	O	O
:	O	O
the	O	O
agent	O	O
has	O	O
appropriate	O	O
stability	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
tumor	O	O
cells	O	O
and	O	O
rat	O	O
liver	O	O
microsomes	O	O
and	O	O
achieves	O	O
rapid	O	O
ingress	O	O
into	O	O
cell	O	O
nuclei	O	O
where	O	O
the	O	O
putative	O	O
molecular	O	O
target	O	O
is	O	O
located	O	O
.	O	O
l	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenylalanine	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
ester	I-IUPAC	I-IUPAC
complex	B-MODIFIER	B-MODIFIER
(	O	O
5	O	O
)	O	O
,	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
boraadamantane	I-IUPAC	I-IUPAC
.	I-IUPAC	O
In	O	O
a	O	O
preliminary	O	O
behavioral	O	O
study	O	O
on	O	O
rats	O	O
(	O	O
+	O	O
)	O	O
-	O	O
14b	O	O
,	O	O
and	O	O
to	O	O
a	O	O
greater	O	O
extent	O	O
(	O	O
+	O	O
)	O	O
-	O	O
15b	O	O
,	O	O
promoted	O	O
episodes	O	O
of	O	O
intense	O	O
grooming	O	O
,	O	O
thus	O	O
indicating	O	O
that	O	O
they	O	O
act	O	O
as	O	O
central	O	O
D1	O	O
agonists	O	O
.	O	O
The	O	O
antiviral	O	O
activity	O	O
of	O	O
TFPe	O	O
-	O	O
dUrd	O	O
was	O	O
determined	O	O
in	O	O
cell	O	O
culture	O	O
against	O	O
herpes	O	O
simplex	O	O
virus	O	O
type	O	O
1	O	O
(	O	O
HSV	O	O
-	O	O
1	O	O
)	O	O
,	O	O
herpes	O	O
simplex	O	O
virus	O	O
type	O	O
2	O	O
(	O	O
HSV	O	O
-	O	O
2	O	O
)	O	O
,	O	O
and	O	O
vaccinia	O	O
virus	O	O
and	O	O
compared	O	O
concurrently	O	O
with	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
,	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bromovinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
,	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
iodo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
,	O	O
and	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
trifluoromethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
.	O	O
The	O	O
metabolite	O	O
-	O	O
corrected	O	O
blood	O	O
half	O	O
-	O	O
life	O	O
was	O	O
41	O	O
min	O	O
.	O	O
These	O	O
conjugates	O	O
exhibited	O	O
very	O	O
strong	O	O
antibacterial	O	O
activity	O	O
in	O	O
vitro	O	O
against	O	O
Gram	O	O
-	O	O
negative	O	O
bacterial	O	O
pathogens	O	O
including	O	O
Pseudomonas	O	O
aeruginosa	O	O
,	O	O
Stenotrophomonas	O	O
maltophilia	O	O
,	O	O
Escherichia	O	O
coli	O	O
,	O	O
Klebsiella	O	O
pneumoniae	O	O
,	O	O
and	O	O
Serratia	O	O
marcescens	O	O
.	O	O
In	O	O
the	O	O
2,6	O	O
series	O	O
activity	O	O
against	O	O
both	O	O
microsomal	O	O
systems	O	O
varied	O	O
only	O	O
over	O	O
a	O	O
relatively	O	O
narrow	O	O
range	O	O
,	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
allyloxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyacetophenone	I-IUPAC	I-IUPAC
(	O	O
19	O	O
)	O	O
being	O	O
the	O	O
most	O	O
potent	O	O
inhibitor	O	O
.	O	O
Boron	O	O
tribromide	O	O
demethylation	O	O
afforded	O	O
the	O	O
racemic	O	O
ring	O	O
-	O	O
fluorinated	O	O
norepinephrines	O	O
.	O	O
The	O	O
site	O	O
of	O	O
glycosylation	O	O
and	O	O
anomeric	O	O
configuration	O	O
of	O	O
6a	O	O
and	O	O
6c	O	O
were	O	O
assigned	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
spectral	O	O
studies	O	O
as	O	O
well	O	O
as	O	O
conversion	O	O
to	O	O
allopurinol	O	O
ribonucleoside	O	O
,	O	O
whereas	O	O
the	O	O
structural	O	O
assignment	O	O
of	O	O
6b	O	O
was	O	O
made	O	O
by	O	O
single	O	O
-	O	O
crystal	O	O
X	O	O
-	O	O
ray	O	O
analysis	O	O
.	O	O
These	O	O
glucagon	O	O
analogues	O	O
have	O	O
been	O	O
made	O	O
by	O	O
either	O	O
deleting	O	O
or	O	O
substituting	O	O
hydrophobic	O	O
groups	O	O
,	O	O
hydrophilic	O	O
groups	O	O
,	O	O
aromatic	O	O
amino	O	O
acids	O	O
,	O	O
or	O	O
a	O	O
D	O	B-IUPAC
-	O	I-IUPAC
phenylalanine	O	I-IUPAC
residue	O	B-MODIFIER
at	O	O
this	O	O
position	O	O
.	O	O
The	O	O
very	O	O
potent	O	O
AMPA	O	O
agonist	O	O
effect	O	O
of	O	O
7f	O	O
(	O	O
IC50	O	O
=	O	O
0.15	O	O
+	O	O
/	O	O
-	O	O
0.03	O	O
microM	O	O
;	O	O
EC50	O	O
=	O	O
1.7	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O
Several	O	O
N	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
N'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylene	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
dioxamic	I-IUPAC	I-IUPAC
acids	I-IUPAC	I-IUPAC
were	O	O
synthesized	O	O
also	O	O
in	O	O
the	O	O
same	O	O
manner	O	O
starting	O	O
with	O	O
the	O	O
requisite	O	O
p	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenylenediamines	I-IUPAC	I-IUPAC
.	O	O
Reaction	O	O
of	O	O
2	O	O
with	O	O
ethylene	O	O
oxide	O	O
resulted	O	O
in	O	O
a	O	O
mixture	O	O
of	O	O
two	O	O
compounds	O	O
,	O	O
the	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dinitroimidazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethanol	I-IUPAC	I-IUPAC
(	O	O
4	O	O
)	O	O
and	O	O
2,3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nitroimidazo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
oxazole	I-IUPAC	I-IUPAC
(	O	O
5	O	O
)	O	O
.	O	O
For	O	O
derivatives	O	O
unsubstituted	O	O
at	O	O
the	O	O
benzene	O	O
ring	O	O
,	O	O
the	O	O
highest	O	O
activity	O	O
was	O	O
obtained	O	O
for	O	O
the	O	O
9	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
rac	O	O
-	O	O
20	O	O
,	O	O
previously	O	O
prepared	O	O
by	O	O
our	O	O
group	O	O
.	O	O
They	O	O
were	O	O
tested	O	O
in	O	O
radioligand	O	O
binding	O	O
assays	O	O
on	O	O
sigma	O	O
(	O	O
[	O	O
3H	O	O
]	O	O
DTG	O	O
and	O	O
[	O	O
3H	O	O
]	O	O
-	O	O
(	O	O
+	O	O
)	O	O
-	O	O
pentazocine	O	O
)	O	O
,	O	O
D	O	O
-	O	O
2	O	O
dopaminergic	O	O
,	O	O
5	O	O
-	O	O
HT1A	O	O
and	O	O
5	O	O
-	O	O
HT2	O	O
serotonergic	O	O
,	O	O
and	O	O
PCP	O	O
(	O	O
phencyclidine	O	O
)	O	O
receptors	O	O
.	O	O
Judging	O	O
from	O	O
the	O	O
investigation	O	O
of	O	O
selected	O	O
compounds	O	O
,	O	O
it	O	O
appears	O	O
that	O	O
they	O	O
are	O	O
also	O	O
potent	O	O
at	O	O
human	O	O
A	O	O
(	O	O
1	O	O
)	O	O
ARs	O	O
and	O	O
selective	O	O
not	O	O
only	O	O
versus	O	O
A	O	O
(	O	O
2A	O	O
)	O	O
ARs	O	O
but	O	O
also	O	O
highly	O	O
selective	O	O
versus	O	O
A	O	O
(	O	O
2B	O	O
)	O	O
and	O	O
A	O	O
(	O	O
3	O	O
)	O	O
ARs	O	O
.	O	O
The	O	O
most	O	O
potent	O	O
compound	O	O
of	O	O
the	O	O
series	O	O
was	O	O
(	B-IUPAC	B-IUPAC
1S	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
2R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cis	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
hydroxyamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxoethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
methylamino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
carbonyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
cyclohexanecarboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
21a	O	O
)	O	O
with	O	O
an	O	O
IC50	O	O
value	O	O
of	O	O
7.0	O	O
nM	O	O
compared	O	O
with	O	O
the	O	O
value	O	O
of	O	O
3.0	O	O
nM	O	O
for	O	O
captopril	O	O
.	O	O
cruzi	O	O
.	O	O
In	O	O
this	O	O
study	O	O
we	O	O
designed	O	O
,	O	O
prepared	O	O
,	O	O
and	O	O
analyzed	O	O
a	O	O
water	O	O
-	O	O
soluble	O	O
,	O	O
long	O	O
-	O	O
acting	O	O
insulin	O	O
derivative	O	O
whose	O	O
protracted	O	O
action	O	O
in	O	O
vivo	O	O
is	O	O
based	O	O
on	O	O
a	O	O
new	O	O
principle	O	O
rather	O	O
than	O	O
on	O	O
slower	O	O
absorption	O	O
rates	O	O
of	O	O
suspended	O	O
insulin	O	O
formulations	O	O
.	O	O
It	O	O
is	O	O
suggested	O	O
that	O	O
different	O	O
conformations	O	O
of	O	O
the	O	O
5	O	O
-	O	O
HT	O	O
-	O	O
receptor	O	O
agonists	O	O
(	B-IUPAC	B-IUPAC
1R	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
2S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
di	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
n	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propylcyclopropylamine	I-IUPAC	I-IUPAC
[	O	O
(	O	O
1R	O	O
,	O	O
2S	O	O
)	O	O
-	O	O
4	O	O
]	O	O
and	O	O
its	O	O
3	B-IUPAC	O
-	I-IUPAC	O
hydroxy	I-IUPAC	O
isomer	B-MODIFIER	O
(	O	O
1R	O	O
,	O	O
2S	O	O
)	O	O
-	O	O
5	O	O
are	O	O
able	O	O
to	O	O
activate	O	O
5	O	O
-	O	O
HT	O	O
receptors	O	O
.	O	O
gondii	O	O
)	O	O
were	O	O
compared	O	O
.	O	O
Studies	O	O
have	O	O
now	O	O
shown	O	O
that	O	O
exo	O	O
-	O	O
active	O	O
-	O	O
site	O	O
-	O	O
directed	O	O
reagents	O	O
can	O	O
act	O	O
as	O	O
isozyme	O	O
-	O	O
or	O	O
species	O	O
-	O	O
selective	O	O
enzyme	O	O
inhibitors	O	O
.	O	O
The	O	O
new	O	O
derivatives	O	O
(	O	O
1c	O	O
-	O	O
g	O	O
)	O	O
and	O	O
also	O	O
the	O	O
known	O	O
diethyl	O	O
ester	O	O
of	O	O
1a	O	O
(	O	O
1b	O	O
)	O	O
were	O	O
tested	O	O
for	O	O
their	O	O
inhibition	O	O
of	O	O
purified	O	O
L1210	O	O
thymidylate	O	O
synthase	O	O
(	O	O
TS	O	O
)	O	O
and	O	O
for	O	O
their	O	O
inhibition	O	O
of	O	O
the	O	O
growth	O	O
of	O	O
L1210	O	O
cells	O	O
in	O	O
culture	O	O
.	O	O
Replacement	O	O
of	O	O
the	O	O
methyl	O	O
with	O	O
hydrophilic	O	O
substituents	O	O
on	O	O
the	O	O
benzylic	O	O
carbon	O	O
lowered	O	O
affinity	O	O
.	O	O
Stannic	O	O
chloride	O	O
catalyzed	O	O
condensation	O	O
of	O	O
pertrimethylsilyl	O	O
ketoaglycon	O	O
4a	O	O
with	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
chloromethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
toluoyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethane	I-IUPAC	I-IUPAC
to	O	O
give	O	O
ketonucleoside	O	O
6,7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
toluoyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethoxy	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
imidazo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
diazepin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
(	O	O
9a	O	O
)	O	O
was	O	O
followed	O	O
by	O	O
deprotection	O	O
to	O	O
6,7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
imidazo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
diazepin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
(	O	O
9b	O	O
)	O	O
and	O	O
then	O	O
reduction	O	O
to	O	O
the	O	O
racemic	O	O
acyclic	O	O
pentostatin	O	O
analogue	O	O
(	B-IUPAC	B-IUPAC
+	I-IUPAC	I-IUPAC
/	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,6,7,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
imidazo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
diazepin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ol	I-IUPAC	I-IUPAC
(	O	O
2	O	O
)	O	O
.	O	O
The	O	O
greatest	O	O
improvement	O	O
in	O	O
FT	O	O
inhibitory	O	O
potency	O	O
was	O	O
observed	O	O
for	O	O
the	O	O
Tic	O	O
derivative	O	O
(	O	O
IC50	O	O
=	O	O
1	O	O
nM	O	O
)	O	O
;	O	O
however	O	O
,	O	O
this	O	O
compound	O	O
was	O	O
ineffective	O	O
in	O	O
blocking	O	O
oncogenic	O	O
Ras	O	O
-	O	O
induced	O	O
transformation	O	O
of	O	O
NIH	O	O
-	O	O
3T3	O	O
fibroblast	O	O
cells	O	O
.	O	O
Because	O	O
of	O	O
its	O	O
decreased	O	O
receptor	O	O
-	O	O
binding	O	O
affinity	O	O
,	O	O
(	O	O
FMS	O	O
)	O	O
(	O	O
3	O	O
)	O	O
-	O	O
insulin	O	O
evades	O	O
receptor	O	O
-	O	O
mediated	O	O
endocytosis	O	O
and	O	O
degradation	O	O
and	O	O
,	O	O
hence	O	O
,	O	O
persists	O	O
for	O	O
a	O	O
long	O	O
period	O	O
in	O	O
the	O	O
circulation	O	O
.	O	O
A	O	O
similar	O	O
dehydration	O	O
of	O	O
the	O	O
precursor	O	O
tetraacetyl	B-IUPAC	O
derivative	B-MODIFIER	O
of	O	O
4	O	O
gave	O	O
the	O	O
corresponding	O	O
carbonitrile	O	O
,	O	O
which	O	O
on	O	O
deprotection	O	O
and	O	O
subsequent	O	O
treatment	O	O
with	O	O
hydroxylamine	O	O
furnished	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
benzyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ribofuranosylpyrazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamidoxime	I-IUPAC	I-IUPAC
(	O	O
13	O	O
)	O	O
.	O	O
3	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
[	I-PARTIUPAC	I-IUPAC
4	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
(	O	I-IUPAC
ortho	B-IUPAC	I-IUPAC
-	O	I-IUPAC
Substituted	B-MODIFIER	I-IUPAC
phenyl	B-IUPAC	I-IUPAC
)	O	I-IUPAC
piperazin	B-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
1	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
yl	I-PARTIUPAC	I-IUPAC
]	I-PARTIUPAC	I-IUPAC
propylamines	I-PARTIUPAC	I-IUPAC
were	O	O
derivatized	O	O
with	O	O
N	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
anthranilamides	I-IUPAC	I-IUPAC
,	O	O
nicotinamides	O	O
,	O	O
as	O	O
well	O	O
as	O	O
carboxamides	O	O
of	O	O
quinoline	O	O
,	O	O
1,8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
naphthyridine	I-IUPAC	I-IUPAC
,	O	O
pyrazolo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyridine	I-IUPAC	I-IUPAC
,	O	O
isoxazolo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyridine	I-IUPAC	I-IUPAC
,	O	O
imidazo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyridine	I-IUPAC	I-IUPAC
,	O	O
and	O	O
pyrazolo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
1,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidines	I-IUPAC	I-IUPAC
.	O	O
A	O	O
variety	O	O
of	O	O
mesoionic	O	O
xanthines	O	O
including	O	O
mesoionic	B-MODIFIER	O
thiazolo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
3,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidines	I-IUPAC	I-IUPAC
,	O	O
benzothiazolopyrimidines	B-IUPAC	O
,	O	O
and	O	O
1,3,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
thiadiazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidines	I-IUPAC	I-IUPAC
were	O	O
antagonists	O	O
of	O	O
A1	O	O
-	O	O
adenosine	O	O
receptors	O	O
(	O	O
inhibition	O	O
of	O	O
binding	O	O
of	O	O
[	B-IUPAC	B-IUPAC
3H	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyclohexyladenosine	I-IUPAC	I-IUPAC
)	O	O
and	O	O
A2	O	O
-	O	O
adenosine	O	O
receptors	O	O
(	O	O
inhibition	O	O
of	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloroadenosine	I-IUPAC	I-IUPAC
-	O	O
elicited	O	O
accumulations	O	O
of	O	O
cyclic	O	O
AMP	O	O
)	O	O
in	O	O
brain	O	O
tissue	O	O
.	O	O
Three	O	O
derivatives	O	O
(	O	O
5g	O	O
,	O	O
i	O	O
,	O	O
k	O	O
)	O	O
show	O	O
a	O	O
hypoxic	O	O
cytotoxicity	O	O
ratio	O	O
(	O	O
HCR	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
or	O	O
=	O	O
200	O	O
,	O	O
better	O	O
than	O	O
that	O	O
of	O	O
tirapazamine	O	O
(	O	O
HCR	O	O
=	O	O
75	O	O
)	O	O
in	O	O
V79	O	O
cells	O	O
.	O	O
Catechol	O	O
estrogens	O	O
are	O	O
implicated	O	O
as	O	O
possible	O	O
causative	O	O
agents	O	O
in	O	O
estrogen	O	O
-	O	O
induced	O	O
tumorigenesis	O	O
.	O	O
Following	O	O
metabolism	O	O
of	O	O
2	O	O
by	O	O
rat	O	O
liver	O	O
microsomes	O	O
the	O	O
predicted	O	O
formation	O	O
of	O	O
4,4,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
trifluorocrotonaldehyde	I-IUPAC	I-IUPAC
(	O	O
5	O	O
)	O	O
was	O	O
confirmed	O	O
by	O	O
isolation	O	O
and	O	O
identification	O	O
,	O	O
by	O	O
mass	O	O
spectrometry	O	O
,	O	O
of	O	O
its	O	O
dinitrophenylhydrazone	O	O
.	O	O
Noteworthy	O	O
,	O	O
all	O	O
compounds	O	O
within	O	O
the	O	O
series	O	O
induced	O	O
elongations	O	O
in	O	O
K562	O	O
cells	O	O
similar	O	O
to	O	O
vinblastine	O	O
-	O	O
treated	O	O
cells	O	O
.	O	O
These	O	O
compounds	O	O
will	O	O
serve	O	O
as	O	O
templates	O	O
in	O	O
the	O	O
design	O	O
of	O	O
still	O	O
further	O	O
sigma	O	O
-	O	O
2	O	O
subtype	O	O
selective	O	O
ligands	O	O
.	O	O
A	O	O
series	O	O
of	O	O
thieno	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
oxazin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
and	O	O
thieno	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
thiazin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
were	O	O
synthesized	O	O
and	O	O
investigated	O	O
as	O	O
inhibitors	O	O
of	O	O
the	O	O
alpha	O	O
/	O	O
beta	O	O
hydrolases	O	O
cholesterol	O	O
esterase	O	O
(	O	O
CEase	O	O
)	O	O
and	O	O
acetylcholinesterase	O	O
(	O	O
AChE	O	O
)	O	O
.	O	O
A	O	O
series	O	O
of	O	O
new	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iodoethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
and	O	O
uridine	B-IUPAC	B-IUPAC
compounds	B-MODIFIER	B-MODIFIER
(	O	O
11	O	O
,	O	O
16	O	O
)	O	O
was	O	O
synthesized	O	O
by	O	O
the	O	O
regiospecific	O	O
addition	O	O
of	O	O
HOI	O	O
to	O	O
the	O	O
vinyl	O	O
substituent	O	O
of	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
vinyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
(	O	O
10a	O	O
)	O	O
,	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
vinyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
(	O	O
10b	O	O
)	O	O
,	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
vinyluridine	I-IUPAC	I-IUPAC
(	O	O
10c	O	O
)	O	O
,	O	O
and	O	O
(	B-IUPAC	B-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iodovinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
(	O	O
4b	O	O
)	O	O
.	O	O
The	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
iodo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nitroimidazole	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
were	O	O
more	O	O
efficient	O	O
as	O	O
sensitizers	O	O
than	O	O
the	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
iodo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nitroimidazole	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
,	O	O
and	O	O
the	O	O
sensitizing	O	O
efficiency	O	O
of	O	O
this	O	O
class	O	O
of	O	O
agents	O	O
was	O	O
found	O	O
to	O	O
have	O	O
significant	O	O
correlation	O	O
with	O	O
their	O	O
partition	O	O
coefficients	O	O
.	O	O
(	O	B-IUPAC
3S	O	I-IUPAC
,	O	I-IUPAC
4R	O	I-IUPAC
)	O	I-IUPAC
-	O	I-IUPAC
4	O	I-IUPAC
-	O	I-IUPAC
(	O	I-IUPAC
4	O	I-IUPAC
-	O	I-IUPAC
Fluorophenyl	O	I-IUPAC
)	O	I-IUPAC
-	O	I-IUPAC
3	O	I-IUPAC
-	O	I-IUPAC
[	O	I-IUPAC
[	O	I-IUPAC
3,4	O	I-IUPAC
-	O	I-IUPAC
(	O	I-IUPAC
methylenedioxy	O	I-IUPAC
)	O	I-IUPAC
phenoxy	O	I-IUPAC
]	O	I-IUPAC
methyl	O	I-IUPAC
]	O	I-IUPAC
piperidine	O	I-IUPAC
[	O	O
(	O	O
3S	O	O
,	O	O
9R	O	O
)	O	O
-	O	O
3	O	O
,	O	O
paroxetine	O	O
]	O	O
is	O	O
a	O	O
selective	O	O
serotonin	O	O
reuptake	O	O
inhibitor	O	O
(	O	O
SSRI	O	O
)	O	O
used	O	O
as	O	O
an	O	O
antidepressant	O	O
in	O	O
humans	O	O
.	O	O
Methyl	B-IUPAC	B-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
isothiocyanatomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
thiazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carbamate	I-IUPAC	I-IUPAC
and	O	O
methyl	B-IUPAC	B-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
isothiocyanatomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
selenazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carbamate	I-IUPAC	I-IUPAC
have	O	O
been	O	O
prepared	O	O
via	O	O
chemical	O	O
transformations	O	O
involving	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
chloromethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
thiazole	I-IUPAC	I-IUPAC
(	O	O
1	O	O
)	O	O
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
chloromethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
selenazole	I-IUPAC	I-IUPAC
(	O	O
2	O	O
)	O	O
,	O	O
respectively	O	O
,	O	O
as	O	O
starting	O	O
materials	O	O
.	O	O
A	O	O
series	O	O
of	O	O
unsaturated	O	O
analogues	O	O
of	O	O
nucleosides	O	O
were	O	O
prepared	O	O
and	O	O
their	O	O
cytotoxic	O	O
,	O	O
antitumor	O	O
,	O	O
and	O	O
antiviral	O	O
activities	O	O
were	O	O
investigated	O	O
.	O	O
Both	O	O
analogues	O	O
were	O	O
evaluated	O	O
in	O	O
vitro	O	O
as	O	O
inhibitors	O	O
of	O	O
DHFRs	O	O
from	O	O
(	O	O
recombinant	O	O
)	O	O
human	O	O
,	O	O
human	O	O
CCRF	O	O
-	O	O
CEM	O	O
cells	O	O
,	O	O
and	O	O
Lactobacillus	O	O
casei	O	O
.	O	O
No	O	O
intermediates	O	O
were	O	O
detected	O	O
in	O	O
the	O	O
incubation	O	O
mixture	O	O
.	O	O
The	O	O
compound	O	O
inhibited	O	O
(	O	O
IC50	O	O
=	O	O
20	O	O
nM	O	O
)	O	O
the	O	O
conversion	O	O
of	O	O
[	O	O
14C	O	O
]	O	O
formate	O	O
to	O	O
[	B-IUPAC	O
14C	I-IUPAC	O
]	I-IUPAC	O
-	I-IUPAC	O
formylglycinamide	I-IUPAC	O
ribonucleotide	I-IUPAC	O
by	O	O
MOLT	O	O
-	O	O
4	O	O
cells	O	O
in	O	O
culture	O	O
.	O	O
Our	O	O
results	O	O
show	O	O
dihydropyrimidines	B-IUPAC	O
3	O	O
are	O	O
significantly	O	O
more	O	O
potent	O	O
than	O	O
corresponding	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
heteroalkyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydropyrimidines	I-IUPAC	I-IUPAC
2	O	O
and	O	O
only	O	O
slightly	O	O
less	O	O
potent	O	O
than	O	O
similarly	O	O
substituted	B-MODIFIER	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
heteroalkyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydropyridines	I-IUPAC	I-IUPAC
4	O	O
and	O	O
5	O	O
.	O	O
Selectivity	O	O
at	O	O
the	O	O
receptor	O	O
subclasses	O	O
was	O	O
examined	O	O
by	O	O
performing	O	O
an	O	O
A2	O	O
adenosine	O	O
receptor	O	O
affinity	O	O
assay	O	O
with	O	O
[	O	O
3H	O	O
]	O	O
CGS	O	O
21680	O	O
.	O	O
Studies	O	O
indicate	O	O
that	O	O
there	O	O
is	O	O
now	O	O
a	O	O
cis	O	O
-	O	O
amide	O	O
bond	O	O
present	O	O
which	O	O
redirects	O	O
the	O	O
carboxylate	O	O
toward	O	O
the	O	O
pharmacophoric	O	O
gem	O	O
-	O	O
dimethyl	O	O
groups	O	O
.	O	O
With	O	O
the	O	O
exception	O	O
of	O	O
II	O	O
and	O	O
III	O	O
,	O	O
all	O	O
the	O	O
other	O	O
analogs	O	O
had	O	O
very	O	O
low	O	O
intrinsic	O	O
activities	O	O
,	O	O
per	O	O
se	O	O
.	O	O
The	O	O
growth	O	O
-	O	O
promoting	O	O
ability	O	O
of	O	O
each	O	O
was	O	O
evaluated	O	O
with	O	O
the	O	O
siderophore	O	O
biosynthesis	O	O
mutant	O	O
Shigella	O	O
flexneri	O	O
SA240	O	O
(	O	O
SA	O	O
100	O	O
iucD	O	O
:	O	O
Tn5	O	O
)	O	O
.	O	O
d	O	O
.	O	O
Similarly	O	O
,	O	O
they	O	O
also	O	O
showed	O	O
improved	O	O
inhibition	O	O
of	O	O
L1210	O	O
cell	O	O
growth	O	O
(	O	O
1.5-5	O	O
-	O	O
fold	O	O
)	O	O
,	O	O
and	O	O
this	O	O
activity	O	O
was	O	O
prevented	O	O
by	O	O
co	O	O
-	O	O
incubation	O	O
with	O	O
thymidine	O	O
.	O	O
[	B-IUPAC	B-IUPAC
125I	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
17	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
Azido	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iodophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
18,19,20	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trinorprostaglandin	I-IUPAC	I-IUPAC
F2	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
was	O	O
utilized	O	O
in	O	O
a	O	O
preliminary	O	O
photoaffinity	O	O
cross	O	O
-	O	O
linking	O	O
experiment	O	O
.	O	O
Treatment	O	O
of	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bipyridine	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thiol	I-IUPAC	I-IUPAC
(	O	O
59	O	O
)	O	O
with	O	O
ethyl	B-IUPAC	B-IUPAC
bromoacetate	B-IUPAC	I-IUPAC
and	O	O
ethyl	B-IUPAC	B-IUPAC
bromodifluoroacetate	B-IUPAC	I-IUPAC
gave	O	O
pyridothiazinones	O	O
60	O	O
and	O	O
61	O	O
,	O	O
respectively	O	O
.	O	O
Against	O	O
the	O	O
EO771	O	O
mammary	O	O
adenocarcinoma	O	O
in	O	O
mice	O	O
,	O	O
6	O	O
produced	O	O
greater	O	O
antitumor	O	O
effect	O	O
than	O	O
MTX	O	O
.	O	O
These	O	O
observations	O	O
of	O	O
good	O	O
brain	O	O
penetration	O	O
and	O	O
high	O	O
affinity	O	O
and	O	O
selectivity	O	O
for	O	O
D	O	O
-	O	O
2	O	O
receptors	O	O
indicate	O	O
that	O	O
the	O	O
corresponding	O	O
iodine	O	O
-	O	O
123	O	O
-	O	O
labeled	O	O
benzamide	O	O
may	O	O
be	O	O
a	O	O
useful	O	O
ligand	O	O
for	O	O
the	O	O
noninvasive	O	O
visualization	O	O
study	O	O
of	O	O
dopamine	O	O
D	O	O
-	O	O
2	O	O
receptor	O	O
sites	O	O
in	O	O
vivo	O	O
by	O	O
single	O	O
photon	O	O
emission	O	O
computed	O	O
tomography	O	O
.	O	O
The	O	O
length	O	O
of	O	O
the	O	O
intermediate	O	O
side	O	O
chain	O	O
between	O	O
the	O	O
catechol	O	O
and	O	O
imidazoline	O	O
ring	O	O
or	O	O
the	O	O
amine	O	O
of	O	O
the	O	O
ethylenediamine	O	O
segment	O	O
was	O	O
shown	O	O
to	O	O
affect	O	O
the	O	O
adrenergic	O	O
activity	O	O
.	O	O
The	O	O
structure	O	O
-	O	O
activity	O	O
relationship	O	O
studies	O	O
on	O	O
the	O	O
binding	O	O
affinity	O	O
and	O	O
the	O	O
inhibition	O	O
of	O	O
AII	O	O
-	O	O
induced	O	O
pressor	O	O
response	O	O
suggested	O	O
that	O	O
straight	O	O
chains	O	O
of	O	O
a	O	O
certain	O	O
length	O	O
(	O	O
e.g.	O	O
,	O	O
ethoxy	O	O
groups	O	O
,	O	O
ethyl	O	O
groups	O	O
)	O	O
were	O	O
the	O	O
best	O	O
as	O	O
substituents	O	O
at	O	O
the	O	O
2	O	O
-	O	O
position	O	O
and	O	O
that	O	O
their	O	O
steric	O	O
factors	O	O
,	O	O
lipophilicity	O	O
,	O	O
and	O	O
electronic	O	O
effects	O	O
affected	O	O
the	O	O
potency	O	O
of	O	O
the	O	O
AII	O	O
antagonistic	O	O
action	O	O
.	O	O
Compounds	O	O
constructed	O	O
with	O	O
the	O	O
dideoxy	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
L	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
erythro	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
or	O	I-IUPAC
-	B-PARTIUPAC	I-IUPAC
threo	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
hexono	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
1,4	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
lactone	I-PARTIUPAC	I-IUPAC
template	O	O
were	O	O
synthesized	O	O
stereospecifically	O	O
from	O	O
tri	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
glucal	I-IUPAC	I-IUPAC
and	O	O
L	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
galactono	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
lactone	I-IUPAC	I-IUPAC
,	O	O
respectively	O	O
.	O	O
In	O	O
contrast	O	O
,	O	O
related	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
azirinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
uracil	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
(	O	O
10b	O	O
,	O	O
c	O	O
)	O	O
were	O	O
devoid	O	O
of	O	O
anti	O	O
-	O	O
DHBV	O	O
activity	O	O
,	O	O
indicating	O	O
that	O	O
an	O	O
acyclic	O	O
side	O	O
chain	O	O
at	O	O
C	O	O
-	O	O
5	O	O
position	O	O
of	O	O
the	O	O
pyrimidine	O	O
ring	O	O
is	O	O
essential	O	O
for	O	O
anti	O	O
-	O	O
HBV	O	O
activity	O	O
.	O	O
The	O	O
nature	O	O
of	O	O
the	O	O
substituent	O	O
introduced	O	O
in	O	O
the	O	O
7	O	O
-	O	O
position	O	O
as	O	O
well	O	O
as	O	O
the	O	O
nature	O	O
of	O	O
the	O	O
alkylamino	O	B-IUPAC
side	O	B-MODIFIER
chain	O	I-MODIFIER
in	O	O
the	O	O
3	O	O
-	O	O
position	O	O
strongly	O	O
affected	O	O
both	O	O
potency	O	O
and	O	O
tissue	O	O
selectivity	O	O
of	O	O
4H	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
1,2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzothiadiazine	I-IUPAC	I-IUPAC
1,1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dioxides	I-IUPAC	I-IUPAC
.	O	O
The	O	O
syn	O	O
/	O	O
anti	O	O
-	O	O
energy	O	O
barrier	O	O
for	O	O
these	O	O
nucleoside	O	O
analogues	O	O
is	O	O
5-6	O	O
kcal	O	O
/	O	O
mol	O	O
higher	O	O
than	O	O
for	O	O
common	O	O
nucleosides	O	O
.	O	O
Several	O	O
7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
,	O	O
12b	O	O
,	O	O
13b	O	O
.1	O	O
,	O	O
b	O	O
.2	O	O
,	O	O
and	O	O
14b	O	O
,	O	O
and	O	O
the	O	O
dimer	O	O
16b	O	O
have	O	O
been	O	O
prepared	O	O
and	O	O
evaluated	O	O
in	O	O
order	O	O
to	O	O
determine	O	O
the	O	O
optimum	O	O
lateral	O	O
chain	O	O
in	O	O
position	O	O
3	O	O
,	O	O
which	O	O
appears	O	O
to	O	O
be	O	O
the	O	O
[	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
moiety	B-MODIFIER	B-MODIFIER
.	O	O
From	O	O
the	O	O
results	O	O
of	O	O
this	O	O
study	O	O
,	O	O
we	O	O
conclude	O	O
that	O	O
a	O	O
phenyl	O	O
group	O	O
situated	O	O
at	O	O
C	O	O
-	O	O
3	O	O
(	O	O
alpha	O	O
to	O	O
the	O	O
lactone	O	O
carbonyl	O	O
group	O	O
)	O	O
in	O	O
both	O	O
the	O	O
5	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
iodomethylidene	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
furanone	I-IUPAC	I-IUPAC
(	O	O
I	O	O
)	O	O
and	O	O
6	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
iodomethylidene	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyranone	I-IUPAC	I-IUPAC
(	O	O
II	O	O
)	O	O
series	O	O
is	O	O
essential	O	O
for	O	O
their	O	O
activity	O	O
as	O	O
mechanism	O	O
-	O	O
based	O	O
irreversible	O	O
inactivators	O	O
of	O	O
chymotrypsin	O	O
.	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
m	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
Hydroxystyryl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
DMPX	I-IUPAC	I-IUPAC
(	O	O
7	O	O
)	O	O
and	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxypropyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
m	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxystyryl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propargylxanthine	I-IUPAC	I-IUPAC
(	O	O
5e	O	O
,	O	O
MSX	O	O
-	O	O
2	O	O
)	O	O
were	O	O
the	O	O
most	O	O
potent	O	O
and	O	O
A	O	O
(	O	O
2A	O	O
)	O	O
-	O	O
selective	O	O
compounds	O	O
and	O	O
were	O	O
selected	O	O
for	O	O
prodrug	O	O
formation	O	O
.	O	O
These	O	O
analogues	O	O
are	O	O
1	O	O
,	O	O
d	O	O
-	O	O
(	O	O
CH2	O	O
)	O	O
5	O	O
-	O	O
D	O	O
-	O	O
Phe2	O	O
,	O	O
Ile4AVP	O	O
;	O	O
2	O	O
,	O	O
d	O	O
(	O	O
CH2	O	O
)	O	O
5	O	O
-	O	O
D	O	O
-	O	O
Phe2	O	O
,	O	O
Abu4AVP	O	O
;	O	O
3	O	O
,	O	O
d	O	O
(	O	O
CH2	O	O
)	O	O
5	O	O
-	O	O
D	O	O
-	O	O
Phe2	O	O
,	O	O
Thr4AVP	O	O
;	O	O
4	O	O
,	O	O
d	O	O
(	O	O
CH2	O	O
)	O	O
5	O	O
-	O	O
D	O	O
-	O	O
Phe2	O	O
,	O	O
Ala4AVP	O	O
;	O	O
5	O	O
,	O	O
d	O	O
(	O	O
CH2	O	O
)	O	O
5	O	O
-	O	O
D	O	O
-	O	O
Phe2AVP	O	O
;	O	O
6	O	O
,	O	O
d	O	O
(	O	O
CH2	O	O
)	O	O
5	O	O
-	O	O
D	O	O
-	O	O
Phe2	O	O
,	O	O
Lys4AVP	O	O
;	O	O
7	O	O
,	O	O
d	O	O
(	O	O
CH2	O	O
)	O	O
5	O	O
-	O	O
D	O	O
-	O	O
Phe2	O	O
,	O	O
Cha4AVP	O	O
;	O	O
8	O	O
,	O	O
d	O	O
(	O	O
CH2	O	O
)	O	O
5	O	O
-	O	O
D	O	O
-	O	O
Phe2	O	O
,	O	O
Nle4AVP	O	O
;	O	O
9	O	O
,	O	O
d	O	O
(	O	O
CH2	O	O
)	O	O
5	O	O
-	O	O
D	O	O
-	O	O
Phe2	O	O
,	O	O
Nva4AVP	O	O
;	O	O
10	O	O
,	O	O
d	O	O
(	O	O
CH2	O	O
)	O	O
5	O	O
-	O	O
D	O	O
-	O	O
Phe2	O	O
,	O	O
Phe4AVP	O	O
;	O	O
11	O	O
,	O	O
d	O	O
(	O	O
CH2	O	O
)	O	O
5	O	O
-	O	O
D	O	O
-	O	O
Phe2	O	O
,	O	O
Leu4AVP	O	O
;	O	O
12	O	O
,	O	O
d	O	O
(	O	O
CH2	O	O
)	O	O
5	O	O
-	O	O
D	O	O
-	O	O
Phe2	O	O
,	O	O
Gly4AVP	O	O
;	O	O
13	O	O
,	O	O
d	O	O
(	O	O
CH2	O	O
)	O	O
5	O	O
-	O	O
D	O	O
-	O	O
Phe2	O	O
,	O	O
Tyr4AVP	O	O
;	O	O
14	O	O
,	O	O
d	O	O
(	O	O
CH2	O	O
)	O	O
5	O	O
-	O	O
D	O	O
-	O	O
Phe2	O	O
,	O	O
Pro4AVP	O	O
.	O	O
The	O	O
most	O	O
active	O	O
compounds	O	O
synthesized	O	O
were	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aminoisoquinoline	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxaldehyde	I-IUPAC	I-IUPAC
thiosemicarbazone	I-IUPAC	I-IUPAC
(	O	O
9a	O	O
)	O	O
and	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
methylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
isoquinoline	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxaldehyde	I-IUPAC	I-IUPAC
thiosemicarbazone	I-IUPAC	I-IUPAC
(	O	O
9b	O	O
)	O	O
,	O	O
which	O	O
both	O	O
produced	O	O
optimum	O	O
%	O	O
T	O	O
/	O	O
C	O	O
values	O	O
of	O	O
177	O	O
against	O	O
the	O	O
L1210	O	O
leukemia	O	O
in	O	O
mice	O	O
when	O	O
used	O	O
at	O	O
a	O	O
daily	O	O
dosage	O	O
of	O	O
40	O	O
mg	O	O
/	O	O
kg	O	O
for	O	O
6	O	O
consecutive	O	O
days	O	O
.	O	O
The	O	O
trans	O	O
-	O	O
[	O	O
PtCl2	O	O
(	O	O
NH3	O	O
)	O	O
(	O	O
pip	O	O
-	O	O
pip	O	O
)	O	O
]	O	O
x	O	O
HCl	O	O
was	O	O
significantly	O	O
more	O	O
potent	O	O
than	O	O
cisplatin	O	O
in	O	O
all	O	O
the	O	O
cisplatin	O	O
-	O	O
resistant	O	O
ovarian	O	O
cancer	O	O
cell	O	O
lines	O	O
and	O	O
was	O	O
nearly	O	O
as	O	O
cytotoxic	O	O
as	O	O
cisplatin	O	O
against	O	O
colon	O	O
cancer	O	O
cells	O	O
.	O	O
The	O	O
effect	O	O
of	O	O
the	O	O
lead	O	O
compound	O	O
9h	O	O
on	O	O
K562	O	O
cell	O	O
growth	O	O
was	O	O
associated	O	O
with	O	O
cell	O	O
cycle	O	O
arrest	O	O
in	O	O
G2	O	O
/	O	O
M	O	O
.	O	O
Among	O	O
the	O	O
compound	O	O
synthesized	O	O
,	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluorocytosine	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
29	O	O
was	O	O
found	O	O
to	O	O
exhibit	O	O
the	O	O
most	O	O
potent	O	O
anti	O	O
-	O	O
HIV	O	O
activity	O	O
(	O	O
EC50	O	O
=	O	O
0.0012	O	O
microM	O	O
)	O	O
although	O	O
it	O	O
was	O	O
toxic	O	O
(	O	O
IC50	O	O
=	O	O
10.0	O	O
microM	O	O
)	O	O
.	O	O
Additionally	O	O
,	O	O
we	O	O
reported	O	O
that	O	O
cyclo	O	O
(	O	O
30-33	O	O
)	O	O
[	O	O
DPhe12	O	O
,	O	O
Nle21	O	O
,	O	O
38	O	O
,	O	O
Glu30	O	O
,	O	O
DHis32	O	O
,	O	O
Lys33	O	O
]	O	O
hCRF	O	O
(	O	O
12-41	O	O
)	O	O
(	O	O
3	O	O
)	O	O
and	O	O
dicyclo	O	O
(	O	O
26-36,30-33	O	O
)	O	O
[	O	O
Ac	O	O
-	O	O
Asp9	O	O
,	O	O
DPhe12	O	O
,	O	O
Nle21	O	O
,	O	O
38	O	O
,	O	O
Cys26	O	O
,	O	O
Glu30	O	O
,	O	O
Lys33	O	O
,	O	O
Cys36	O	O
]	O	O
hCRF	O	O
(	O	O
9-41	O	O
)	O	O
were	O	O
ca.	O	O
twice	O	O
and	O	O
1/100	O	O
as	O	O
potent	O	O
as	O	O
astressin	O	O
,	O	O
respectively	O	O
,	O	O
suggesting	O	O
a	O	O
putative	O	O
turn	O	O
that	O	O
encompasses	O	O
residues	O	O
30-33	O	O
(	O	O
previous	O	O
paper	O	O
:	O	O
Koerber	O	O
et	O	O
al.	O	O
J	O	O
.	O	O
D	O	O
.	O	O
The	O	O
most	O	O
active	O	O
were	O	O
analogues	O	O
4c	O	O
,	O	O
4d	O	O
,	O	O
4e	O	O
,	O	O
and	O	O
6e	O	O
(	O	O
IC50	O	O
10-20	O	O
microM	O	O
)	O	O
.	O	O
This	O	O
compound	O	O
had	O	O
the	O	O
following	O	O
binding	O	O
affinities	O	O
:	O	O
IC50	O	O
(	O	O
sigma	O	O
1	O	O
)	O	O
=	O	O
16	O	O
nM	O	O
,	O	O
IC50	O	O
(	O	O
sigma	O	O
2	O	O
)	O	O
=	O	O
0.27	O	O
nM	O	O
,	O	O
IC50	O	O
(	O	O
5	O	O
-	O	O
HT1A	O	O
)	O	O
=	O	O
22,000	O	O
nM	O	O
,	O	O
IC50	O	O
(	O	O
5	O	O
-	O	O
HT2A	O	O
)	O	O
=	O	O
270	O	O
nM	O	O
,	O	O
IC50	O	O
(	O	O
D2	O	O
)	O	O
=	O	O
4200	O	O
nM	O	O
,	O	O
IC50	O	O
(	O	O
alpha	O	O
1	O	O
)	O	O
=	O	O
220	O	O
nM	O	O
.	O	O
Novel	O	O
derivatives	O	O
of	O	O
benzo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
thieno	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
c	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
quinolones	I-IUPAC	I-IUPAC
3a	O	O
-	O	O
j	O	O
were	O	O
synthesized	O	O
in	O	O
a	O	O
multistep	O	O
synthesis	O	O
starting	O	O
from	O	O
substituted	B-MODIFIER	B-MODIFIER
benzo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
thiophene	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carbonyl	I-IUPAC	I-IUPAC
chlorides	I-IUPAC	I-IUPAC
,	O	O
to	O	O
their	O	O
corresponding	O	O
benzo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
thiophene	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamides	I-IUPAC	I-IUPAC
,	O	O
which	O	O
were	O	O
photochemically	O	O
dehydrohalogenated	O	O
to	O	O
their	O	O
corresponding	O	O
substituted	O	B-MODIFIER
benzo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
thieno	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
c	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
quinolones	I-IUPAC	I-IUPAC
.	O	O
To	O	O
enhance	O	O
the	O	O
intrinsic	O	O
potency	O	O
of	O	O
dihydropyrimidine	O	O
calcium	O	O
channel	O	O
blockers	O	O
,	O	O
we	O	O
have	O	O
modified	O	O
the	O	O
structure	O	O
of	O	O
previously	O	O
described	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
heteroalkyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydropyrimidines	I-IUPAC	I-IUPAC
2	O	O
to	O	O
3	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
1,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydropyrimidines	I-IUPAC	I-IUPAC
3	O	O
.	O	O
In	O	O
addition	O	O
,	O	O
it	O	O
was	O	O
significantly	O	O
inhibitory	O	O
for	O	O
thymidine	O	O
kinase	O	O
deficient	O	O
strain	O	O
of	O	O
HSV	O	O
-	O	O
1	O	O
(	O	O
EC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
2.3-15.3	O	O
microM	O	O
)	O	O
.	O	O
In	O	O
earlier	O	O
reports	O	O
we	O	O
identified	O	O
specific	O	O
point	O	O
substitutions	O	O
(	O	O
DPhe12	O	O
,	O	O
Nle21	O	O
,	O	O
38	O	O
)	O	O
,	O	O
cyclization	O	O
strategies	O	O
[	O	O
in	O	O
particular	O	O
,	O	O
introduction	O	O
of	O	O
lactam	O	O
rings	O	O
such	O	O
as	O	O
that	O	O
of	O	O
cyclo	O	O
(	O	O
Glu30	O	O
,	O	O
Lys33	O	O
)	O	O
]	O	O
,	O	O
and	O	O
deletions	O	O
(	O	O
residues	O	O
1-7	O	O
)	O	O
in	O	O
the	O	O
CRF	O	O
molecule	O	O
that	O	O
led	O	O
to	O	O
agonists	O	O
.	O	O
Ligands	O	O
were	O	O
administered	O	O
to	O	O
mice	O	O
[	O	O
30	O	O
mumol	O	O
kg	O	O
-	O	O
1	O	O
ip	O	O
at	O	O
1	O	O
h	O	O
or	O	O
orally	O	O
at	O	O
3	O	O
min	O	O
after	O	O
iv	O	O
injection	O	O
of	O	O
plutonium	O	O
(	O	O
IV	O	O
)	O	O
-	O	O
238	O	O
citrate	O	O
,	O	O
kill	O	O
at	O	O
24	O	O
h	O	O
]	O	O
.	O	O
The	O	O
structures	O	O
of	O	O
4	O	O
,	O	O
10	O	O
,	O	O
14	O	O
,	O	O
18	O	O
,	O	O
and	O	O
20	O	O
have	O	O
been	O	O
established	O	O
by	O	O
270	O	O
-	O	O
MHz	O	O
1H	O	O
NMR	O	O
spectroscopic	O	O
analyses	O	O
.	O	O
LDA	O	O
(	O	O
lithium	O	O
diisopropylamide	O	O
)	O	O
lithiation	O	O
of	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ethyluracil	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
7	O	O
and	O	O
8	O	O
and	O	O
subsequent	O	O
reaction	O	O
with	O	O
an	O	O
aryl	O	O
aldehyde	O	O
gave	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
arylhydroxymethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethyluracil	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
9-12	O	O
.	O	O
These	O	O
show	O	O
that	O	O
a	O	O
carbon	O	O
rather	O	O
than	O	O
a	O	O
nitrogen	O	O
atom	O	O
at	O	O
the	O	O
5	O	O
-	O	O
position	O	O
leads	O	O
to	O	O
significant	O	O
conformational	O	O
changes	O	O
in	O	O
the	O	O
molecule	O	O
(	O	O
a	O	O
longer	O	O
C5a	O	O
-	O	O
C4	O	O
bond	O	O
and	O	O
a	O	O
30	O	O
degrees	O	O
out	O	O
-	O	O
of	O	O
-	O	O
plane	O	O
rotation	O	O
of	O	O
the	O	O
phenyl	O	B-IUPAC
group	O	B-MODIFIER
)	O	O
,	O	O
due	O	O
to	O	O
the	O	O
requirement	O	O
to	O	O
relieve	O	O
nonbonding	O	O
interactions	O	O
between	O	O
the	O	O
C5	O	O
and	O	O
N9	O	O
protons	O	O
.	O	O
Med.	O	O
Chem.	O	O
1996	O	O
,	O	O
39	O	O
,	O	O
781-788	O	O
)	O	O
.	O	O
The	O	O
phenyl	O	O
ring	O	O
appended	O	O
analogues	O	O
were	O	O
designed	O	O
to	O	O
specifically	O	O
interact	O	O
with	O	O
Phe69	O	O
of	O	O
dihydrofolate	O	O
reductase	O	O
(	O	O
DHFR	O	O
)	O	O
from	O	O
Pneumocystis	O	O
carinii	O	O
(	O	O
pc	O	O
)	O	O
to	O	O
afford	O	O
selective	O	O
inhibitors	O	O
of	O	O
pcDHFR	O	O
.	O	O
However	O	O
,	O	O
as	O	O
expected	O	O
,	O	O
incubation	O	O
of	O	O
these	O	O
prodrugs	O	O
with	O	O
beta	O	O
-	O	O
glucuronidase	O	O
in	O	O
the	O	O
culture	O	O
medium	O	O
led	O	O
to	O	O
much	O	O
more	O	O
efficient	O	O
cell	O	O
killing	O	O
by	O	O
BCNU	O	O
as	O	O
a	O	O
result	O	O
of	O	O
the	O	O
liberation	O	O
of	O	O
the	O	O
more	O	O
potent	O	O
inactivators	O	O
,	O	O
O	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzylguanine	I-IUPAC	I-IUPAC
and	O	O
O	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyguanosine	I-IUPAC	I-IUPAC
.	O	O
Experimentally	O	O
and	O	O
theoretically	O	O
,	O	O
the	O	O
n	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
was	O	O
found	O	O
to	O	O
approximate	O	O
the	O	O
ideal	O	O
size	O	O
for	O	O
the	O	O
alkyl	O	O
group	O	O
in	O	O
both	O	O
the	O	O
5	O	O
and	O	O
7	O	O
positions	O	O
;	O	O
5,7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
di	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
n	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethoxycarbonylpyrazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
(	O	O
5e	O	O
)	O	O
was	O	O
the	O	O
most	O	O
potent	O	O
inhibitor	O	O
of	O	O
both	O	O
lung	O	O
and	O	O
heart	O	O
PDE	O	O
.	O	O
Ring	O	O
annulation	O	O
was	O	O
achieved	O	O
with	O	O
methanolic	O	O
ammonia	O	O
affording	O	O
the	O	O
7	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bromopyrrolo+	I-IUPAC	I-IUPAC
+	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carbonitrile	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
3a	O	O
-	O	O
k	O	O
.	O	O
5	B-IUPAC	O
-	I-IUPAC	O
Fluoronorepinephrine	I-IUPAC	O
retains	O	O
both	O	O
beta	O	B-PARTIUPAC
-	O	I-PARTIUPAC
and	O	O
alpha	O	O
-	O	O
adrenergic	O	O
agonist	O	O
properties	O	O
.	O	O
Most	O	O
of	O	O
them	O	O
[	O	O
rac	O	O
-	O	O
27-31	O	O
,	O	O
(	O	O
-	O	O
)	O	O
-	O	O
28	O	O
,	O	O
and	O	O
(	O	O
-	O	O
)	O	O
-	O	O
30	O	O
]	O	O
,	O	O
which	O	O
are	O	O
more	O	O
active	O	O
than	O	O
(	O	O
-	O	O
)	O	O
-	O	O
huperzine	O	O
A	O	O
as	O	O
AChE	O	O
inhibitors	O	O
,	O	O
turned	O	O
out	O	O
to	O	O
be	O	O
quite	O	O
selective	O	O
for	O	O
AChE	O	O
,	O	O
although	O	O
not	O	O
so	O	O
selective	O	O
as	O	O
(	O	O
-	O	O
)	O	O
-	O	O
huperzine	O	O
A	O	O
.	O	O
An	O	O
N5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
pivaloyl	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
,	O	O
which	O	O
was	O	O
less	O	O
potent	O	O
than	O	O
27	O	O
at	O	O
A1	O	O
,	O	O
A2A	O	O
,	O	O
and	O	O
A3	O	O
receptors	O	O
,	O	O
retained	O	O
moderate	O	O
potency	O	O
at	O	O
A2B	O	O
receptors	O	O
.	O	O
Isoornithines	O	O
were	O	O
not	O	O
taken	O	O
up	O	O
by	O	O
H	O	O
-	O	O
35	O	O
hepatoma	O	O
cells	O	O
;	O	O
hence	O	O
they	O	O
did	O	O
not	O	O
affect	O	O
their	O	O
ODC	O	O
activity	O	O
.	O	O
New	O	O
acylated	O	O
bis	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
catecholates	I-IUPAC	I-IUPAC
and	O	O
1,3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
benzoxazine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dione	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
based	O	O
on	O	O
secondary	O	O
diamino	O	O
acids	O	O
(	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
aminoalkyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
glycines	I-IUPAC	I-IUPAC
,	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aminopropyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alanine	I-IUPAC	I-IUPAC
,	O	O
and	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aminopropyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminovaleric	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
)	O	O
,	O	O
on	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
aminoalkyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
aminomethyl	I-IUPAC	I-IUPAC
benzoic	I-IUPAC	I-IUPAC
acids	I-IUPAC	I-IUPAC
,	O	O
on	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
aminoalkyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
aminomethyl	I-IUPAC	I-IUPAC
phenoxyacetic	I-IUPAC	I-IUPAC
acids	I-IUPAC	I-IUPAC
,	O	O
or	O	O
on	O	O
3,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diaminobenzoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
were	O	O
synthesized	O	O
as	O	O
artificial	O	O
siderophores	O	O
.	O	O
The	O	O
(	O	O
SS	O	O
)	O	O
-	O	O
and	O	O
(	O	O
SR	O	O
)	O	O
-	O	O
isomers	O	O
were	O	O
also	O	O
more	O	O
selective	O	O
on	O	O
cerebral	O	O
tissue	O	O
when	O	O
compared	O	O
with	O	O
ileal	O	O
and	O	O
cardiac	O	O
preparations	O	O
.	O	O
It	O	O
is	O	O
well	O	O
known	O	O
that	O	O
1	O	O
is	O	O
metabolized	O	O
to	O	O
its	O	O
phenolic	O	O
derivative	O	O
dextrorphan	O	O
(	O	O
2	O	O
)	O	O
and	O	O
this	O	O
metabolite	O	O
is	O	O
also	O	O
a	O	O
potent	O	O
anticonvulsant	O	O
.	O	O
Among	O	O
these	O	O
compounds	O	O
that	O	O
had	O	O
a	O	O
lower	O	O
activity	O	O
toward	O	O
sigma	O	O
binding	O	O
sites	O	O
,	O	O
a	O	O
high	O	O
5	O	O
-	O	O
HT1A	O	O
affinity	O	O
was	O	O
found	O	O
for	O	O
the	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylpropyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
21	O	O
(	O	O
Ki	O	O
=	O	O
4.4	O	O
nM	O	O
)	O	O
which	O	O
demonstrated	O	O
very	O	O
good	O	O
selectivity	O	O
.	O	O
HCl	O	O
.	O	O
When	O	O
tested	O	O
for	O	O
their	O	O
antagonistic	O	O
activity	O	O
in	O	O
the	O	O
above	O	O
tissues	O	O
,	O	O
only	O	O
VII	O	O
and	O	O
VIII	O	O
were	O	O
found	O	O
to	O	O
inhibit	O	O
responses	O	O
to	O	O
angiotensin	O	O
II	O	O
.	O	O
The	O	O
synthesis	O	O
and	O	O
biological	O	O
activities	O	O
of	O	O
14	O	O
6	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diaminoquinazolines	I-IUPAC	I-IUPAC
are	O	O
reported	O	O
.	O	O
When	O	O
3	O	O
was	O	O
given	O	O
ip	O	O
in	O	O
water	O	O
to	O	O
P388	O	O
leukemic	O	O
mice	O	O
at	O	O
400	O	O
mg	O	O
/	O	O
kg	O	O
(	O	O
b	O	O
.	O	O
Focused	O	O
libraries	O	O
incorporating	O	O
6	B-PARTIUPAC	O
-	I-PARTIUPAC	O
,	O	O
7	B-PARTIUPAC	O
-	I-PARTIUPAC	O
,	O	O
and	O	O
8	B-IUPAC	O
-	I-IUPAC	O
aryl	I-IUPAC	O
and	O	O
heteroaryl	B-IUPAC	B-IUPAC
substituents	B-MODIFIER	B-MODIFIER
were	O	O
prepared	O	O
.	O	O
It	O	O
is	O	O
transported	O	O
into	O	O
the	O	O
tumor	O	O
cells	O	O
by	O	O
the	O	O
neuronal	O	O
norepinephrine	O	O
(	O	O
NE	O	O
)	O	O
transporter	O	O
(	O	O
NET	O	O
)	O	O
which	O	O
is	O	O
expressed	O	O
in	O	O
almost	O	O
all	O	O
neuroblastoma	O	O
cells	O	O
.	O	O
The	O	O
substitution	O	O
of	O	O
an	O	O
n	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
with	O	O
different	O	O
alkylphenyl	O	O
groups	O	O
,	O	O
to	O	O
give	O	O
compounds	O	O
18b	O	O
-	O	O
e	O	O
,	O	O
increases	O	O
the	O	O
affinity	O	O
for	O	O
the	O	O
D	O	O
-	O	O
2	O	O
subtype	O	O
from	O	O
19	O	O
-	O	O
fold	O	O
to	O	O
36	O	O
-	O	O
fold	O	O
.	O	O
With	O	O
an	O	O
antiantidiuretic	O	O
"	O	O
effective	O	O
dose	O	O
"	O	O
of	O	O
0.46	O	O
+	O	O
/	O	O
-	O	O
0.07	O	O
nmol	O	O
/	O	O
kg	O	O
and	O	O
a	O	O
pA2	O	O
value	O	O
of	O	O
8.24	O	O
+	O	O
/	O	O
-	O	O
0.08	O	O
,	O	O
d	O	O
(	O	O
CH2	O	O
)	O	O
5	O	O
-	O	O
D	O	O
-	O	O
Phe2	O	O
,	O	O
Ile4AVP	O	O
(	O	O
1	O	O
)	O	O
appears	O	O
to	O	O
be	O	O
the	O	O
most	O	O
potent	O	O
antidiuretic	O	O
antagonist	O	O
reported	O	O
to	O	O
date	O	O
.	O	O
of	O	O
less	O	O
than	O	O
10	O	O
nM	O	O
.	O	O
Introduction	O	O
of	O	O
an	O	O
alkyl	O	O
substituent	O	O
in	O	O
the	O	O
5	O	O
-	O	O
position	O	O
of	O	O
the	O	O
thienyl	O	O
group	O	O
of	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
thien	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
or	O	O
substitution	O	O
of	O	O
the	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
deoxyribofuranose	I-IUPAC	I-IUPAC
ring	B-MODIFIER	O
by	O	O
an	O	O
arabinofuranose	O	O
moiety	O	O
gave	O	O
decreased	O	O
activity	O	O
against	O	O
HSV	O	O
-	O	O
1	O	O
and	O	O
VZV	O	O
replication	O	O
when	O	O
compared	O	O
with	O	O
the	O	O
5	B-IUPAC	O
"	I-IUPAC	O
-	I-IUPAC	O
halogenated	I-IUPAC	O
-	I-IUPAC	O
5	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
thien	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridines	I-IUPAC	I-IUPAC
.	O	O
In	O	O
a	O	O
preliminary	O	O
screening	O	O
,	O	O
several	O	O
of	O	O
these	O	O
compounds	O	O
have	O	O
demonstrated	O	O
significant	O	O
broad	O	O
-	O	O
spectrum	O	O
antiviral	O	O
activity	O	O
against	O	O
certain	O	O
DNA	O	O
and	O	O
RNA	O	O
viruses	O	O
in	O	O
vitro	O	O
,	O	O
as	O	O
well	O	O
as	O	O
moderate	O	O
activity	O	O
against	O	O
L1210	O	O
and	O	O
P388	O	O
leukemia	O	O
in	O	O
cell	O	O
culture	O	O
.	O	O
Little	O	O
or	O	O
no	O	O
activity	O	O
was	O	O
observed	O	O
against	O	O
a	O	O
range	O	O
of	O	O
other	O	O
DNA	O	O
and	O	O
RNA	O	O
viruses	O	O
.	O	O
Introduction	O	O
of	O	O
two	O	O
m	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
groups	B-MODIFIER	B-MODIFIER
into	O	O
the	O	O
phenylthio	B-IUPAC	O
ring	B-MODIFIER	O
also	O	O
potentiated	O	O
the	O	O
activity	O	O
.	O	O
A	O	O
series	O	O
of	O	O
analogues	O	O
including	O	O
esters	O	O
of	O	O
ethanol	O	O
and	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxysuccinimide	I-IUPAC	I-IUPAC
,	O	O
amides	O	O
,	O	O
a	O	O
hydrazide	O	O
,	O	O
an	O	O
acylurea	O	O
,	O	O
and	O	O
anilides	O	O
were	O	O
prepared	O	O
.	O	O
The	O	O
most	O	O
potent	O	O
analogue	O	O
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethoxy	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
adenosine	I-IUPAC	I-IUPAC
19	O	O
,	O	O
has	O	O
an	O	O
EC50	O	O
for	O	O
coronary	O	O
vasodilation	O	O
of	O	O
190	O	O
pM	O	O
and	O	O
an	O	O
A1	O	O
/	O	O
A2	O	O
selectivity	O	O
ratio	O	O
of	O	O
44,000	O	O
.	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Morpholino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
formylpyridine	I-IUPAC	I-IUPAC
thiosemicarbazone	I-IUPAC	I-IUPAC
was	O	O
the	O	O
most	O	O
active	O	O
antineoplastic	O	O
agent	O	O
of	O	O
this	O	O
series	O	O
in	O	O
mice	O	O
bearing	O	O
Sarcoma	O	O
180	O	O
ascites	O	O
cells	O	O
and	O	O
was	O	O
significantly	O	O
superior	O	O
to	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
formylpyridine	I-IUPAC	I-IUPAC
thiosemicarbazone	I-IUPAC	I-IUPAC
in	O	O
this	O	O
test	O	O
system	O	O
.	O	O
Crystallographic	O	O
data	O	O
for	O	O
the	O	O
ternary	O	O
complex	O	O
of	O	O
hDHFR	O	O
-	O	O
NADPH	O	O
and	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
5'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethoxybenzyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylamino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
,	O	O
1c	O	O
,	O	O
reveal	O	O
the	O	O
first	O	O
structural	O	O
details	O	O
for	O	O
a	O	O
reversed	O	O
N9	O	O
-	O	O
C10	O	O
folate	O	O
bridge	O	O
geometry	O	O
as	O	O
well	O	O
as	O	O
the	O	O
first	O	O
conformational	O	O
details	O	O
of	O	O
a	O	O
hybrid	O	O
piritrexim	O	O
-	O	O
trimetrexate	O	O
analogue	O	O
.	O	O
At	O	O
the	O	O
A2	O	O
receptor	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenethoxyadenosine	I-IUPAC	I-IUPAC
is	O	O
the	O	O
most	O	O
potent	O	O
of	O	O
the	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenylalkyladenosines	I-IUPAC	I-IUPAC
.	O	O
K	O	O
(	O	O
i	O	O
)	O	O
values	O	O
for	O	O
spermidine	O	O
uptake	O	O
were	O	O
also	O	O
determined	O	O
in	O	O
L1210	O	O
cells	O	O
.	O	O
Several	O	O
new	O	O
analogues	O	O
of	O	O
L	B-IUPAC	O
-	I-IUPAC	O
fucose	I-IUPAC	O
modified	O	O
in	O	O
the	O	O
2	O	O
position	O	O
and	O	O
the	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
have	O	O
been	O	O
synthesized	O	O
as	O	O
potential	O	O
plasma	O	O
-	O	O
membrane	O	O
glycoconjugate	O	O
inhibitors	O	O
or	O	O
modifiers	O	O
,	O	O
and	O	O
their	O	O
biological	O	O
effects	O	O
have	O	O
been	O	O
studied	O	O
.	O	O
(	O	O
+	O	O
)	O	O
-	O	O
and	O	O
(	O	O
-	O	O
)	O	O
-	O	O
8	O	O
were	O	O
obtained	O	O
in	O	O
greater	O	O
than	O	O
98%	O	O
optical	O	O
purity	O	O
through	O	O
three	O	O
recrystallizations	O	O
from	O	O
ethanol	O	O
of	O	O
the	O	O
(	B-PARTIUPAC	O
S	I-PARTIUPAC	O
)	I-PARTIUPAC	O
-	I-PARTIUPAC	O
(	I-PARTIUPAC	O
+	I-PARTIUPAC	O
)	I-PARTIUPAC	O
-	I-PARTIUPAC	O
and	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
mandelate	I-IUPAC	I-IUPAC
salts	I-IUPAC	B-MODIFIER
of	O	O
intermediate	O	O
(	B-IUPAC	B-IUPAC
+	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cis	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bicyclo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3.1.0	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
hexylamine	I-IUPAC	I-IUPAC
(	O	O
[	O	O
(	O	O
+	O	O
/	O	O
-	O	O
)	O	O
-	O	O
16	O	O
]	O	O
.	O	O
These	O	O
compounds	O	O
were	O	O
found	O	O
to	O	O
be	O	O
active	O	O
in	O	O
vitro	O	O
for	O	O
LTC4	O	O
/	O	O
D4	O	O
inhibition	O	O
with	O	O
the	O	O
potencies	O	O
(	O	O
IC50	O	O
's	O	O
)	O	O
ranging	O	O
from	O	O
0.2	O	O
to	O	O
85	O	O
microM	O	O
.	O	O
Analogues	O	O
6b	O	O
,	O	O
d	O	O
-	O	O
h	O	O
and	O	O
5	O	B-IUPAC
-	O	I-IUPAC
hydroxymethyl	O	I-IUPAC
-	O	O
dUMP	O	O
,	O	O
similar	O	O
to	O	O
N	O	B-IUPAC
(	O	I-IUPAC
4	O	I-IUPAC
)	O	I-IUPAC
-	O	I-IUPAC
hydroxy	O	I-IUPAC
-	O	I-IUPAC
dCMP	O	I-IUPAC
(	O	O
6a	O	O
)	O	O
and	O	O
FdUMP	O	O
,	O	O
were	O	O
also	O	O
N	O	B-IUPAC
(	O	I-IUPAC
5	O	I-IUPAC
)	O	I-IUPAC
,	O	I-IUPAC
N	B-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
10	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylenetetrahydrofolate	I-IUPAC	I-IUPAC
-	O	I-IUPAC
dependent	O	I-IUPAC
,	O	O
hence	O	O
mechanism	O	O
-	O	O
based	O	O
,	O	O
slow	O	O
-	O	O
binding	O	O
inhibitors	O	O
.	O	O
In	O	O
contrast	O	O
,	O	O
2a	O	O
,	O	O
3a	O	O
,	O	O
and	O	O
3b	O	O
induced	O	O
differentiation	O	O
of	O	O
only	O	O
a	O	O
very	O	O
small	O	O
percentage	O	O
of	O	O
the	O	O
cells	O	O
.	O	O
The	O	O
best	O	O
inhibitors	O	O
for	O	O
calpain	O	O
II	O	O
were	O	O
Z	O	O
-	O	O
Leu	O	O
-	O	O
Abu	O	O
-	O	O
CONH	O	O
-	O	O
CH2	O	O
-	O	O
CHOH	O	O
-	O	O
C6H5	O	O
(	O	O
Ki	O	O
=	O	O
15	O	O
nM	O	O
)	O	O
,	O	O
Z	O	O
-	O	O
Leu	O	O
-	O	O
Abu	O	O
-	O	O
CONH	O	O
-	O	O
CH2	O	O
-	O	O
2	O	O
-	O	O
pyridyl	O	O
(	O	O
Ki	O	O
=	O	O
17	O	O
nM	O	O
)	O	O
,	O	O
and	O	O
Z	O	O
-	O	O
Leu	O	O
-	O	O
Abu	O	O
-	O	O
CONH	O	O
-	O	O
CH2	O	O
-	O	O
C6H3	O	O
(	O	O
3,5	O	O
(	O	O
OMe	O	O
)	O	O
2	O	O
)	O	O
(	O	O
Ki	O	O
=	O	O
22	O	O
nM	O	O
)	O	O
.	O	O
The	O	O
indolin	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
imidazoline	I-IUPAC	I-IUPAC
4b	O	O
was	O	O
found	O	O
to	O	O
possess	O	O
potent	O	O
alpha	O	O
2	O	O
-	O	O
adrenergic	O	O
agonist	O	O
and	O	O
antagonist	O	O
activity	O	O
.	O	O
A	O	O
series	O	O
of	O	O
straight	O	O
chain	O	O
alkyl	O	O
amides	O	O
demonstrated	O	O
that	O	O
the	O	O
optimal	O	O
chain	O	O
length	O	O
occurs	O	O
with	O	O
the	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propionyl	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
,	O	O
3	O	O
,	O	O
which	O	O
had	O	O
a	O	O
Ki	O	O
value	O	O
of	O	O
7.7	O	O
nM	O	O
at	O	O
human	O	O
A3	O	O
receptors	O	O
,	O	O
and	O	O
was	O	O
40	O	O
-	O	O
and	O	O
14	O	O
-	O	O
fold	O	O
selective	O	O
vs	O	O
rat	O	O
A1	O	O
and	O	O
A2A	O	O
receptors	O	O
,	O	O
respectively	O	O
.	O	O
Additionally	O	O
methyl	B-IUPAC	B-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chlorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxobut	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
enoate	I-IUPAC	I-IUPAC
(	O	O
2d	O	O
)	O	O
,	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chlorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxobut	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
enoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
3d	O	O
)	O	O
,	O	O
methyl	B-IUPAC	B-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxobut	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
enoate	I-IUPAC	I-IUPAC
(	O	O
2f	O	O
)	O	O
,	O	O
and	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxobut	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
enoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
3f	O	O
)	O	O
prevent	O	O
the	O	O
increase	O	O
in	O	O
the	O	O
interferon	O	O
-	O	O
gamma	O	O
-	O	O
induced	O	O
synthesis	O	O
of	O	O
quinolinic	O	O
acid	O	O
in	O	O
primary	O	O
cultures	O	O
of	O	O
cultured	O	O
human	O	O
peripheral	O	O
blood	O	O
monocyte	O	O
-	O	O
derived	O	O
macrophages	O	O
.	O	O
C	O	O
.	O	O
The	O	O
dissociation	O	O
constant	O	O
(	O	O
Kd	O	O
)	O	O
for	O	O
our	O	O
synthetic	O	O
[	O	O
111In	O	O
]	O	O
DTPA	O	O
-	O	O
D	O	O
-	O	O
Phe1	O	O
-	O	O
octreotide	O	O
was	O	O
4.31	O	O
nM	O	O
,	O	O
which	O	O
is	O	O
comparable	O	O
to	O	O
a	O	O
Kd	O	O
=	O	O
5.57	O	O
nM	O	O
obtained	O	O
with	O	O
commercially	O	O
available	O	O
DTPA	O	O
-	O	O
D	O	O
-	O	O
Phe1	O	O
-	O	O
octreotide	O	O
.	O	O
More	O	O
significantly	O	O
,	O	O
some	O	O
piperazines	O	O
derivatives	O	O
of	O	O
[	B-IUPAC	B-IUPAC
1,2,4	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
triazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
triazine	I-IUPAC	I-IUPAC
also	O	O
possessed	O	O
good	O	O
oral	O	O
efficacy	O	O
in	O	O
rodent	O	O
models	O	O
of	O	O
Parkinson	O	O
's	O	O
disease	O	O
.	O	O
Compound	O	O
6	O	O
thus	O	O
represents	O	O
a	O	O
new	O	O
structural	O	O
class	O	O
of	O	O
GluR5	O	O
agonists	O	O
.	O	O
Two	O	O
syntheses	O	O
have	O	O
been	O	O
elaborated	O	O
for	O	O
the	O	O
preparation	O	O
of	O	O
the	O	O
compounds	O	O
represented	O	O
by	O	O
the	O	O
general	O	O
formulas	O	O
II	O	O
-	O	O
V	O	O
where	O	O
R1	O	O
=	O	O
hydrogen	O	O
,	O	O
halogen	O	O
,	O	O
or	O	O
methyl	B-IUPAC	O
;	O	O
Y	O	O
=	O	O
CONHR	O	O
,	O	O
OCOR	O	O
,	O	O
or	O	O
CO	O	O
(	O	O
CH2	O	O
)	O	O
nNHR	O	O
,	O	O
in	O	O
which	O	O
R	O	O
=	O	O
alkyl	O	O
or	O	O
aralkyl	O	O
or	O	O
NHR	O	O
=	O	O
cyclic	O	O
amine	O	O
and	O	O
n	O	O
=	O	O
1-2	O	O
.	O	O
Compound	O	O
1	O	O
also	O	O
displayed	O	O
significant	O	O
activity	O	O
against	O	O
rhinovirus	O	O
type	O	O
34	O	O
.	O	O
The	O	O
latter	O	O
derivatives	O	O
were	O	O
also	O	O
more	O	O
effective	O	O
than	O	O
O6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
benzylguanine	I-IUPAC	I-IUPAC
at	O	O
inactivating	O	O
AGT	O	O
in	O	O
intact	O	O
HT29	O	O
colon	O	O
tumor	O	O
cells	O	O
.	O	O
The	O	O
CoMSIA	O	O
models	O	O
displayed	O	O
r	O	O
(	O	O
2	O	O
)	O	O
(	O	O
cv	O	O
)	O	O
0.663-0.729	O	O
,	O	O
r	O	O
(	O	O
2	O	O
)	O	O
(	O	O
ncv	O	O
)	O	O
0.909-0.998	O	O
,	O	O
r	O	O
(	O	O
2	O	O
)	O	O
(	O	O
pred	O	O
)	O	O
0.554-0.855	O	O
.	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
Bromothien	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
caused	O	O
prompt	O	O
healing	O	O
of	O	O
HSV	O	O
-	O	O
1	O	O
keratitis	O	O
when	O	O
administered	O	O
as	O	O
eye	O	O
drops	O	O
(	O	O
0.2%	O	O
)	O	O
to	O	O
rabbits	O	O
.	O	O
Similar	O	O
glycosylations	O	O
of	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
cyanoallopurinol	I-IUPAC	I-IUPAC
and	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
methylthio	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
allopurinol	I-IUPAC	I-IUPAC
furnished	O	O
the	O	O
corresponding	O	O
protected	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
glycosyl	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
(	O	O
5b	O	O
and	O	O
5c	O	O
)	O	O
.	O	O
The	O	O
metabolic	O	O
study	O	O
using	O	O
isolated	O	O
Langendorff	O	O
perfused	O	O
rat	O	O
hearts	O	O
demonstrated	O	O
that	O	O
approximately	O	O
67%	O	O
of	O	O
perfused	O	O
[	O	O
99mTc	O	O
]	O	O
CpTT	O	O
-	O	O
PA	O	O
was	O	O
incorporated	O	O
and	O	O
[	O	O
99mTc	O	O
]	O	O
CpTT	O	O
-	O	O
propionic	O	O
acid	O	O
,	O	O
the	O	O
metabolite	O	O
after	O	O
six	O	O
cycles	O	O
of	O	O
beta	O	O
-	O	O
oxidation	O	O
of	O	O
[	O	O
99mTc	O	O
]	O	O
CpTT	O	O
-	O	O
PA	O	O
,	O	O
was	O	O
detected	O	O
as	O	O
the	O	O
major	O	O
radiometabolite	O	O
in	O	O
the	O	O
perfusate	O	O
and	O	O
myocardium	O	O
.	O	O
Synthetic	O	O
routes	O	O
to	O	O
the	O	O
heretofore	O	O
unknown	O	O
ylidenemalononitriles	O	O
,	O	O
and	O	O
the	O	O
ketone	O	O
precursors	O	O
thereof	O	O
,	O	O
were	O	O
developed	O	O
.	O	O
In	O	O
particular	O	O
,	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1,2,5,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thiazolamine	I-IUPAC	I-IUPAC
(	O	O
4c	O	O
,	O	O
PD	O	O
118440	O	O
)	O	O
and	O	O
its	O	O
allyl	B-IUPAC	O
analogue	B-MODIFIER	O
(	O	O
4i	O	O
,	O	O
PD	O	O
120697	O	O
)	O	O
have	O	O
been	O	O
identified	O	O
as	O	O
orally	O	O
active	O	O
dopamine	O	O
(	O	O
DA	O	O
)	O	O
agonists	O	O
with	O	O
pronounced	O	O
central	O	O
nervous	O	O
system	O	O
effects	O	O
in	O	O
tests	O	O
that	O	O
include	O	O
[	B-IUPAC	O
3H	I-IUPAC	O
]	I-IUPAC	O
-	I-IUPAC	O
haloperidol	I-IUPAC	O
and	O	O
[	B-IUPAC	O
3H	I-IUPAC	O
]	I-IUPAC	O
-	I-IUPAC	O
N	I-IUPAC	O
-	I-IUPAC	O
propylnorapomorphine	I-IUPAC	O
binding	O	O
,	O	O
inhibition	O	O
of	O	O
striatal	O	O
DA	O	O
synthesis	O	O
,	O	O
inhibition	O	O
of	O	O
DA	O	O
neuronal	O	O
firing	O	O
,	O	O
inhibition	O	O
of	O	O
spontaneous	O	O
locomotor	O	O
activity	O	O
,	O	O
and	O	O
reversal	O	O
of	O	O
reserpine	O	O
-	O	O
induced	O	O
depression	O	O
in	O	O
rats	O	O
.	O	O
Also	O	O
,	O	O
the	O	O
activity	O	O
of	O	O
some	O	O
of	O	O
these	O	O
compounds	O	O
inhibiting	O	O
butyrylcholinesterase	B-IUPAC	O
(	O	O
BChE	O	O
)	O	O
was	O	O
tested	O	O
.	O	O
In	O	O
mediated	O	O
influx	O	O
into	O	O
L1210	O	O
cells	O	O
,	O	O
5	O	O
and	O	O
6	O	O
were	O	O
transported	O	O
2.7	O	O
-	O	O
and	O	O
8.5	O	O
-	O	O
fold	O	O
,	O	O
respectively	O	O
,	O	O
more	O	O
readily	O	O
than	O	O
MTX	O	O
.	O	O
To	O	O
further	O	O
elucidate	O	O
the	O	O
binding	O	O
requirements	O	O
for	O	O
this	O	O
site	O	O
,	O	O
we	O	O
synthesized	O	O
several	O	O
hydantoin	O	O
analogs	O	O
and	O	O
evaluated	O	O
these	O	O
in	O	O
in	O	O
vitro	O	O
sodium	O	O
channel	O	O
-	O	O
binding	O	O
and	O	O
/	O	O
or	O	O
in	O	O
vivo	O	O
whole	O	O
animal	O	O
anticonvulsant	O	O
assays	O	O
.	O	O
Compound	O	O
10	O	O
was	O	O
also	O	O
the	O	O
best	O	O
inhibitor	O	O
of	O	O
T	O	O
.	O	O
The	O	O
SARs	O	O
developed	O	O
from	O	O
the	O	O
new	O	O
compounds	O	O
,	O	O
together	O	O
with	O	O
those	O	O
collected	O	O
from	O	O
our	O	O
previous	O	O
studies	O	O
,	O	O
confirmed	O	O
the	O	O
hypothesis	O	O
of	O	O
different	O	O
binding	O	O
modes	O	O
for	O	O
5	O	O
-	O	O
substituted	O	O
and	O	O
5	O	O
-	O	O
unsubstituted	O	O
indoles	O	O
,	O	O
suggesting	O	O
that	O	O
the	O	O
shape	O	O
of	O	O
the	O	O
lipophilic	O	O
pocket	O	O
L	O	O
(	O	O
1	O	O
)	O	O
(	O	O
notation	O	O
in	O	O
accordance	O	O
with	O	O
Cook	O	O
's	O	O
BzR	O	O
topological	O	O
model	O	O
)	O	O
is	O	O
asymmetric	O	O
and	O	O
highlighted	O	O
the	O	O
stereoelectronic	O	O
and	O	O
conformational	O	O
properties	O	O
of	O	O
the	O	O
amide	O	O
side	O	O
chain	O	O
required	O	O
for	O	O
high	O	O
potency	O	O
.	O	O
New	O	O
siderophore	O	O
penicillin	O	O
V	O	O
conjugates	O	O
with	O	O
the	O	O
siderophore	O	O
component	O	O
attached	O	O
to	O	O
the	O	O
phenyl	O	O
ring	O	O
of	O	O
penicillin	O	O
V	O	O
are	O	O
inactive	O	O
against	O	O
these	O	O
Gram	O	O
-	O	O
negative	O	O
bacteria	O	O
.	O	O

